US20090028857A1 - Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof - Google Patents
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof Download PDFInfo
- Publication number
- US20090028857A1 US20090028857A1 US12/178,122 US17812208A US2009028857A1 US 20090028857 A1 US20090028857 A1 US 20090028857A1 US 17812208 A US17812208 A US 17812208A US 2009028857 A1 US2009028857 A1 US 2009028857A1
- Authority
- US
- United States
- Prior art keywords
- cells
- antibody
- cytokine
- tumor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 178
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 178
- 238000000034 method Methods 0.000 title claims abstract description 88
- 230000003248 secreting effect Effects 0.000 title abstract description 74
- 210000004027 cell Anatomy 0.000 claims abstract description 289
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 232
- 201000011510 cancer Diseases 0.000 claims abstract description 91
- 238000009169 immunotherapy Methods 0.000 claims description 187
- 210000004881 tumor cell Anatomy 0.000 claims description 118
- 230000001413 cellular effect Effects 0.000 claims description 117
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 114
- 239000000203 mixture Substances 0.000 claims description 58
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 44
- 241000282414 Homo sapiens Species 0.000 claims description 37
- 230000000735 allogeneic effect Effects 0.000 claims description 37
- 230000000981 bystander Effects 0.000 claims description 33
- 230000004083 survival effect Effects 0.000 claims description 23
- 230000001225 therapeutic effect Effects 0.000 claims description 23
- 201000001441 melanoma Diseases 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 16
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 238000002619 cancer immunotherapy Methods 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 9
- 230000006023 anti-tumor response Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 230000032832 immune response to tumor cell Effects 0.000 abstract description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 107
- 241000699670 Mus sp. Species 0.000 description 84
- 210000001744 T-lymphocyte Anatomy 0.000 description 63
- 239000000427 antigen Substances 0.000 description 60
- 108091007433 antigens Proteins 0.000 description 60
- 102000036639 antigens Human genes 0.000 description 60
- 238000011282 treatment Methods 0.000 description 51
- 241001465754 Metazoa Species 0.000 description 47
- 108090000623 proteins and genes Proteins 0.000 description 41
- 238000002648 combination therapy Methods 0.000 description 35
- 230000028993 immune response Effects 0.000 description 34
- 239000013598 vector Substances 0.000 description 32
- 150000007523 nucleic acids Chemical group 0.000 description 30
- 210000004988 splenocyte Anatomy 0.000 description 28
- 108010058846 Ovalbumin Proteins 0.000 description 25
- 238000001727 in vivo Methods 0.000 description 25
- 229940092253 ovalbumin Drugs 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 22
- 108010074328 Interferon-gamma Proteins 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 102100037850 Interferon gamma Human genes 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 210000000952 spleen Anatomy 0.000 description 20
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 238000011220 combination immunotherapy Methods 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 230000028327 secretion Effects 0.000 description 18
- 238000009396 hybridization Methods 0.000 description 17
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 16
- 230000027455 binding Effects 0.000 description 16
- 210000000987 immune system Anatomy 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 230000005867 T cell response Effects 0.000 description 14
- 238000013459 approach Methods 0.000 description 14
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 230000001976 improved effect Effects 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 230000008595 infiltration Effects 0.000 description 12
- 238000001764 infiltration Methods 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000009097 single-agent therapy Methods 0.000 description 11
- 229940032072 GVAX vaccine Drugs 0.000 description 10
- 241001529936 Murinae Species 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 239000012830 cancer therapeutic Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000011740 C57BL/6 mouse Methods 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 8
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 238000011853 postimmunotherapy Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108010002616 Interleukin-5 Proteins 0.000 description 7
- 102000000743 Interleukin-5 Human genes 0.000 description 7
- 230000005809 anti-tumor immunity Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 210000003071 memory t lymphocyte Anatomy 0.000 description 7
- 229920000314 poly p-methyl styrene Polymers 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 6
- 108090000467 Interferon-beta Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- -1 MIP3a Proteins 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000005975 antitumor immune response Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003184 complementary RNA Substances 0.000 description 6
- 230000001461 cytolytic effect Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 229940076144 interleukin-10 Drugs 0.000 description 6
- 229940100602 interleukin-5 Drugs 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 108010075205 OVA-8 Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 102000048362 human PDCD1 Human genes 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 5
- 108020004491 Antisense DNA Proteins 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 241000021375 Xenogenes Species 0.000 description 4
- 239000003816 antisense DNA Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003259 immunoinhibitory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000009877 rendering Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 3
- 102100020990 Interferon lambda-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000001608 teratocarcinoma Diseases 0.000 description 3
- 101150079396 trpC2 gene Proteins 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002220 organoid Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000015240 negative regulation of T cell cytokine production Effects 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005851 tumor immunogenicity Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Definitions
- the present invention relates to methods and compositions for enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising an antibody that specifically binds to human Programmed Death 1 (PD-1) and a cytokine-secreting cell, and methods of administering the combination for enhanced generation of an immune response to tumor cells in a patient.
- PD-1 Human Programmed Death 1
- cytokine-secreting cell a cytokine-secreting cell
- the immune system plays a critical role in the pathogenesis of a wide variety of cancers. When cancers progress, it is widely believed that the immune system either fails to respond sufficiently or fails to respond appropriately, allowing cancer cells to grow.
- standard medical treatments for cancer including chemotherapy, surgery, radiation therapy and cellular therapy, have clear limitations with regard to both efficacy and toxicity. To date, these approaches have met with varying degrees of success dependent upon the type of cancer, general health of the patient, stage of disease at the time of diagnosis, etc.
- Improved strategies that combine specific manipulation of the immune response to cancer in combination with standard medical treatments may provide a means for enhanced efficacy and decreased toxicity.
- cytokines Numerous cytokines have been shown to play a role in regulation of the immune response to tumors.
- U.S. Pat. No. 5,098,702 describes using combinations of TNF, IL-2 and IFN-beta in synergistically effective amounts to combat existing tumors.
- U.S. Pat. Nos. 5,078,996, 5,637,483 and 5,904,920 describe the use of GM-CSF for treatment of tumors.
- direct administration of cytokines for cancer therapy may not be practical, as they are often systemically toxic. (See, for example, Asher et al., J. Immunol. 146: 3227-3234, 1991 and Havell et al, J. Exp. Med. 167: 1067-1085, 1988.)
- autologous tumor cells were genetically altered to produce a costimulatory molecule, such as B7-1 or allogeneic histocompatibility antigens (Salvadori et al. Hum. Gene Ther. 6:1299-1306, 1995 and Plaksin et al. Int. J. Cancer 59:796-801, 1994). While the use of genetically modified tumor cells has met with success in treatment of some forms of cancer, there remains a need for improved treatment regimens with greater potency and/or efficacy and fewer side effects than the therapies currently in use.
- a costimulatory molecule such as B7-1 or allogeneic histocompatibility antigens
- the invention provides improved compositions and methods for the treatment of cancer in a mammal, typically a human, by administering a combination of a cytokine-expressing cellular immunotherapy and an antibody that specifically binds to human Programmed Death (PD)-1.
- a mammal typically a human
- PD Human Programmed Death
- the cytokine-expressing cellular immunotherapy expresses GM-CSF.
- the cytokine-expressing cellular immunotherapy is rendered proliferation-incompetent by irradiation.
- administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular immunotherapy or the anti-PD-1 antibody alone.
- the cytokine-expressing cellular immunotherapy is typically administered subcutaneously, intratumorally, or intradermally.
- the injection of irradiated GM-CSF-expressing tumor cells results in a local reaction characterized by the infiltration of dendritic cells (DCs), macrophages, and granulocytes.
- DCs dendritic cells
- the anti-PD-1 antibody may be administered prior to, at the same time as, or following administration of the cytokine-expressing cellular immunotherapy component of the combination.
- the anti-PD-1 antibody may be administered via parenteral, e.g., subcutaneous, intratumoral, intravenous, intradermal, oral, transmucosal, or rectal administration. While not intending to be bound to a particular theory of operation, it is believed that blockade of PD-1 through the administration of an anti-PD-1 antibody potentiates anti-tumor immunity by negatively modulating the immunoinhibitory effects of PD-1 signaling in activated T-cells, B-cells and myeloid cells.
- the invention further provides a combination of cytokine-expressing cells and an anti-PD-1 antibody, wherein the combination comprises cells that are autologous, allogeneic, or bystander cells.
- the autologous, allogeneic, or bystander cell is rendered proliferation-incompetent by irradiation.
- the invention further provides compositions and kits comprising cytokine-expressing cellular immunotherapy combinations for use according to the description provided herein.
- FIG. 1A illustrates the anti-tumor T-cell response in an adoptive transfer model in C57BL/6 mice challenged with live B16F10 tumor cells modified to express ovalbumin as a surrogate antigen (B16.ova) and immunized with GM-CSF-secreting B16.ova cells (GM.ova) alone, or in combination with an anti-PD-1 antibody.
- B16.ova a surrogate antigen
- GM-CSF-secreting B16.ova cells GM.ova
- the number of ovalbumin-specific T-cells in draining lymph-nodes (DLN) (top panel) and spleens (bottom panel) were determined by tetramer staining at 3, 7, 10, 14 and 20 days following immunotherapy.
- FIG. 1B illustrates the cytolytic activity of T-cells in mice challenged with live B16 tumor cells modified to express ovalbumin as a surrogate antigen (B16.ova) and immunized with GM-CSF secreting B16.ova cells (GM.ova) alone, or in combination with an anti-PD-1 antibody.
- Cytolytic activity was determined by assessing the ratio of CSFE-labeled cells in isolated splenocytes following injection of CSFE-labeled non-pulsed and SIINFEKL peptide pulsed syngeneic splenocytes. Cytolytic activity was assessed at 7, 14, 21 and 28 days post immunotherapy.
- FIG. 1C illustrates the number of IFN ⁇ -secreting cells per 5 ⁇ 10 5 splenocytes isolated from mice challenged with live B16 tumor cells, then immunized with allogeneic GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Control animals were administered HBSS at the time of immunization. Isolated splenocytes were stimulated with trp2 peptide (top panel) or irradiated B16F10 cells (bottom panel) before being assayed by ELISPOT.
- FIG. 2A illustrates the secretion of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF ⁇ ) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion.
- TNF ⁇ tumor necrosis factor-alpha
- FIG. 2B illustrates the secretion of the pro-inflammatory cytokine interferon-gamma (IFN ⁇ ) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion.
- IFN ⁇ pro-inflammatory cytokine interferon-gamma
- FIG. 2C illustrates the secretion of the pro-inflammatory cytokine interleukin-5 (IL-5) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion.
- IL-5 pro-inflammatory cytokine interleukin-5
- FIG. 2D illustrates the secretion of the pro-inflammatory cytokine interleukin-6 (IL-6) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion.
- IL-6 pro-inflammatory cytokine interleukin-6
- FIG. 2E illustrates the secretion of the pro-inflammatory cytokine interleukin-10 (IL-10) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion.
- IL-10 pro-inflammatory cytokine interleukin-10
- FIG. 2F illustrates the secretion of the pro-inflammatory cytokine monocyte chemotactic protein (MCP)-1 from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion.
- MCP cytokine monocyte chemotactic protein
- FIG. 3A illustrates effector CD8 f-cell infiltration into tumors of mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or with GM-CSF-secreting B16F10 cells in combination with an anti-PD-1 antibody (combo). Shown are the percentage of IFN ⁇ and CD107 ⁇ expressing cells in the CD8 TIL subpopulation.
- FIG. 3B illustrates effector CD8 T-cell infiltration into tumors of mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or with GM-CSF-secreting B16F10 cells in combination with an anti-PD-1 antibody. Shown is the ratio of CD8+/FoxP3+ cells in the tumor at 3 wks post cellular immunotherapy.
- FIG. 3C illustrates the kinetics of CD4 + T-cell infiltration into tumor cells (as measured per 1 ⁇ 10 6 tumor cells) in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody.
- CD4 + T-cell counts were determined at 7, 14 and 21 days post cellular immunotherapy.
- FIG. 3D illustrates the kinetics of CD8 + T-cell infiltration into tumor cells (as measured per 1 ⁇ 10 6 tumor cells) in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody.
- CD8 + T-cell counts were determined at 7, 14 and 21 days post cellular immunotherapy.
- FIG. 3E illustrates the kinetics of CD8 + /107a + T-cell infiltration into tumor cells (as measured per 1 ⁇ 10 6 tumor cells) in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody.
- CD8 + /107a + T-cell counts were determined at 7, 14 and 21 days post cellular immunotherapy.
- FIG. 3F illustrates the kinetics of CD8 + /IFN ⁇ + T-cell infiltration into tumor cells (as measured per 1 ⁇ 10 6 tumor cells) in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody.
- CD8 + /IFN ⁇ + T-cell counts were determined at 7, 14 and 21 days post cellular immunotherapy.
- FIG. 3G illustrates tumor progression in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody.
- FIG. 4A illustrates the survival of B16F10 tumor-bearing animals following administration of GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody, when given on day 3 post tumor challenge.
- FIG. 4B illustrates the survival of B16F10 tumor-bearing animals following administration of GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody, when given on day 7 post tumor challenge.
- FIG. 4C illustrates the survival of B16F10 tumor-bearing animals following administration of GM-CSF-secreting cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody, when given on day 11 post tumor challenge.
- FIG. 4D illustrates the memory response of mice which survived an initial tumor challenge following administration of GM-CSF-secreting cells alone or in combination with an anti-PD-1 antibody.
- animals were re-challenged with 5 ⁇ 10 5 (2.5 fold of initial dose) B16 tumor cells and monitored for survival. A Kaplan-Meier survival curve was used for evaluation.
- FIG. 5A illustrates the survival of CT26 tumor-bearing animals following administration of GM-CSF-secreting CT26 cells alone (CT26.GM), anti-PD-1 antibody alone (anti-PD-1) or CT26.GM in combination with an anti-PD-1 antibody when given on day 3 post tumor challenge.
- FIG. 5B illustrates the tumor burden of animals following administration of GM-CSF-secreting CT26 cells alone (CT26.GM), anti-PD-1 antibody alone (anti-PD-1) or CT26.GM in combination with an anti-PD-1 antibody when given on day 3 post tumor challenge.
- FIG. 6A illustrates the percentage of CD4 + T-cells in the spleens of mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody.
- FIG. 6B illustrates the percentage of CD8 + T-cells in the spleens of mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody.
- FIG. 6C illustrates the percentage of CD11c + T-cells in the spleens of mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody.
- FIG. 6D illustrates the percentage of DX5 + T-cells in the spleens of mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody.
- FIG. 7A illustrates the percentage of memory T-cells (Ly6C + /CD69 ⁇ ) in the CD4 subpopulation from spleen taken from mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody.
- FIG. 7B illustrates the percentage of memory T-cells (Ly6C + /CD69 ⁇ ) in the CD8 subpopulation from spleen taken from mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody.
- FIG. 8 illustrates the reversal of anergy and augmentation of a tumor-specific T-cell response in C57BL/6 mice injected with SIINFEKL peptide (to induce anergy in adoptively transferred OT-1 transgenic T-cells) and immunized with GM-CSF-secreting B16.ova cells (GM.ova) alone, or in combination with an anti-PD-1 antibody.
- the percentage of antigen-specific T-cells in peripheral blood lymphocytes was determined by tetramer staining at 4, 10, 14, 17, 25 and 31 days following adoptive transfer.
- FIG. 9 illustrates the expansion and contraction of the population of ovalbumin-specific CD8 T-cells in spleens of mice treated with an initial therapy cycle of GM.ova immunotherapy, followed by either (i) anti-PD-1 and immunotherapy administered biweekly; (ii) GM.ova immunotherapy only administered biweekly; or (iii) anti-PD-1 administered biweekly and GM.ova immunotherapy administered monthly. Shown are the absolute numbers of ovalbumin-specific CD8 T-cells in the spleen by tetramer staining (A) and ovalbumin-specific CD8 T-cells co-stained with the activation marker CD107a (B) and IFN- ⁇ (C).
- the present invention represents improved cellular immunotherapies for the treatment of cancer in that the compositions and methods described herein comprise at least two components that act in concert to effect an improved therapeutic outcome for the cancer patient under treatment.
- regulating the immune response or “modulating the immune response” as used herein refers to any alteration in a cell of the immune system or any alteration in the activity of a cell involved in the immune response. Such regulation or modulation includes an increase or decrease in the number of various cell types, an increase or decrease in the activity of these cells, or any other changes which can occur within the immune system.
- Cells involved in the immune response include, but are not limited to, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils.
- regulating” or “modulating” the immune response means the immune response is stimulated or enhanced, and in other cases “regulating” or “modulating” the immune response means suppression of the immune system. Stimulation of the immune system may include memory responses and/or future protection against subsequent antigen challenge.
- cytokine or “cytokines” as used herein refers to the general class of biological molecules which effect/affect cells of the immune system.
- the definition is meant to include, but is not limited to, those biological molecules that act locally or may circulate in the blood, and which, when used in the compositions or methods of the present invention serve to regulate or modulate an individual's immune response to cancer.
- Exemplary cytokines for use in practicing the invention include but are not limited to interferon-alpha (IFN- ⁇ ), interferon-beta (IFN- ⁇ ), and interferon-gamma (IFN- ⁇ ), interleukins (e.g., IL-1 to IL-29, in particular, IL-2, IL-5, IL-6, IL-7, IL-10, IL-12, IL-15 and IL-18), tumor necrosis factors (e.g., TNF-alpha and TNF-beta), erythropoietin (EPO), MIP3a, monocyte chemotactic protein (MCP)-1, intracellular adhesion molecule (ICAM), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF).
- IFN- ⁇ interferon-alpha
- IFN- ⁇ interferon-beta
- cytokine-expressing cellular immunotherapy refers to a composition comprising a population of cells that has been genetically modified to express a cytokine, e.g., GM-CSF, and that is administered to a patient as part of a cancer treatment regimen.
- the cells of such a “cytokine-expressing cellular immunotherapy” comprise a cytokine-encoding DNA sequence operably linked to expression and control elements such that the cytokine is expressed by the cells.
- the cells of the “cytokine-expressing cellular immunotherapy” are typically tumor cells and may be autologous or allogeneic to the patient undergoing treatment and or may be “bystander cells” that are mixed with tumor cells taken from the patient.
- a GM-CSF-expressing “cytokine-expressing cellular immunotherapy” may be referred to herein as “GVAX®”.
- operably linked as used herein relative to a recombinant DNA construct or vector means nucleotide components of the recombinant DNA construct or vector are directly linked to one another for operative control of a selected coding sequence.
- “operably linked” DNA sequences are contiguous, and, in the case of a secretory leader, contiguous and in reading frame; however, some sequences, e.g., enhancers do not have to be contiguous to be operative and therefore “operably linked.”
- the term “gene” or “coding sequence” means the nucleic acid sequence which is transcribed (DNA) and translated (mRNA) into a polypeptide in vitro or in vivo when operably linked to appropriate regulatory sequences.
- a “gene” typically comprises the coding sequence plus any non-coding sequences associated with the gene (e.g., regulatory sequences) and hence may or may not include regions preceding and following the coding region, e.g., 5′ untranslated (5′UTR) or “leader” sequences and 3′ UTR or “trailer” sequences, as well as intervening sequences (introns) between individual coding segments (exons).
- a “coding sequence” does not include non-coding DNA.
- nucleic acid sequence may be heterologous to the cell(s), or it may be an additional copy or altered version of a nucleic acid sequence already present in the cell(s). This term also encompasses cells or a population of cells with altered, e.g., increased or decreased, expression of a nucleic acid sequence endogenous to the cell or population of cells.
- the cell(s) may be genetically-modified by physical or chemical methods or by the use of recombinant viruses.
- viral vectors which find utility in effective delivery of genes into mammalian cells include, for example, retroviral vectors, adenovirus vectors, adenovirus-associated vectors (AAV), herpes virus vectors, pox virus vectors.
- non-viral means of introduction for example, naked DNA delivered via liposomes, receptor-mediated delivery, calcium phosphate transfection, electroporation, particle bombardment (gene gun), or pressure-mediated delivery may also be employed to introduce a nucleic acid sequence into a cell or population of cells to render them “gene-modified” or “genetically-modified.
- cancer refers to cells that exhibit relatively autonomous growth, so that they exhibit an aberrant growth phenotype or aberrant cell status characterized by a significant loss of control of cell proliferation.
- a tumor cell may be a hyperplastic cell, a cell that shows a lack of contact inhibition of growth in vitro or in vivo, a cell that is incapable of metastasis in vivo, or a cell that is capable of metastasis in vivo.
- Neoplastic cells can be malignant or benign. It follows that cancer cells are considered to have an aberrant cell status.
- tumor antigen from a tumor cell and “tumor antigen” and “tumor cell antigen” may be used interchangeably herein and refer to any protein, carbohydrate or other component derived from or expressed by a tumor cell which is capable of eliciting an immune response.
- the definition is meant to include, but is not limited to whole tumor cells that express some or all of the tumor-associated antigens, tumor cell fragments, plasma membranes taken from a tumor cell, proteins purified from the cell surface or membrane of a tumor cell, or unique carbohydrate moieties associated with the cell surface of a tumor cell.
- the definition also includes those antigens from the surface of the cell which require special treatment of the cells to access.
- a “tumor cell line” comprises cells that were initially derived from a tumor. Such cells typically are transformed (i.e., exhibit indefinite growth in culture).
- systemic immune response means an immune response which is not localized, but affects the individual as a whole.
- gene therapy means the treatment or prevention of cancer by means of ex vivo or in vivo delivery, through viral or non-viral vectors, of compositions containing a recombinant genetic material.
- ex vivo delivery means the introduction, outside of the body of a human, of compositions containing a genetic material into a cell, tissue, organoid, organ, or the like, followed by the administration of cell, tissue, organoid, organ, or the like which contains such introduced compositions into the body of the same (autologous) or a different (allogeneic) human, without limitation as to the formulation, site or route of administration.
- inactivated cells may be used interchangeably herein and refer to cells that have been treated rendering them proliferation incompetent, e.g., by irradiation. Such treatment results in cells that are unable to undergo mitosis, but retain the capability to express proteins such as cytokines or other cancer therapeutic agents. Typically a minimum dose of about 3500 rads is sufficient, although doses up to about 30,000 rads are acceptable. Effective doses include, but are not limited to, 5000 to 10000 rads. Numerous methods of inactivating cells, such as treatment with Mitomycin C, are known in the art. Any method of inactivation which renders cells incapable of cell division, but allows the cells to retain the ability to express proteins may be used in accordance with the present invention.
- treatment of an individual or a cell is any type of intervention used in an attempt to alter the natural course of the individual or cell.
- Treatment includes, but is not limited to, administration of e.g., a cytokine-expressing cellular immunotherapy and at least one additional cancer therapeutic agent or treatment, e.g. an anti-PD-1 antibody, and may be performed either prophylactically or subsequent to diagnosis as part of a primary or follow-up therapeutic regimen.
- administering refers to the physical introduction of a composition comprising a cytokine-expressing cellular immunotherapy and at least one additional cancer therapeutic agent or treatment to a patient with cancer. Any and all methods of introduction are contemplated according to the invention; the method is not dependent on any particular means of introduction. Means of introduction are well-known to those skilled in the art, examples of which are provided herein.
- co-administering means a process whereby the combination of a cytokine-expressing cellular immunotherapy and at least one additional cancer therapeutic agent, e.g., an anti-PD-1 antibody, is administered to the same patient.
- the cytokine-expressing cellular immunotherapy and additional cancer therapeutic may be administered simultaneously, at essentially the same time, or sequentially. If administration takes place sequentially the cytokine-expressing cellular immunotherapy may be administered before or after a given additional cancer therapeutic agent or treatment.
- the cytokine-expressing cellular immunotherapy and additional cancer therapeutic agent or treatment need not be administered by means of the same vehicle.
- the cellular immunotherapy and the additional agent or treatment may be administered one or more times and the number of administrations of each component of the combination may be the same or different.
- the cytokine-expressing cellular immunotherapy and additional cancer therapeutic agent or treatment need not be administered at the same site.
- terapéuticaally effective amount refers to an amount or dose of a cytokine-expressing cellular immunotherapy together with the amount or dose of an additional agent or treatment, e.g. an anti-PD-1 antibody, that is sufficient to modulate, either by stimulation or suppression, the systemic immune response of an individual.
- the amount of cytokine-expressing cellular immunotherapy in a given therapeutically effective combination may be different for different individuals and different tumor types, and will be dependent upon the one or more additional agents or treatments included in the combination.
- the “therapeutically effective amount” is determined using procedures routinely employed by those of skill in the art such that an “improved therapeutic outcome” results.
- the terms “improved therapeutic outcome” and “enhanced therapeutic efficacy,” relative to cancer refers to a slowing or diminution of the growth of cancer cells or a solid tumor, or a reduction in the total number of cancer cells or total tumor burden.
- An “improved therapeutic outcome” or “enhanced therapeutic efficacy” therefore means there is an improvement in the condition of the patient according to any clinically acceptable criteria, including, for example, decreased tumor size, an increase in time to tumor progression, increased progression-free survival, increased overall survival time, an increase in life expectancy, or an improvement in quality of life.
- “improved” or “enhanced” refers to an improvement or enhancement of 1%, 5%, 10%, 25% 50%, 75%, 100%, or greater than 100% of any clinically acceptable indicator of therapeutic outcome or efficacy.
- the term “synergism,” “synergistic” or “synergistically” refers to the combined action of two or more agents wherein the combined action is greater than the sum of the actions of each of the agents used alone.
- comparing the activity and/or efficacy of a combination composition comprising the cytokine-expressing cellular immunotherapy (GVAX) plus an anti-PD-1 antibody (anti-PD-1) to either GVAX or anti-PD-1 alone, refers to a comparison using amounts known to be comparable according to one of skill in the art.
- Comparable amounts of GVAX when comparing the combination therapy to GVAX alone, may be based on cell number, cytokine expression, cytokine secretion, or cytokine activity on a per cell basis.
- Comparable amounts of anti-PD-1 when comparing the combination therapy to PD-1 alone, may be based on equimolar amounts, weight-to-weight equivalents, or units of PD-1 binding activity.
- reversal of an established tumor means the suppression, regression, partial or complete disappearance of a pre-existing tumor.
- the definition is meant to include any diminution, for example, in the size, growth rate, appearance or cellular compositions of a preexisting tumor.
- the terms “individual” or “subject” as referred to herein is a vertebrate, preferably a mammal, and typically refers to a human.
- programmed death-1 is synonymous with one another, and include variants, isoforms, species homologs of human PD-1, and analogs having at least one common epitope with PD-1.
- the full length human PD-1 cDNA is 2106 nucleotides long and encodes a protein of 288 amino acid residues.
- the human PD-1 and murine PD-1 genes share 70% homology at the nucleotide level and 60% homology at the amino acid level.
- the complete cDNA sequence of human PD-1 has the Genbank accession number U64863 (Shinohara et al., Genomics 23(3): 704-706 (1994).
- An intact “antibody” comprises at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
- Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region.
- the heavy chain constant region is comprised of three domains, CH1, CH2 and CH3.
- Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region.
- the light chain constant region is comprised of one domain, CL.
- the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
- CDR complementarity determining regions
- Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3. FR4.
- the variable regions of the heavy and light chains contain a binding domain that interacts with PD-1.
- the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
- the term antibody includes antigen-binding portions of an intact antibody that retain capacity to bind PD-1.
- binding examples include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR).
- a Fab fragment a monovalent fragment consisting of the VL, VH, CL and CH1 domains
- a F(ab′)2 fragment a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region
- a Fd fragment consist
- the two domains of the Fv fragment, VL and VH are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); See, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).
- single chain Fv single chain Fv
- Such single chain antibodies are included by reference to the term “antibody.” Fragments can be prepared by recombinant techniques or enzymatic or chemical cleavage of intact antibodies.
- Constant substitution refers to the substitution in a polypeptide of an amino acid with a functionally similar amino acid.
- the following six groups each contain amino acids that are conservative substitutions for one another:
- I Isoleucine
- L Leucine
- M Methionine
- V Valine
- stringent conditions refers to conditions under which a probe will hybridize preferentially to its target subsequence, and to a lesser extent to, or not at all to, other sequences. “Stringent hybridization” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments such as Southern and northern hybridizations are sequence dependent, and are different under different environmental parameters.
- highly stringent hybridization and wash conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.
- Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.
- Very stringent conditions are selected to be equal to the Tm for a particular probe.
- stringent hybridization conditions for hybridization of complementary nucleic acids which have more than about 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42° C., with the hybridization being carried out overnight.
- An example of highly stringent wash conditions is 0.15 M NaCl at 72° C. for about 15 minutes.
- An example of stringent wash conditions is a 0.2 ⁇ SSC wash at 65° C. for 15 minutes. See Sambrook et al. for a description of SSC buffer. A high stringency wash can be preceded by a low stringency wash to remove background probe signal.
- An exemplary medium stringency wash for a duplex of, e.g., more than about 100 nucleotides, is 1 ⁇ SSC at 45° C. for 15 minutes.
- An exemplary low stringency wash for a duplex of, e.g., more than about 100 nucleotides, is 4-6 ⁇ SSC at 40° C. for 15 minutes.
- a signal to noise ratio of 2 ⁇ (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.
- % sequence identity is used interchangeably herein with the term “% identity” and refers to the level of amino acid sequence identity between two or more peptide sequences or the level of nucleotide sequence identity between two or more nucleotide sequences, when aligned using a sequence alignment program.
- 80% identity means the same thing as 80% sequence identity determined by a defined algorithm, and means that a given sequence is at least 80% identical to another length of another sequence.
- Exemplary levels of sequence identity include, but are not limited to, 60, 70, 80, 85, 90, 95, 98% or more sequence identity to a given sequence.
- % sequence homology is used interchangeably herein with the term “% homology” and refers to the level of amino acid sequence homology between two or more peptide sequences or the level of nucleotide sequence homology between two or more nucleotide sequences, when aligned using a sequence alignment program.
- 80% homology means the same thing as 80% sequence homology determined by a defined algorithm, and accordingly a homologue of a given sequence has greater than 80% sequence homology over a length of the given sequence.
- Exemplary levels of sequence homology include, but are not limited to, 60, 70, 80, 85, 90, 95, 98% or more sequence homology to a given sequence.
- the BLASTX program is preferred for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases. Both BLASTP and BLASTX are run using default parameters of an open gap penalty of 11.0, and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix. See id.
- Another alignment of selected sequences in order to determine “% identity” between two or more sequences is performed using for example, the CLUSTAL-W-program in MacVector version 6.5, operated with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM 30 similarity matrix.
- the term “about 5 ⁇ g/kg” means a range of from 4.5 ⁇ g/kg to 5.5 ⁇ g/kg.
- “about 1 hour” means a range of from 54 minutes to 66 minutes.
- An appropriate viral vector includes, but is not limited to, a retrovirus, a lentivirus, an adenovirus (AV), an adeno-associated virus (AAV), a simian virus 40 (SV-40), a bovine papilloma virus, an Epstein-Barr virus, a herpes virus, a vaccinia virus, a Moloney murine leukemia virus, a Harvey murine sarcoma virus, a murine mammary tumor virus, and a Rous sarcoma virus.
- Non-viral vectors are also included within the scope of the invention.
- any suitable vector can be employed that is appropriate for introduction of nucleic acids into eukaryotic tumor cells, or more particularly animal tumor cells, such as mammalian, e.g., human, tumor cells.
- the vector is compatible with the tumor cell, e.g., is capable of imparting expression of the coding sequence for a cytokine and is stably maintained or relatively stably maintained in the tumor cell.
- the vector comprises an origin of replication and the vector may or may not also comprise a “marker” or “selectable marker” function by which the vector can be identified and selected. While any selectable marker can be used, selectable markers for use in such expression vectors are generally known in the art and the choice of the proper selectable marker will depend on the host cell.
- selectable marker genes which encode proteins that confer resistance to antibiotics or other toxins include ampicillin, methotrexate, tetracycline, neomycin (Southern and Berg, J., 1982), myco-phenolic acid (Mulligan and Berg, 1980), puromycin, zeo-mycin, hygromycin (Sugden et al., 1985) or G418.
- references to a vector or other DNA sequences as “recombinant” merely acknowledges the operable linkage of DNA sequences which are not typically operably linked as isolated from or found in nature.
- a “promoter” is a DNA sequence that directs the binding of RNA polymerase and thereby promotes RNA synthesis.
- “Enhancers” are cis-acting elements that stimulate or inhibit transcription of adjacent genes. An enhancer that inhibits transcription also is termed a “silencer.” Enhancers can function (i.e. be operably linked to a coding sequence) in either orientation, over distances of up to several kilobase pairs (kb) from the coding sequence and from a position downstream of a transcribed region.
- expression/control sequences are operatively linked to a nucleic acid coding sequence when the expression/control sequences regulate the transcription and, as appropriate, translation of the nucleic acid sequence.
- expression/control sequences can include promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of the coding sequence, a splicing signal for introns, and stop codons.
- Recombinant vectors for the production of cellular immunotherapies of the invention provide the proper transcription, translation and processing signals (e.g., splicing and polyadenylation signals) such that the coding sequence for the cytokine is appropriately transcribed and translated in the tumor cells into which the vector is introduced.
- the manipulation of such signals to ensure appropriate expression in host cells is within the skill of the ordinary skilled artisan.
- the coding sequence for the cytokine may be under control of (i.e., operably linked to) its own native promoter, or a non-native (e.g.
- heterologous promoter including a constitutive promoter, e.g., the cytomegalovirus (CMV) immediate early promoter/enhancer, the Rous sarcoma virus long terminal repeat (RSV-LTR) or the SV-40 promoter.
- CMV cytomegalovirus
- RSV-LTR Rous sarcoma virus long terminal repeat
- tissue-specific promoter a promoter that is preferentially activated in a particular type of tissue and results in expression of a gene product in that tissue
- promoters include but are not limited to a liver specific promoter (III CR, et al., Blood Coagul Fibrinolysis 8 Suppl 2:S23-30, 1997) and the EF-1 alpha promoter (Kim D W et al. Gene. 91(2):217-23, 1990, Guo Z S et al. Gene Ther. 3(9):802-10, 1996; U.S. Pat. Nos. 5,266,491 and 5,225,348, each of which expressly incorporated by reference herein).
- Inducible promoters also find utility in practicing the methods described herein, such as a promoter containing the tet responsive element (TRE) in the tet-on or tet-off system as described (ClonTech and BASF), the metallothienein promoter which can be upregulated by addition of certain metal salts and rapamycin inducible promoters (Rivera et al., 1996, Nature Med, 2(9): 1028-1032; Ye et al., 2000, Science 283: 88-91; Sawyer T K et al., 2002, Mini Rev Med Chem. 2(5):475-88). Large numbers of suitable tissue-specific or regulatable vectors and promoters for use in practicing the current invention are known to those of skill in the art and many are commercially available.
- TRE tet responsive element
- Exemplary vector systems for use in practicing the invention include the retroviral MFG vector, described in U.S. Pat. No. 5,637,483, expressly incorporated by reference herein.
- Other useful retroviral vectors include pLJ, pEm and [alpha]SGC, described in U.S. Pat. No. 5,637,483 (in particular Example 12), U.S. Pat. Nos. 6,506,604, 5,955,331 and U.S. Ser. No. 09/612,808, each of which is expressly incorporated by reference herein.
- vector systems for use in practicing the invention include second, third and fourth generation lentiviral vectors, U.S. Pat. Nos. 6,428,953, 5,665,577 and 5,981,276 and WO 00/72686, each of which is expressly incorporated by reference herein.
- Additional exemplary vector systems for use in practicing the present invention include adenoviral vectors, described for example in U.S. Pat. No. 5,872,005 and International Patent Publication No. WO 00/72686, each of which is expressly incorporated by reference herein.
- rAAV recombinant adeno-associated vector
- Cytokines and combinations of cytokines have been shown to play an important role in the stimulation of the immune system.
- the term “cytokine” is understood by those of skill in the art, as referring to any immunopotentiating protein (including a modified protein such as a glycoprotein) that enhances or modifies the immune response to a tumor present in the host.
- the cytokine typically enhances or modifies the immune response by activating or enhancing the activity of cells of the immune system and is not itself immunogenic to the host.
- cytokines for use in practicing the invention include but are not limited to interferon-alpha (IFN- ⁇ ), interferon-beta (IFN- ⁇ ), and interferon-gamma (IFN- ⁇ ), interleukins (e.g., IL-1 to IL-29, in particular, IL-2, IL-7, IL-12, IL-15 and IL-18), tumor necrosis factors (e.g., TNF-alpha and TNF-beta), erythropoietin (EPO), MIP3a, intracellular adhesion molecule (ICAM), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF).
- IFN- ⁇ interferon-alpha
- IFN- ⁇ interferon-beta
- IFN-gamma IFN- ⁇
- interleukins e.g., IL-1 to IL-
- the cytokine may be from any source, however, optimally the cytokine is of murine or human origin (a native human or murine cytokine) or is a sequence variant of such a cytokine, so long as the cytokine has a sequence with substantial homology to the human form of the cytokine and exhibits a similar activity on the immune system.
- cytokines with substantial homology to the human forms of IFN-alpha, IFN-beta, and IFN-gamma, IL-1 to IL-29, TNF-alpha, TNF-beta, EPO, MIP3a, ICAM, M-CSF, G-CSF and GM-CSF are useful in practicing the invention, so long as the homologous form exhibits the same or a similar effect on the immune system.
- Proteins that are substantially similar to any particular cytokine, but have relatively minor changes in protein sequence find use in the present invention. It is well known that small alterations in protein sequence may not disturb the functional activity of a protein molecule, and thus proteins can be made that function as cytokines in the present invention but differ slightly from current known or native sequences.
- sequence identity means nucleic acid or amino acid sequence identity between two or more aligned sequences and is typically expressed as a percentage (“%”).
- % homology is used interchangeably herein with the term “% identity” or “% sequence identity” and refers to the level of nucleic acid or amino acid sequence identity between two or more aligned sequences, when aligned using a sequence alignment program. For example, as used herein, 80% homology has the same meaning as 80% sequence identity as determined by a defined algorithm, and accordingly a homologue of a given sequence typically has greater than 80% sequence identity over a length of the given sequence.
- Preferred levels of sequence identity include, but are not limited to, 80, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% or more sequence identity to a native cytokine amino acid or nucleic acid sequence, as described herein.
- Exemplary computer programs that can be used to determine the degree of identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, BLASTX, TBLASTX, BLASTP and TBLASTN, all of which are publicly available on the Internet. See, also, Altschul, S. F. et al. Mol. Biol. 215:403-410, 1990 and Altschul, S. F. et al. Nucleic Acids Res. 25:3389-3402, 1997, expressly incorporated by reference herein. Sequence searches are typically carried out using the BLASTN program when evaluating a given nucleic acid sequence relative to nucleic acid sequences in the GenBank DNA Sequences and other public databases.
- the BLASTX program is preferred for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases.
- both BLASTN and BLASTX i.e. version 2.2.5 are run using default parameters of an open gap penalty of 11.0, and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix.
- a preferred alignment of selected sequences in order to determine “% identity” between two or more sequences is performed using for example, the CLUSTAL-W program in Mac Vector, version 6.5, operated with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM 30 similarity matrix.
- a nucleic acid sequence is considered to be “selectively hybridizable” to a reference nucleic acid sequence if the two sequences specifically hybridize to one another under moderate to high stringency hybridization and wash conditions.
- Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe.
- Tm melting temperature
- maximum stringency typically occurs at about TM-5° C. (5° below the Tm of the probe)
- high stringency at about 5-10° below the Tm
- intermediate stringency at about 10-20° below the Tm of the probe
- low stringency at about 20-25° below the Tm.
- maximum stringency conditions may be used to identify sequences having strict identity or near-strict identity with the hybridization probe, while high stringency conditions are used to identify sequences having about 80% or more sequence identity with the probe.
- An example of high stringency conditions includes hybridization at about 42° C. in 50% formamide, 5 ⁇ SSC, 5 ⁇ Denhardt's solution, 0.5% SDS and 100 fig/ml denatured carrier DNA followed by washing two times in 2 ⁇ SSC and 0.5% SDS at room temperature and two additional times in 0.1 ⁇ SSC and 0.5% SDS at 42° C.
- Moderate and high stringency hybridization conditions are well known in the art. See, for example, Sambrook, et al, 1989, Chapters 9 and 11, and in Ausubel, F. M., et al, 1993, (expressly incorporated by reference herein).
- the present invention is directed to a method of improving an individual's immune response to cancer (e.g., a target cancer antigen or antigens) by co-administering a cytokine-expressing cellular immunotherapy (e.g., GM-CSF) and at an antibody which specifically binds to human Programmed Death (PD)-1 to a patient with cancer.
- cancer e.g., a target cancer antigen or antigens
- a cytokine-expressing cellular immunotherapy e.g., GM-CSF
- PD Human Programmed Death
- PD-1 is an immunoinhibitory receptor belonging to the CD28 family (Freeman et al., J. Exp. Med. 192: 1027 (2000); Okazaki et al., Curr. Opim. Immunol. 14: 779 (2002)) and binds to two ligands, PD-L1 and PD-L2.
- PD-1 is induced on T-cells, B-cells and myeloid cells in-vitro (Agata et al., Int. Immunol. 8:765 (1996)), but is predominantly expressed on previously activated T-cells in vivo (Iwai et al., Immunol. Lett. 83:215 (2002)).
- PD-1 plays a critical role in immune responses. Engagement of PD-1 by PD-L1 leads to inhibition of T cell proliferation and cytokine production such as IL-2 and IFN-gamma (Freeman et al., J. Exp. Med. 192: 1027 (2000). In addition, PD-1 deficient mice exhibit a breakdown of peripheral tolerance and develop systemic autoimmune disease (Nishimura et al., Immunity 11: 141-151 (1999); Nishimura et al., Science 291: 319-322 (2001)).
- PD-L1 Over-expression of PD-L1 has been observed in numerous human cancers, including melanomas and carcinomas of lung, ovary, colon, bladder, breast, cervix, liver, and head and neck, and glioblastoma (Dong et al. Nat. Med. 8:793-800 (2002); Brown et al., J. Immunol. 170:1257-66 (2003). Strome et al. Cancer Res. 63: 6501 (2003); Wintterle et al., Cancer Res. 63:7462-7467 (2003)), and PD-L1/PD-1 interaction has been suggested to play a pivotal role in the immune evasion of tumors from the host immune system (Blank et al. Cancer Immunol. Immunother. 54(4):307-14 (2005)). Therefore, blockade of PD-L1/PD-1 interaction, e.g., with an antibody which specifically binds PD-1, serves as one possible mechanism for enhancing anti-tum
- antibodies for use in the present invention include, but are not limited to, monoclonal antibodies, synthetic antibodies, polyclonal antibodies, multispecific antibodies (including bi-specific antibodies), human antibodies, humanized antibodies, chimeric antibodies, single-chain Fvs (scfv) (including bi-specific scFvs), single chain antibodies, Fab fragments, F(ab′) fragments, disulfide-linked Fvs (sdFv), and epitope-binding fragments of any of the above.
- antibodies for use in the present invention include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain a PD-1 binding site that immunospecifically binds to PD-1.
- the immunoglobulin molecules for use in the invention can be of any type (e.g. IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.
- the antibodies for use in the invention are IgG, more preferably, IgG1.
- the antibodies for use in the invention may be from any animal origin including birds and mammals (e.g., human, murine, donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken).
- the antibodies are human or humanized monoclonal antibodies.
- “human” antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from mice or other animals that express antibodies from human genes.
- the antibodies for use in the present invention may be monospecific, bispecific, trispecific or of greater multispecificity.
- Multispecific antibodies may immunospecifically bind to different epitopes of a polypeptide or may immunospecifically bind to both a polypeptide as well a heterologous epitope, such as a heterologous polypeptide or solid support material.
- WO 93/17715, WO 92/08802, WO 91/00360, and WO 92/05793 Tutt, et al., 1991, J. Immunol. 147:60-69; U.S. Pat. Nos. 4,474,893, 4,714,681, 4,925,648, 5,573,920, and 5,601,819; and Kostelny et al., 1992, J. Immunol. 148:1547-1553.
- the antibodies for use in the invention include derivatives of the antibodies.
- Standard techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding an antibody to be used with the methods for use in the invention, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis which result in amino acid substitutions.
- the derivatives include less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the original molecule.
- the derivatives have conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
- a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art.
- amino acids with basic side chains e.g., lysine, arginine, histidine
- acidic side chains e.g., aspartic acid, glutamic acid
- uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
- nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
- beta-branched side chains e.g., threonine, valine, isoleucine
- aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
- mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed and the activity of the protein can be determined.
- the antibodies for use in the present invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody.
- the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, synthesis in the presence of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.
- the present invention also provides antibodies for use in the invention that comprise a framework region known to those of skill in the art.
- one or more framework regions, preferably, all of the framework regions, of an antibody to be used in the compositions and methods for use in the invention are human.
- the fragment region of an antibody for use in the invention is humanized.
- the antibody to be used with the methods for use in the invention is a synthetic antibody, a monoclonal antibody, an intrabody, a chimeric antibody, a human antibody, a humanized chimeric antibody, a humanized antibody, a glycosylated antibody, a multispecific antibody, a human antibody, a single-chain antibody, or a bispecific antibody.
- an antibody for use in the invention has a high binding affinity for PD-1.
- an antibody for use in the invention has an association rate constant or k on rate of about 10 5 M-1s-1 or more, about 5 ⁇ 10 5 M-1s-1 or more, about 10 6 M-1s-1 or more, about 5 ⁇ 10 6 M-1s-1 or more, about 10 7 M-1s-1 or more, about 5 ⁇ 10 7 M-1s-1 or more, about 10 8 M-1s-1 or more, about 5 ⁇ 10 8 M-1s-1 or more, or about 1 ⁇ 10 9 M-1s-1 or more.
- an antibody for use in the invention has a k off rate for PD-1 of about 5 ⁇ 10 ⁇ 1 s-1 or less, about 10 ⁇ 1 s-1 or less, about 5 ⁇ 10 ⁇ 2 s-1 or less, about 10 ⁇ 2 s-1 or less, about 5 ⁇ 10 ⁇ 3 S-1 or less, about 10 ⁇ 3 s-1 or less, about 5 ⁇ 10 ⁇ 4 s-1 or less, about 10 ⁇ 4 s-1 or less, about 5 ⁇ 10 ⁇ 5 s-1 or less, about 10 ⁇ 5 s-1 or less, about 5 ⁇ 10 ⁇ 6 s-1 or less, about 10 ⁇ 6 s-1 or less, about 5 ⁇ 10 ⁇ 7 s-1 or less, about 10 ⁇ 7 s-1 or less, about 5 ⁇ 10 ⁇ 8 s-1 or less, about 10 ⁇ 8 s-1 or less, about 5 ⁇ 10 ⁇ 9 s-1 or less, about 10 ⁇ 9 s-1 or less, about 5 ⁇ 10 ⁇ 10 s-1 or less, or about 10
- an antibody for use in the invention has an affinity constant or K a (k on /k off ) for PD-1 of about 10 2 M-1 or more, about 5 ⁇ 10 2 M-1 or more, about 10 3 M-1 or more, about 5 ⁇ 10 3 M-1 or more, about 10 4 M-1 or more, about 5 ⁇ 10 4 M-1 or more, about 10 5 M-1 or more, about 5 ⁇ 10 5 M-1 or more, about 10 6 M-1 or more, about 5 ⁇ 10 6 M-1 or more, about 10 7 M-1 or more, about 5 ⁇ 10 7 M-1 or more, about 10 8 M-1 or more, about 5 ⁇ 10 8 M-1 or more, about 10 9 M-1 or more, about 5 ⁇ 10 9 M-1 or more, about 10 10 M-1 or more, about 5 ⁇ 10 10 M-1 or more, about 1 ⁇ 10 11 M-1 or more, about 5 ⁇ 10 11 M-1 or more, about 10 12 M-1 or more, about 5 ⁇ 10 12 M-1 or more, about 10 13 M-1 or more, about 5 ⁇ 10 13 M-1 or more, about 10 14
- an antibody for use in the invention has a low dissociation constant.
- the antibody-binding domain of a carrier construct for use in the invention has a dissociation constant or K d (k off /k on ) for antibody about 5 ⁇ 10 ⁇ 1 M or less, about 10 ⁇ 1 M or less, about 5 ⁇ 10 ⁇ 2 M or less, about 10 ⁇ 2 M or less, about 5 ⁇ 10 ⁇ 3 M or less, about 10 ⁇ 3 M or less, about 5 ⁇ 10 ⁇ 4 M or less, about 10 ⁇ 4 M or less, about 5 ⁇ 10 ⁇ 5 M or less, about 10 ⁇ 5 M or less, about 5 ⁇ 10 ⁇ 6 M or less, about 10 ⁇ 6 M or less, about 5 ⁇ 10 ⁇ 7 M or less, about 10 ⁇ 7 M or less, about 5 ⁇ 10 ⁇ 8 M or less, about 10 ⁇ 8 M or less, about 5 ⁇ 10 ⁇ 9 M or less, about 10 ⁇ 9 M or less, about 5 ⁇ 10 ⁇ 10 M or less,
- an antibody for use in the present invention has a median effective concentration (EC 50 ) of less than 0.01 nM, less than 0.025 nM, less than 0.05 nM, less than 0.1 nM, less than 0.25 nM, less than 0.5 nM, less than 0.75 nM, less than 1 nM, less than 1.25 nM, less than 1.5 nM, less than 1.75 nM, or less than 2 nM, in an in vitro microneutralization assay.
- the median effective concentration is the concentration of antibody that neutralizes 50% of PD-1 in an in vitro microneutralization assay.
- an antibody for use in the invention has a half-life in a subject, preferably a human, of about 12 hours or more, about 1 day or more, about 3 days or more, about 6 days or more, about 10 days or more, about 15 days or more, about 20 days or more, about 25 days or more, about 30 days or more, about 35 days or more, about 40 days or more, about 45 days or more, about 2 months or more, about 3 months or more, about 4 months or more, or about 5 months or more.
- Antibodies with increased in vivo half-lives can be generated by techniques known to those of skill in the art.
- antibodies with increased in vivo half-lives can be generated by modifying (e.g., substituting, deleting or adding) amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor (see, e.g., International Publication No. WO 97/34631 and U.S. patent application Ser. No. 10/020,354, entitled “Molecules with Extended Half-Lives, Compositions and Uses Thereof”, filed Dec. 12, 2001, by Johnson et al.; and U.S. Publication Nos. 2005/003700 and 2005/0064514, which are incorporated herein by reference in their entireties).
- Such antibodies can be tested for binding activity to antigens as well as for in vivo efficacy using methods known to those skilled in the art, for example, by immunoassays described herein.
- antibodies with increased in vivo half-lives can be generated by attaching to the antibodies polymer molecules such as high molecular weight polyethyleneglycol (PEG).
- PEG polymer molecules
- PEG can be attached to the antibodies with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C-terminus of the antibodies or via epsilon-amino groups present on lysine residues. Linear or branched polymer derivatization that results in minimal loss of biological activity will be used. The degree of conjugation will be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies.
- Unreacted PEG can be separated from antibody-PEG conjugates by, e.g., size exclusion or ion-exchange chromatography.
- PEG-derivatized antibodies can be tested for binding activity to antigens as well as for in vivo efficacy using methods known to those skilled in the art, for example, by immunoassays described herein.
- an antibody for use in the present invention includes antigen-binding portions of an intact antibody that retain capacity to bind PD-1.
- examples include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, ambivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR).
- CDR complementarity determining region
- the two domains of the Fv fragment, VL and VH are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); See, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad Sci. USA 85:5879-5883).
- single chain Fv single chain Fv
- Such single chain antibodies are included by reference to the term “antibody.”
- the methods of the invention utilize combination immunotherapies that comprise additional molecules that have the capacity to bind PD-1 and/or antagonize PD-1 function.
- a potential PD-1 antagonist may be a protein closely related to a ligand of PD-1, for example, a mutated form of PD-L1 or PD-L2, that recognizes the PD-1 receptor but imparts no signaling effect, thereby competitively inhibiting the immunoinhibitory action of the ligand.
- Other potential PD-1 antagonists include small molecules that bind to the receptor binding site or other relevant binding site of PD-1, thereby blocking its normal biological activity.
- small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds. These small molecules can be identified by screening techniques well known for those skilled in the art.
- antagonists may include oligonucleotides that bind to PD-1-encoding nucleic acids, such as antisense RNA or DNA constructs prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of PD-1 mRNA by hybridizing to targeted mRNA and preventing protein translation.
- Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA.
- the 5′ coding portion of the polynucleotide sequence which encodes a mature tumor antigen herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length.
- a DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix—see, Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (1991)), thereby preventing transcription and the production of the target polypeptide.
- the antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the target polypeptide (antisense-Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, Fla., 1988).
- oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of the PD-1 polypeptide.
- antisense DNA oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about ⁇ 10 and +10 positions of the target gene nucleotide sequence, are preferred.
- Granulocyte-macrophage colony stimulating factor is a cytokine produced by fibroblasts, endothelial cells, T cells and macrophages. This cytokine has been shown to induce the growth of hematopoetic cells of granulocyte and macrophage lineages. In addition, the cytokine activates the antigen processing and presenting function of dendritic cells, which are the major antigen presenting cells (APC) of the immune system. Results from animal model experiments have convincingly shown that GM-CSF producing tumor cells are able to induce an immune response against parental, non-transduced tumor cells.
- APC antigen presenting cells
- cytokine e.g. GM-CSF
- a cytokine e.g. GM-CSF
- a form of GM-CSF-expressing genetically modified cancer cells or a “cytokine-expressing cellular immunotherapy” for the treatment of pancreatic cancer is described in U.S. Pat. Nos. 6,033,674 and 5,985,290, expressly incorporated by reference herein.
- a universal immunomodulatory cytokine-expressing bystander cell line is described in U.S. Pat. No.
- the present invention provides an improved method of stimulating an immune response to cancer in a mammalian, preferably a human, subject.
- the method effects a systemic immune response, i.e., a T-cell response and/or a B-cell response, to the cancer.
- the method comprises administering to the patient a cytokine-expressing cellular immunotherapy and an antibody that specifically binds to PD-1, wherein the cellular immunotherapy comprises cells which express a cancer antigen or various cancer antigens.
- the cancer antigen/antigens can be one of the antigens of the cancer found in the patient under treatment.
- the cells can be rendered proliferation incompetent, such as e.g., by irradiation.
- an immune response to the cancer can be elicited or enhanced.
- the cytokine expressing cellular immunotherapy comprises a single population of cells that is modified to express a cytokine, e.g. GM-CSF.
- the immunotherapy comprises a single population of cells that is modified to express a cytokine as well as a single chain antibody that specifically binds to PD-1.
- the immunotherapy comprises a combination of two or more populations of cells individually modified to express one component of the immunotherapy, e.g. a cytokine and a single chain anti-PD-1 antibody.
- the cells of the cytokine-expressing cellular immunotherapy are administered to the same individual from whom they were derived (autologous).
- the cells of the cytokine-expressing cellular immunotherapy and the tumor are derived from different individuals (allogeneic or bystander).
- genetically modified GM-CSF expressing tumor cells are provided as an allogeneic or bystander cell line and one or more additional cancer therapeutic agents, e.g.
- an anti-PD-1 antibody is included in the treatment regimen.
- one or more additional transgenes are expressed by an allogeneic or bystander cell line while a cytokine (i.e., GM-CSF) is expressed by autologous or allogeneic cells, and one or more additional cancer therapeutic agents, e.g. an anti-PD-1 antibody, is included in the treatment regimen.
- a cytokine i.e., GM-CSF
- additional cancer therapeutic agents e.g. an anti-PD-1 antibody
- the tumor being treated is selected from the group consisting of cancer of the bladder, breast, colon, kidney, liver, lung, ovary, cervix, pancreas, rectum, prostate, stomach, epidermis, a hematopoetic tumor of lymphoid or myeloid lineage, a tumor of mesenchymal origin such as a fibrosarcoma or rhabdomyosarcoma, melanoma, teratocarcinoma, neuroblastoma, glioma, adenocarcinoma and non-small lung cell carcinoma.
- cancer of the bladder breast, colon, kidney, liver, lung, ovary, cervix, pancreas, rectum, prostate, stomach, epidermis, a hematopoetic tumor of lymphoid or myeloid lineage, a tumor of mesenchymal origin such as a fibrosarcoma or rhabdomyosarcoma, melanoma, ter
- the cytokine expressed by the cytokine-expressing cellular immunotherapy of the invention is GM-CSF.
- the preferred coding sequence for GM-CSF is the genomic sequence described in Huebner K. et al, Science 230(4731): 1282-5, 1985.
- the cDNA form of GM-CSF finds utility in practicing the invention (Cantrell et al., Proc. Natl. Acad. Sci., 82, 6250-6254, 1985).
- the cells of the cytokine-expressing cellular immunotherapy are cryopreserved prior to administration.
- the cells of a cytokine-expressing cellular immunotherapy of the invention are rendered proliferation incompetent. While a number of means of rendering cells proliferation incompetent are known, irradiation is the preferred method.
- the cytokine-expressing cellular immunotherapy combination is irradiated at a dose of from about 50 to about 200 rads/min, even more preferably, from about 120 to about 140 rads/min prior to administration to the patient.
- the cells are irradiated with a total radiation dose sufficient to inhibit growth of substantially 100% of the cells, from further proliferation.
- the cells are irradiated with a total dose of from about 10,000 to 20,000 rads, optimally, with about 15,000 rads.
- cytokine e.g., GM-CSF
- multiple injections may be given at a single time point with the treatment repeated at various time intervals.
- an initial or “priming” treatment may be followed by one or more “booster” treatments.
- Such “priming” and “booster” treatments are typically delivered by the same route of administration and/or at about the same site.
- the first immunization dose may be higher than subsequent immunization doses.
- a 5 ⁇ 10 6 prime dose may be followed by several booster doses of 10 6 to 3 ⁇ 10 6 GM-CSF producing cells.
- a single injection of cytokine-producing cells is typically between about 10 6 to 10 8 cells, e.g., 1 ⁇ 10 6 , 2 ⁇ 10 6 , 3 ⁇ 10 6 , 4 ⁇ 10 6 , 5 ⁇ 10 6 , 6 ⁇ 10 6 , 7 ⁇ 10 6 , 8 ⁇ 10 6 , 9 ⁇ 10 6 , 10 7 , 2 ⁇ 10 7 , 5 ⁇ 10 7 , or as many as 10 8 cells.
- the number of cytokine-producing cells may be adjusted according, for example, to the level of cytokine produced by a given cytokine producing cellular immunotherapy.
- cytokine-expressing cells in a immunotherapy of the invention provides advantages since each patient's tumor expresses a unique set of tumor antigens that can differ from those found on histologically-similar, MHC-matched tumor cells from another patient. See, e.g., Kawakami et al, J. Immunol, 148, 638-643 (1992); Darrow et al., J. Immunol., 142, 3329-3335 (1989); and Horn et al., J. Immunother., 10, 153-164 (1991).
- MHC-matched tumor cells provide the advantage that the patient need not be taken to surgery to obtain a sample of their tumor for immunotherapy production.
- the present invention comprises a method of treating cancer by carrying out the steps of: (a) obtaining tumor cells from a mammal, preferably a human, harboring a tumor; (b) modifying the tumor cells to render them capable of producing a cytokine or an increased level of a cytokine naturally produced by the cells relative to unmodified tumor cells; (c) rendering the modified tumor cells proliferation incompetent; and (d) readministering the modified tumor cells to the mammal from which the tumor cells were obtained or to a mammal with the same MHC type as the mammal from which the tumor cells were obtained, in combination with administration of an anti-PD-1 antibody.
- the administered tumor cells are autologous or MHC-matched to the host.
- the invention provides a method for treating cancer by carrying out the steps of: (a) obtaining a tumor cell line; (b) modifying the tumor cell line to render the cells capable of producing an increased level of a cytokine relative to the unmodified tumor cell line; (c) rendering the modified tumor cell line proliferation incompetent; and (d) administering the tumor cell line to a mammalian host having at least one tumor that is the same type of tumor as that from which the tumor cell line was obtained or wherein the tumor cell line and host tumor express at least one common antigen, in combination with administration of an anti-PD-1 antibody.
- the administered tumor cell line is allogeneic and is not MHC-matched to the host.
- allogeneic lines provide the advantage that they can be prepared in advance, characterized, aliquoted in vials containing known numbers of cytokine-expressing cells and stored such that well-characterized cells are available for administration to the patient.
- Methods for the production of gene-modified allogeneic cells are described for example in International Patent Publication No. WO 00/72686A, expressly incorporated by reference herein.
- cytokine-encoding nucleic acid sequences are introduced into a cell line that is an allogeneic tumor cell line (i.e., derived from an individual other than the individual being treated).
- the tumor cell line may be of the same type as the tumor or cancer being treated.
- the tumor and/or tumor cell line may be from any form of cancer, including, but not limited to, carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, cervix, pancreas, rectum, prostate, stomach, epidermis, a hematopoietic tumor of lymphoid or myeloid lineage, a tumor of mesenchymal origin such as a fibrosarcoma or rhabdomyosarcoma, melanoma, teratocarcinoma, neuroblastoma, glioma, adenocarcinoma, and non-small lung cell carcinoma.
- carcinoma of the bladder breast, colon, kidney, liver, lung, ovary, cervix, pancreas, rectum, prostate, stomach, epidermis, a hematopoietic tumor of lymphoid or myeloid lineage, a tumor of mesenchymal origin such as a fibrosarcoma or rhabdomy
- the allogeneic cell line expresses GM-CSF in a range from 200-1000 ng/10 6 cells/24 h.
- the universal bystander cell line expresses at least about 200 ng GM-CSF/10 6 cells/24 hours.
- one or more allogeneic cell lines can be incubated with an autologous cancer antigen, e.g., an autologous tumor cell (which together comprise an allogeneic cell line composition), then the allogeneic cell line composition can be administered to the patient.
- an autologous cancer antigen e.g., an autologous tumor cell (which together comprise an allogeneic cell line composition)
- the cancer antigen can be provided by (on) a cell of the cancer to be treated, i.e., an autologous cancer cell.
- the composition can be rendered proliferation-incompetent by irradiation, wherein the allogeneic cells and cancer cells are plated in a tissue culture plate and irradiated at room temperature using a Cs source, as detailed above.
- the ratio of allogeneic cells to autologous cancer cells in a given administration will vary dependent upon the combination.
- any suitable route of administration can be used to introduce an allogeneic cell line composition into the patient.
- the composition is administered subcutaneously or intratumorally.
- allogeneic cell lines in practicing the present invention enables administration of a cytokine-expressing allogeneic cell line to a patient with cancer, together with an autologous cancer antigen.
- This treatment can result in an effective immune response to a tumor.
- This approach advantageously obviates the need to culture and transduce autologous tumor cells for each patient, eliminating the problem of variable and inefficient transduction efficiencies.
- the present invention provides a universal immunomodulatory cytokine-expressing bystander cell line and an anti-PD-1 antibody.
- the universal bystander cell line comprises cells which either naturally lack major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens or have been modified so that they lack MHC-I antigens and MHC-II antigens.
- a universal bystander cell line is modified by introduction of a vector comprising a nucleic acid sequence encoding a cytokine operably linked to a promoter and expression control sequences necessary for expression thereof.
- the nucleic acid sequence encoding the cytokine may or may not further comprise a selectable marker sequence operably linked to a promoter.
- the universal bystander cell line preferably grows in defined, e.g., serum-free, medium, preferably as a suspension.
- the universal bystander cell line expresses the cytokine, e.g., GM-CSF in the range from 200-1000 ng/10 6 cells/24 h.
- the universal bystander cell line expresses at least about 200 ng GM-CSF/10 6 cells/24 hours.
- the universal bystander cell lines can be incubated with an autologous cancer antigen, e.g., an autologous tumor cell (which together comprise a universal bystander cell line composition), then the universal bystander cell line composition can be administered to the patient.
- an autologous cancer antigen e.g., an autologous tumor cell (which together comprise a universal bystander cell line composition)
- the universal bystander cell line composition can be administered to the patient.
- Any suitable route of administration can be used to introduce a universal bystander cell line composition into the patient.
- the composition is administered subcutaneously or intratumorally.
- the cancer antigen can be provided by (on) a cell of the cancer to be treated, i.e., an autologous cancer cell.
- the composition can be rendered proliferation-incompetent by irradiation, wherein the bystander cells and cancer cells are plated in a tissue culture plate and irradiated at room temperature using a Cs source, as detailed above.
- the ratio of bystander cells to autologous cancer cells in a given administration will vary dependent upon the combination. With respect to GM-CSF-producing bystander cells, the ratio of bystander cells to autologous cancer cells in a given administration should be such that at least 36 ng GM-CSF/10 6 cells/24 hrs is produced, as the therapeutic effect may be decreased if the concentration of GM-CSF is less than this. In addition to the GM-CSF threshold, the ratio of bystander cells to autologous cancer cells should not be greater than 1:1. Appropriate ratios of bystander cells to tumor cells or tumor antigens can be determined using routine methods in the art.
- bystander cell lines in practicing the present invention enables administration of a cytokine-expressing bystander cell line to a patient with cancer, together with an autologous cancer antigen.
- This treatment can result in an effective immune response to a tumor.
- This approach advantageously obviates the need to culture and transduce autologous tumor cells for each patient, eliminating the problem of variable and inefficient transduction efficiencies.
- the efficacy of a cytokine-expressing cellular immunotherapy co-administered with an anti-PD-1 antibody can be evaluated by carrying out animal studies in the syngeneic B16F10 melanoma tumor model in the treatment setting. See, e.g., Griswold D P Jr., Cancer Chemother Rep 2; 3(1):315-24, 1972 and Berkelhammer J et al, Cancer Res 42(8):3157-63, 1982.
- the murine melanoma cell line B16 is a well-defined cell line which is weakly immunogenic in syngeneic C57B16 mice and therefore readily forms tumors in C57BL6 mice.
- tumor associated antigens have been identified in this model which allow one to monitor tumor specific as well as antigen specific immune responses.
- murine-specific reagents are commercially available and are used to monitor anti-tumor immune responses in the various immunotherapy strategies.
- a typical study in the B16F10 melanoma tumor model makes use of at least 6 and generally 10-15 mice per group in order to obtain statistically significant results. Statistical significance can be evaluated using the Student's t-test.
- Vaccination of C57BL/6 mice with irradiated GM-CSF-secreting B16F10 tumor cells stimulates potent, long-lasting and specific anti-tumor immunity that prevents tumor growth in most mice subsequently challenged with wild-type B16F10 cells.
- this protection is less effective when GM-CSF-producing tumor cell immunotherapies are administered to mice with preexisting tumor burden.
- female C57BL/6 mice are obtained from Taconic and are 6-8 weeks old at the start of each experiment.
- mice are injected with 1-2 ⁇ 10 5 B16BF10 cells on day 0 subcutaneously in a dorsal/anterior location.
- mice are vaccinated in a ventral/posterior location with 1-3 ⁇ 10 6 irradiated (10,000 rads) B16F10 or cytokine-expressing cellular immunotherapy. Mice are followed for tumor development and survival. After 14-21 days, mice are sacrificed and their tumor burden assessed by harvesting the mice lungs and counting the surface tumor metastasis and measuring the weight of the lung.
- An alternative B16F10 melanoma tumor model involves subcutaneous injection of B16F10 tumor cells.
- HBSS only negative control
- cytokine-expressing cellular immunotherapy/HBSS cellular monotherapy control
- anti-PD-1 antibody antibody only control
- cytokine-expressing cellular immunotherapy plus anti-PD-1 antibody cytokine-expressing cellular immunotherapy plus anti-PD-1 antibody.
- GM-CSF-expressing cellular immunotherapies alone were shown to protect from 10-20% of the challenged mice.
- the combination of a cytokine-expressing cellular immunotherapy plus an anti-PD-1 antibody is expected to increase the efficacy of anti-tumor protection.
- the degree of protection depends on several factors, such as the expression level of the cytokine-expressing cellular immunotherapy, the dosage and dosing frequency of the anti-PD-1 antibody, and the relative timing of administration of the anti-PD-1 antibody relative to the timing of administration of the cytokine-expressing cellular immunotherapy.
- tumor antigen-specific T cells can be identified by the release of IFN-gamma following antigenic restimulation in vitro (Hu, H-M. et al, Cancer Research, 2002, 62; 3914-3919) ( FIGS. 2C , 3 B).
- FIGS. 2C , 3 B Yet another example of new methods used to identify tumor antigen-specific T cells is the development of soluble MHC I molecules also known as MHC tetramers (Beckman Coulter, Immunomics), reported to be loaded with specific peptides shown to be involved in an anti-tumor immune response. ( FIG. 2A ).
- Tetramer staining may be used to monitor tumor-specific T-cell responses and to identify very low frequencies of antigen-specific T-cells. Because tetramer staining is performed on freshly isolated lymphocytes within several hours of removal, and without further in vitro stimulation, the technique can be used to estimate the frequency of tumor antigen-specific T-cells in vivo. This provides a means to compare the potency of different tumor immunotherapy strategies.
- Examples within the B16F10 melanoma tumor model include but are not limited to gp100, Trp2, Trp-1, and tyrosinase. Similar melanoma-associated antigens have been identified in humans. Such tools provide information that can then be translated into the clinical arena.
- Tumor burden can be assessed at various time points after tumor challenge using techniques well known in the art.
- Assays for monitoring anti-tumor response and determining the efficacy of combination immunotherapy are described below. While an improved or enhanced anti-tumor immune response may be most dramatically observed shortly following administration of the immunotherapy, e.g. within 5-10 days, the response may be delayed in some instances, depending on factors such as the expression level of the cytokine-expressing cellular immunotherapy, the dosage and dosing frequency of the anti-PD-1 antibody, and the relative timing of administration of the anti-PD-1 antibody relative to the timing of administration of the cytokine-expressing cellular immunotherapy. Thus, the following assays may be performed on biological samples harvested at much later time points than is indicated below in order to fully assess the anti-tumor response following immunotherapy.
- Cytotoxic T lymphocyte (CTL) activity may be determined both in vitro and in vivo.
- spleen cells are assessed for CTL activity by in vitro whole cell stimulation for 5 days.
- Target cells are labeled with 51 Cr and co-incubated with splenic effector CTL, and release of 51 Cr into the supernatants is an indicator of CTL lysis of target cells.
- in vitro stimulated CTL supernatants are tested for IFN-gamma production by CTL.
- wells are coated with coating antibody specific for IFN-gamma, supernatant is then added to wells, and IFN-gamma is detected using an IFN-gamma specific detecting antibody.
- IFN-gamma can also be detected by flow cytometry, in order to measure cell-specific IFN-gamma production.
- CTL activity may be assessed-via carboxyfluoroscein diacetate succinimidyl ester (CSFE) labeling of syngeneic splenocytes.
- CSFE carboxyfluoroscein diacetate succinimidyl ester
- mice An equal number of cells from each population are mixed together and injected into mice immunized with cytokine expressing tumor cell immunotherapy alone, or in combination with anti-PD-1 antibody. 18 hours following injection, splenocytes are harvested and cell suspensions are analyzed by flow cytometry, and cell populations are distinguished based on varying fluorescent intensities. Percent specific lysis is determined by the loss of the peptide-pulsed CSFE hi population compared to the control CSFE lo population. ( FIG. 2B ).
- Another indication of an effective anti-tumor immune response is the production of effector cytokines such as TNF-alpha, IFN-gamma, IL-5, IL-6, IL-10 and monocyte chemotactic protein (MCP)-1 upon restimulation in vitro. Cytokine levels were measured in supernatants from spleen cells restimulated in vitro for 48 hours with irradiated GM-CSF-expressing cells. ( FIG. 3 )
- ICS intracellular cytokine staining
- ICS can be used to monitor tumor-specific T-cell responses and to identify very low frequencies of antigen-specific T-cells. Because ICS is performed on freshly isolated lymphocytes within 5 hours of removal, unlike the CTL and cytokine release assays, which often require 2-7 days of in vitro stimulation, it can be used to estimate the frequency of tumor antigen-specific T-cells in vivo. This provides a powerful technique to compare the potency of different tumor immunotherapy strategies. ICS has been used to monitor T-cell responses to melanoma-associated antigens such as gp 100 and Trp2 following various melanoma immunotherapy strategies. Such T-cells can be identified by the induction of intracellular IFN-gamma expression following stimulation with a tumor-specific peptide bound to MHC I.
- mice in vivo luminescence of tumor bearing mice is monitored by monitoring of B16F10-luciferase (Xenogen Inc.) injected mice.
- B16F10-luciferase Xenogen Inc.
- Balb/c nu/nu mice are injected with 5 ⁇ 10 4 or 2 ⁇ 10 5 cells of B16F10-luc cells via tail vein on day 0.
- Mice are monitored for tumor burden when necessary by intra-peritoneal injection of excess luciferin substrate at 1.5 mg/g mice weight.
- twenty minutes after substrate injection mice are anesthesized and monitored for in vivo luminescence with Xenogen IVIS Imaging System (Xenogen Inc.) luminescence sensitive CCD camera by dorsal or ventral position. Data is collected and analyzed by Living Image 2.11 software.
- GM-CSF-secreting tumor cell immunotherapy provides partial protection of mice when used as a monotherapy for non-immunogenic tumors such as B16 melanoma.
- the results presented herein demonstrate that the combination of GM-CSF-secreting B16 tumor cells and an anti-PD-1 antibody can act synergistically, resulting in highly protective antitumor immune responses.
- possible treatment regimens should be carefully evaluated in preclinical studies.
- GM-CSF-secreting tumor cell immunotherapies or anti-PD-1 antibodies are administered to patients repeatedly over a period of several months.
- Example 4 details studies where a cytokine expressing cellular immunotherapy was tested in both a B16F10 and CT26 tumor model with and without co-administration of an anti-PD-1 antibody.
- the GM-CSF-secreting tumor cell immunotherapy was less effective than the combination therapy of anti-PD-1 antibody and GM-CSF-secreting tumor cell immunotherapies ( FIGS. 4 , 5 ).
- an autologous, allogeneic, or bystander cytokine-expressing cellular immunotherapy may be administered to a cancer patient in combination with an anti-PD-1 antibody, resulting in enhanced therapeutic efficacy and prolonged survival relative to either monotherapy alone.
- a cytokine-expressing cellular immunotherapy is administered in combination with an anti-PD-1 antibody to a cancer patient, wherein the cytokine-expressing cellular immunotherapy comprises mammalian, preferably human tumor cells, and the cells in the cytokine-expressing cellular immunotherapy are rendered proliferation incompetent, such as by irradiation.
- Administration of a cytokine-expressing cellular immunotherapy in combination with an anti-PD-1 antibody results in an enhanced immune response to the cancer as compared to the immune response to the same cancer following administration of the cytokine-expressing cellular immunotherapy or anti-PD-1 antibody alone.
- the cytokine-expressing cellular immunotherapy combination may be administered by any suitable route.
- the composition is administered subcutaneously or intratumorally.
- Local or systemic delivery can be accomplished by administration comprising administration of the combination into body cavities, by parenteral introduction, comprising intramuscular, intravenous, intraportal, intrahepatic, peritoneal, subcutaneous, or intradermal administration.
- the composition is administered in the periphery to prime naive T-cells in the draining lymph nodes.
- the activated tumor-specific T-cells are able to cross the blood/brain barrier to find their targets within the central nervous system.
- the cells of the cytokine-expressing cellular immunotherapy and the anti-PD-1 antibody can be administered at essentially the same time, i.e., concurrently, e.g. within the same hour or same day, etc., or at separately staggered times, i.e. sequentially prior to or subsequent to the administration of the second agent of the combination immunotherapy, e.g. on separate days, weeks, etc.
- the instant methods are therefore to be understood to include all such regimes of simultaneous or non-simultaneous treatment.
- the cells of the cytokine-expressing cellular immunotherapy are administered within 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or more than 18 hours of administration of the anti-PD-1 antibody. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more than 14 days of administration of the anti-PD-1 antibody. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered within 1, 2, 3, 4, 5 or more than 5 weeks of administration of the anti-PD-1 antibody.
- the cells of the cytokine-expressing cellular immunotherapy are administered simultaneously with administration of the anti-PD-1 antibody, for example, with the first administration of the combination therapy and with subsequent administrations of the combination therapy.
- the cells of the cytokine-expressing cellular immunotherapy are administered simultaneously with the first administration of the anti-PD-1 antibody, and the cells of the cytokine-expressing cellular immunotherapy are administered simultaneously with administration of the anti-PD-1 antibody on a biweekly basis thereafter.
- the cells of the cytokine-expressing cellular immunotherapy are administered within 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours of administration of the anti-PD-1 antibody, and the cells of the cytokine-expressing cellular immunotherapy are administered within 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours of administration of the anti-PD-1 antibody, on a biweekly basis thereafter.
- cells of the cytokine-expressing cellular immunotherapy are administered prior to administration of the anti-PD-1 antibody. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered one, two, three, four, five, six, seven, or more days prior to administration of the anti-PD-1 antibody. In other embodiments, cells of the cytokine-expressing cellular immunotherapy are administered after administration of the anti-PD-1 antibody. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered one, two, three, four, five, six, seven, or more days after administration of the anti-PD-1 antibody.
- the optimal treatment regimen will vary. As a result, it will be understood that the status of the cancer patient and the general health of the patient prior to, during, and following administration of a cytokine-expressing cellular immunotherapy in combination with an anti-PD-1 antibody, the patient will be evaluated in order to determine if the dose of each component and relative timing of administration should be optimized to enhance efficacy or additional cycles of administration are indicated. Such evaluation is typically carried out using tests employed by those of skill in the art to evaluate traditional cancer chemotherapy, as further described below in the section entitled “Monitoring Treatment.”
- the therapeutic outcome can be assessed by monitoring attenuation of tumor growth and/or tumor regression and or the level of tumor specific markers.
- the attenuation of tumor growth or tumor regression in response to treatment can be monitored using one or more of several end-points known to those skilled in the art including, for instance, number of tumors, tumor mass or size, or reduction/prevention of metastasis.
- the combination immunotherapy composition can be included in a kit, container, pack, or dispenser together with instructions for administration.
- the composition When the composition is supplied as a kit, the different components of the composition may be packaged in separate containers so as to permit long-term storage without losing the active components' functions.
- the reagents included in the kits can be supplied in containers of any sort such that the life of the different components are preserved, and are not adsorbed or altered by the materials of the container.
- cytokine-expressing cells may be housed in containers such as test tubes, vials, flasks, bottles, syringes, or the like. Sealed glass ampules may be used to contain lyophilized anti-PD-1 antibody that has been packaged under a neutral, non-reacting gas, such as nitrogen.
- Ampoules may consist of any suitable material, such as glass, organic polymers, such as polycarbonate, polystyrene, etc., ceramic, metal or any other material typically employed to hold reagents.
- suitable containers include simple bottles that may be fabricated from similar substances as ampules, and envelopes, that may consist of foil-lined interiors, such as aluminum or an alloy.
- Containers may have a sterile access port, such as a bottle having a stopper that can be pierced by a hypodermic injection needle.
- Other containers may have two compartments that are separated by a readily removable membrane that upon removal permits the components to mix. Removable membranes may be glass, plastic, rubber, etc.
- Kits may also be supplied with instructional materials. Instructions may be printed on paper or other substrate, and/or may be supplied as an electronic-readable medium, such as a floppy disc, CD-ROM, DVD-ROM, Zip disc, videotape, audio tape, etc. Detailed instructions may not be physically associated with the kit; instead, a user may be directed to an internet web site specified by the manufacturer or distributor of the kit, or supplied as electronic mail.
- Immune responses were measured as increases in tumor antigen-specific T-cells.
- T-cells can be identified by immunological monitoring methods, as described above, including (A) tetramer staining, (B) in vivo CTL activity, and (C) the induction of intracellular IFN-gamma expression following stimulation with a tumor-specific peptide or tumor cells.
- FIG. 1A illustrates the anti-tumor T-cell response induced by administration of GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody, as determined by tetramer staining.
- GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody, as determined by tetramer staining.
- 1 ⁇ 10 6 OT-1 transgenic T-cells were adoptively transferred into tumor-bearing C57BL/6 mice which were challenged on day ⁇ 1 with 2 ⁇ 10 5 live B16 cells transduced with the surrogate antigen, ovalbumin (F10.ova).
- mice were immunized with 1 ⁇ 10 6 irradiated GM-CSF-secreting B16 cells expressing ovalbumin as a surrogate antigen (GM.ova) as immunotherapy alone, or immunotherapy was followed by 200 ⁇ g and 100 ⁇ g of anti-PD-1 antibody on days 3 and 4, respectively, as combination therapy.
- draining lymph nodes top panel
- spleens bottom panel
- Immunization with GM.ova plus anti-PD-1 antibody resulted in an increase in the number of antigen specific T-cells in both draining lymph nodes (DLN) and spleen compared to immunization with GM.ova immunotherapy alone. This increase was observed starting at 7 days post immunotherapy and was sustained out to 20 days.
- FIG. 1B illustrates the in vivo cytolytic activity of T-cells in mice treated with GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody.
- mice were inoculated with 2 ⁇ 10 5 live B16F10 cells transduced with the surrogate antigen, ovalbumin (F10.ova).
- mice were immunized with 1 ⁇ 10 6 irradiated GM-CSF-secreting F10.ova cells (GM.ova) as immunotherapy alone, or immunotherapy was followed by 200 ⁇ g and 100 ⁇ g of anti-PD-1 antibody on days 3 and 4, respectively, as combination therapy.
- FIG. 1C illustrates the anti-tumor T-cell response induced by administration of GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody, measured as an increase in IFN ⁇ -secretion.
- mice were inoculated subcutaneously with live B16F10 cells.
- 1 ⁇ 10 6 irradiated GM-CSF-secreting B16F10 cells (B16.Kd.GM) were injected as immunotherapy alone, or immunotherapy was followed by 200 ⁇ g and 100 ⁇ g of anti-PD-1 antibody on days 3 and 4, respectively, as combination therapy.
- the number of IFN ⁇ -secreting cells was significantly higher in splenocytes from mice receiving combination immunotherapy compared to those receiving CM-CSF expressing tumor cell immunotherapy alone (B16.Kd.GM) following stimulation either trp2 or irradiated B16F10 cells.
- anti-PD-1 antibody augments the anti-tumor T-cell response induced by GM-CSF expressing tumor cell immunotherapy, and support the utility of GM-CSF-secreting tumor cell and anti-PD-1 antibody combination immunotherapy for the induction and/or enhancement of anti-tumor immunity.
- a further suggestion as to the potential utility of the combination of GM-CSF-secreting immunotherapies and anti-PD-1 antibody in eliciting an anti-tumor immune response is the production of pro-inflammatory cytokines such as TNF-alpha, IFN-gamma, IL-2, IL-5, IL-6, IL-10 and MCP-1 upon restimulation in vitro. Release of such cytokines is often used as a surrogate marker for monitoring tumor-specific immune responses following immunotherapeutic strategies designed to induce anti-tumor immunity.
- FIG. 2 illustrates the secretion of pro-inflammatory cytokines following administration of GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody.
- mice were inoculated subcutaneously with live B16F10 cells.
- mice were immunized with 1 ⁇ 10 6 irradiated GM-CSF-secreting B16F10 cells (B16.Kd.GM) as immunotherapy alone, or immunotherapy was followed by 200 ⁇ g and 100 ⁇ g of anti-PD-1 antibody on days 3 and 4, respectively, as combination therapy.
- splenocytes from selected mice were cultured with irradiated B16 cells for 48 hrs in 96 well plates.
- cytokines (A) tumor necrosis factor-alpha (TNF ⁇ ), (B) interferon-gamma (IFN ⁇ ), (C) interleukin-5 (IL-5), (D) interleukin-6 (IL-6), (E) interleukin-10 (IL-10), and (F) monocyte chemotactic protein (MCP)-1.
- TNF ⁇ tumor necrosis factor-alpha
- IFN ⁇ interferon-gamma
- C interleukin-5
- IL-6 interleukin-6
- E interleukin-10
- MCP monocyte chemotactic protein
- FIG. 3 illustrates effector CD8 T-cell infiltration into tumors in mice treated with GM-CSF-secreting B16F10 cells alone or in combination with an anti-PD-1 antibody.
- TIL tumor infiltrating lymphocytes
- FIG. 3 shows the percentage of IFN ⁇ and CD107 ⁇ expressing cells in the CD8 tumor infiltrating lymphocyte (TIL) subpopulation from mice immunized with (A) GM-CSF expressing tumor cell immunotherapy alone, and GM-CSF expressing tumor cell immunotherapy alone plus anti-PD-1 antibody.
- TIL tumor infiltrating lymphocyte
- CD8+/FoxP3+ cells in the tumor at 3 wks post cellular immunotherapy (B). Also shown are the kinetics of (C) CD4 + T-cells, (D) CD8 + T-cells, (E) CD8 + and CD107 ⁇ + T-cells, and (F) CD8 + and IFN ⁇ + T-cells per 1 ⁇ 10 6 tumor cells. Tumor progression for these animals is shown in (G).
- CD4/IFN- ⁇ co-staining was used to identify effector CD4 T-cells and CD8/1FN- ⁇ or CD8/CD107a co-staining was used to identify effector CD8 T-cells within tumors.
- IFN-Y secreted by T-cells has previously been shown to correlate with immunoregulatory and anti-tumor properties (Schroder et al., J. Leukoc. Biol. 75(2):163-89 (2004), while expression of CD107a is associated with cytolytic activity of T-cells (Betts et al. J. Immunol. Methods 281(1-2):65-78, (2003); and Rubio et al., Nat Med. 9(11):1377-82 (2003)).
- mice receiving the combination therapy showed an increased in the percentage of activated CD8 effector T-cells within tumors compared to animals that received B16. Kd.GM monotherapy ( FIG. 3A ). Furthermore, HBSS control animals had minimal CD4 and CD8 T-cell infiltration into tumors, correlating with tumor progression of these animals ( FIGS. 3C-D and 3 G). Comparatively, animals treated with B16.Kd.GM monotherapy displayed gradual infiltration of T-cells into the tumor environment with peak infiltration seen on day 14, which correlated with the delay in tumor growth observed in this group (*p ⁇ 0.05 HBSS vs. B16.Kd.GM for all time points).
- mice were inoculated subcutaneously with 2 ⁇ 10 5 live tumor cells on day 0. Mice were then injected with 1 ⁇ 10 6 irradiated GM-CSF-secreting B16F10 cells (B16.Kd.GM) as immunotherapy alone, or as combination therapy with 200 ⁇ g of anti-PD-1, followed by 100 ⁇ g of anti-PD-1 on the following day. Therapy was started at 3 days, 7 days and 11 days following inoculation to assess the effect of delayed administration on efficacy. Mice were monitored for the formation of palpable tumors twice weekly.
- B16.Kd.GM irradiated GM-CSF-secreting B16F10 cells
- mice were assessed daily for any obvious abnormality, and if subcutaneous tumors reached 15-20 mm-diameter in size or started to ulcerate through the skin, animals were euthanized. A Kaplan-Meier survival curve was used for evaluation. Survival curves are shown for mice treated with immunotherapy at 3 days ( FIG. 4A ), 7 days ( FIG. 4B ), or 11 days ( FIG. 4C ) post inoculation.
- mice treated with the combination therapy were significantly enhanced in mice treated with the combination therapy compared to immunotherapy alone.
- MST was further prolonged to 57 days in animals that were treated with the combination therapy on day 3 with 50% long-term survival (*p ⁇ 0.05 B16.Kd.GM+anti-PD-1 vs. B16.Kd.GM) ( FIG. 4A ).
- mice were inoculated subcutaneously with 2 ⁇ 10 5 live tumor cells on day 0. On day 3, mice were then injected with er 1 ⁇ 10 6 irradiated GM-CSF-secreting CT26 cells (CT26.GM) as immunotherapy alone or as combination therapy with 200 ⁇ g of anti-PD-1, followed by 100 ⁇ g of anti-PD-1 on day 4.
- CT26.GM GM-CSF-secreting CT26 cells
- Anti-PD-1 antibody alone was also administered as a control, at 200 ⁇ g on day 3 post challenge followed by 100 ⁇ g anti-PD-1 on day 4.
- anti-PD-1 antibody and CT26.GM monotherapies both prolonged the survival of tumor bearing animals to 25 days compared to HBSS-injected control animals with a MST of 18 days. Consistent with the findings in the B16 model, CT26 tumor-bearing animals treated with the combination therapy showed a significant survival advantage over animals treated with either monotherapy, with 90% of animals surviving long-term (*p ⁇ 0.01 compared to CT26.GM alone).
- anti-PD-1 antibody in combination with GM-CSF-secreting tumor cell immunotherapy significantly prolonged the survival of animals bearing either a non-immunogenic or an immunogenic tumor when compared to either monotherapy.
- FIG. 6 illustrates the enhancement of the percentage of CD8 + T-cells in spleen from mice treated with GM-CSF-secreting B16F10 cells alone or in combination with an anti-PD-1 antibody.
- mice were inoculated subcutaneously with live B16F10 cells.
- 1 ⁇ 10 6 irradiated GM-CSF-secreting B16F10 cells (B16.Kd.GM) were injected as immunotherapy alone, or with 200 ⁇ g and 100 ⁇ g of anti-PD-1 antibody on days 3 and 4, respectively, as combination therapy.
- spleens from mice were excised, digested and stained, and splenocytes were evaluated by flow cytometry.
- the percentage of CD8 positive T-cells are enhanced in B16.Kd.GM+anti-PD1 treated mice.
- FIG. 7 illustrates the percentage of memory T-cells in spleen from mice treated with GM-CSF-secreting B16F10 cells alone or in combination with an anti-PD-1 antibody.
- mice were inoculated subcutaneously with live B16F10 cells.
- 1 ⁇ 10 6 irradiated GM-CSF-secreting B16F10 cells (B16.Kd.GM) were injected as immunotherapy alone, or with 200 ⁇ g and 100 ⁇ g of anti-PD-1 antibody on days 3 and 4, respectively, as combination therapy.
- spleens from mice were excised, digested and stained, and splenocytes were evaluated by flow cytometry.
- the percentage of memory T-cells was assessed by staining cells with for surface markers CD69 and Ly6C.
- Ly6C has been described as a marker for memory CD8 + T cells (Walumas et al., J. Immunol. 155:1973-1883 (1995) while CD69 is a marker for early T-cell activation.
- Memory T-cells were designated as the population of cells that were Ly6C+/CD69 ⁇ within CD4 and CD8 positive cells.
- FIG. 7 shows the percentage of Ly6C + /CD69 ⁇ cells within (A) the CD4 subpopulation; and (B) the CD8 subpopulation.
- the percentage of memory T-cells is significantly enhanced in spleens from mice treated with the B16.Kd.GM+anti-PD1 combination therapy compared to B16.Kd.GM immunotherapy alone.
- mice On day 0, 1 ⁇ 10 6 OT-1 transgenic T-cells were adoptively transferred into C57BL/6 mice. The following day, mice were intravenously injected with 500 mg of SIINFEKL peptide to induce anergy in OT-1 cells. After establishing anergy, on day 11, mice were immunized with 1 ⁇ 10 6 irradiated GM-CSF-secreting B16 cells expressing ovalbumin as a surrogate antigen (GM.ova) as immunotherapy alone or immunotherapy was followed by 200 mg and 100 mg of anti-PD-1 antibody on days 11 and 12, respectively, as combination therapy. At indicated timepoints, peripheral blood leukocyte (PBL) from mice were drawn and evaluated for the percentage of antigen-specific T-cells by tetramer staining.
- PBL peripheral blood leukocyte
- FIG. 8 illustrates an increase in the percentage of antigen-specific T-cells was induced by immunotherapy with both GM.ova and GM.ova plus anti-PD-1 antibody (16 days following adoptive transfer) following the establishment of anergy with SIINFEKL peptide.
- the percentage of antigen-specific T-cells was nearly 2-fold higher at day 16 in GM.ova plus anti-PD-1 antibody treated mice compared to mice treated with GM.ova alone.
- mice received GM.ova immunotherapy and anti-PD-1 antibody at the first therapy cycle.
- OT-1 cells transgenic T-cells
- mice were immunized with 1 ⁇ 10 6 irradiated GM-CSF-secreting B16 cells expressing ovalbumin (GM.ova) as immunotherapy alone or GM.ova immunotherapy was followed by 200 ⁇ g and 100 ⁇ g of anti-PD-1 antibody on days 3 and 4, respectively (the first therapy cycle).
- one group of animals received bi-weekly GM-ova and anti-PD-1 antibody, and another group received bi-weekly anti-PD-1 antibody with GM-ova administered with every other anti-PD-1 treatment (monthly).
- splenocytes from selected animals were isolated and evaluated for the presence of ovalbumin-specific CD8+ T-cells by co-staining the cells with anti-CD8 antibody and the SIINFEKL tetramer.
- the study showed the expansion and contraction of the population of ovalbumin-specific CD8 T-cells in the spleen after each treatment cycle ( FIG. 9A ) and that ovalbumin-specific CD8 T-cells expanded and peaked 7 days after each therapy cycle in animals that received the cellular immunotherapy and the PD-1 blockade concurrently.
- the peak of ovalbumin-specific CD8 T-cell expansion from the second immunotherapy cycle was observed 2 weeks later (day 28).
- the data showed that the combination therapy most efficiently expanded the number of IFN ⁇ -secreting ovalbumin-specific CD8 T-cells (21.92+/ ⁇ 3.31 ⁇ 10 6 cells) and that cellular immunotherapy alone (13.57+/ ⁇ 1.95 ⁇ 106 cells) is more effective than anti-PD-1 antibody alone (6.11+/ ⁇ 1.20 ⁇ 106 cells).
- these data suggested that readministration of the cellular immunotherapy with the anti-PD-1 antibody in subsequent immunotherapy cycles was required to reactivate these T-cell responses.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- This application claims benefit of priority of U.S. provisional application No. 60/961,743, filed on Jul. 23, 2007, the contents of which are hereby incorporated by reference in their entireties.
- The present invention relates to methods and compositions for enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising an antibody that specifically binds to human Programmed Death 1 (PD-1) and a cytokine-secreting cell, and methods of administering the combination for enhanced generation of an immune response to tumor cells in a patient.
- The immune system plays a critical role in the pathogenesis of a wide variety of cancers. When cancers progress, it is widely believed that the immune system either fails to respond sufficiently or fails to respond appropriately, allowing cancer cells to grow. Currently, standard medical treatments for cancer, including chemotherapy, surgery, radiation therapy and cellular therapy, have clear limitations with regard to both efficacy and toxicity. To date, these approaches have met with varying degrees of success dependent upon the type of cancer, general health of the patient, stage of disease at the time of diagnosis, etc. Improved strategies that combine specific manipulation of the immune response to cancer in combination with standard medical treatments may provide a means for enhanced efficacy and decreased toxicity.
- The use of autologous cancer cells as immunotherapies to augment anti-tumor immunity has been explored for some time (Oettgen et al., “The History of Cancer Immunotherapy”, In: Biologic Therapy of Cancer, Devita et al. (eds.) J. Lippincot Co., pp 87-199, 1991). However, due to the weak immunogenicity of many cancers, down regulation of MHC molecules, the lack of adequate costimulatory molecule expression and secretion of immunoinhibitory cytokines by cancer cells, the response to such immunotherapies has not resulted in long term efficacy. See, e.g., Armstrong T D and Jaffee E M, Surg Oncol Clin N Am. 11(3):681-96, 2002 and Bodey B et al. Anticancer Res 20(4):2665-76, 2000.
- Numerous cytokines have been shown to play a role in regulation of the immune response to tumors. For example, U.S. Pat. No. 5,098,702 describes using combinations of TNF, IL-2 and IFN-beta in synergistically effective amounts to combat existing tumors. U.S. Pat. Nos. 5,078,996, 5,637,483 and 5,904,920 describe the use of GM-CSF for treatment of tumors. However, direct administration of cytokines for cancer therapy may not be practical, as they are often systemically toxic. (See, for example, Asher et al., J. Immunol. 146: 3227-3234, 1991 and Havell et al, J. Exp. Med. 167: 1067-1085, 1988.)
- An expansion of this approach involves the use of genetically modified tumor cells which express cytokines locally at the immunotherapy site. Activity has been demonstrated in tumor models using a variety of immunomodulatory cytokines, including IL-4, IL-2, TNF-alpha, G-CSF, IL-7, IL-6 and GM-CSF, as described in Golumbeck P T et al., Science 254:13-716, 1991; Gansbacher B et al, J. Exp. Med. 172:1217-1224, 1990; Fearon E R et al. Cell 60:397-403, 1990; Gansbacher B et al. Cancer Res. 50:7820-25, 1990; Teng M et al, PNAS 88:3535-3539, 1991; Columbo M P et al, J. Exp. Med. 174:1291-1298, 1991; Aoki et al., Proc Natl Acad Sci USA. 89(9):3850-4, 1992; Porgador A, et al., Nat Immun. 13(2-3): 113-30, 1994; Dranoff G et al., PNAS 90:3539-3543, 1993; Lee C T et al, Human Gene Therapy 8:187-193, 1997; Nagai E et al, Cancer Immunol. Immonther. 47:2-80, 1998 and Chang A et al., Human Gene Therapy 11:839-850, 2000, respectively.
- Clinical trials employing GM-CSF-expressing autologous or allogeneic cellular immunotherapies have commenced for treatment of prostate cancer, melanoma, lung cancer, pancreatic cancer, renal cancer, and multiple myeloma (Dummer R., Curr Opin Investig Drugs 2(6):844-8, 2001; Simons J et al, Cancer Res. 15; 59(20):5160-8, 1999; Soiffer R et al., PNAS 95:13141-13146, 1998; Simons J et al., Cancer Res. 15; 57:1537-1546, 1997; Jaffee E et al, J. Clin Oncol. 19:145-156, 2001; and Salgia R et al, J. Clin Oncol. 21:624-630, 2003).
- In yet another approach, autologous tumor cells were genetically altered to produce a costimulatory molecule, such as B7-1 or allogeneic histocompatibility antigens (Salvadori et al. Hum. Gene Ther. 6:1299-1306, 1995 and Plaksin et al. Int. J. Cancer 59:796-801, 1994). While the use of genetically modified tumor cells has met with success in treatment of some forms of cancer, there remains a need for improved treatment regimens with greater potency and/or efficacy and fewer side effects than the therapies currently in use.
- The invention provides improved compositions and methods for the treatment of cancer in a mammal, typically a human, by administering a combination of a cytokine-expressing cellular immunotherapy and an antibody that specifically binds to human Programmed Death (PD)-1.
- In one aspect of the invention, the cytokine-expressing cellular immunotherapy expresses GM-CSF.
- In another aspect of the invention, the cytokine-expressing cellular immunotherapy is rendered proliferation-incompetent by irradiation.
- In yet a further aspect of the invention, administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular immunotherapy or the anti-PD-1 antibody alone.
- In yet another aspect of the invention, the cytokine-expressing cellular immunotherapy is typically administered subcutaneously, intratumorally, or intradermally. The injection of irradiated GM-CSF-expressing tumor cells results in a local reaction characterized by the infiltration of dendritic cells (DCs), macrophages, and granulocytes.
- In another aspect of the invention, the anti-PD-1 antibody may be administered prior to, at the same time as, or following administration of the cytokine-expressing cellular immunotherapy component of the combination. The anti-PD-1 antibody may be administered via parenteral, e.g., subcutaneous, intratumoral, intravenous, intradermal, oral, transmucosal, or rectal administration. While not intending to be bound to a particular theory of operation, it is believed that blockade of PD-1 through the administration of an anti-PD-1 antibody potentiates anti-tumor immunity by negatively modulating the immunoinhibitory effects of PD-1 signaling in activated T-cells, B-cells and myeloid cells.
- The invention further provides a combination of cytokine-expressing cells and an anti-PD-1 antibody, wherein the combination comprises cells that are autologous, allogeneic, or bystander cells.
- In another aspect of the invention, the autologous, allogeneic, or bystander cell is rendered proliferation-incompetent by irradiation.
- The invention further provides compositions and kits comprising cytokine-expressing cellular immunotherapy combinations for use according to the description provided herein.
-
FIG. 1A illustrates the anti-tumor T-cell response in an adoptive transfer model in C57BL/6 mice challenged with live B16F10 tumor cells modified to express ovalbumin as a surrogate antigen (B16.ova) and immunized with GM-CSF-secreting B16.ova cells (GM.ova) alone, or in combination with an anti-PD-1 antibody. The number of ovalbumin-specific T-cells in draining lymph-nodes (DLN) (top panel) and spleens (bottom panel) were determined by tetramer staining at 3, 7, 10, 14 and 20 days following immunotherapy. -
FIG. 1B illustrates the cytolytic activity of T-cells in mice challenged with live B16 tumor cells modified to express ovalbumin as a surrogate antigen (B16.ova) and immunized with GM-CSF secreting B16.ova cells (GM.ova) alone, or in combination with an anti-PD-1 antibody. Cytolytic activity was determined by assessing the ratio of CSFE-labeled cells in isolated splenocytes following injection of CSFE-labeled non-pulsed and SIINFEKL peptide pulsed syngeneic splenocytes. Cytolytic activity was assessed at 7, 14, 21 and 28 days post immunotherapy. -
FIG. 1C illustrates the number of IFNγ-secreting cells per 5×105 splenocytes isolated from mice challenged with live B16 tumor cells, then immunized with allogeneic GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Control animals were administered HBSS at the time of immunization. Isolated splenocytes were stimulated with trp2 peptide (top panel) or irradiated B16F10 cells (bottom panel) before being assayed by ELISPOT. -
FIG. 2A illustrates the secretion of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNFα) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion. -
FIG. 2B illustrates the secretion of the pro-inflammatory cytokine interferon-gamma (IFNγ) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion. -
FIG. 2C illustrates the secretion of the pro-inflammatory cytokine interleukin-5 (IL-5) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion. -
FIG. 2D illustrates the secretion of the pro-inflammatory cytokine interleukin-6 (IL-6) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion. -
FIG. 2E illustrates the secretion of the pro-inflammatory cytokine interleukin-10 (IL-10) from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion. -
FIG. 2F illustrates the secretion of the pro-inflammatory cytokine monocyte chemotactic protein (MCP)-1 from splenocytes isolated from mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Splenocytes were stimulated with irradiated B16 cells for 48 hours before assaying for cytokine secretion. -
FIG. 3A illustrates effector CD8 f-cell infiltration into tumors of mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or with GM-CSF-secreting B16F10 cells in combination with an anti-PD-1 antibody (combo). Shown are the percentage of IFNγ and CD107α expressing cells in the CD8 TIL subpopulation. -
FIG. 3B illustrates effector CD8 T-cell infiltration into tumors of mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or with GM-CSF-secreting B16F10 cells in combination with an anti-PD-1 antibody. Shown is the ratio of CD8+/FoxP3+ cells in the tumor at 3 wks post cellular immunotherapy. -
FIG. 3C illustrates the kinetics of CD4+ T-cell infiltration into tumor cells (as measured per 1×106 tumor cells) in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. CD4+T-cell counts were determined at 7, 14 and 21 days post cellular immunotherapy. -
FIG. 3D illustrates the kinetics of CD8+ T-cell infiltration into tumor cells (as measured per 1×106 tumor cells) in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. CD8+ T-cell counts were determined at 7, 14 and 21 days post cellular immunotherapy. -
FIG. 3E illustrates the kinetics of CD8+/107a+ T-cell infiltration into tumor cells (as measured per 1×106 tumor cells) in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. CD8+/107a+ T-cell counts were determined at 7, 14 and 21 days post cellular immunotherapy. -
FIG. 3F illustrates the kinetics of CD8+/IFNγ+ T-cell infiltration into tumor cells (as measured per 1×106 tumor cells) in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. CD8+/IFNγ+ T-cell counts were determined at 7, 14 and 21 days post cellular immunotherapy. -
FIG. 3G illustrates tumor progression in mice challenged with live tumor cells, then immunized with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM), or in combination with an anti-PD-1 antibody. Tumors from mice (n=5/group) were excised, digested and single cell suspensions from the entire digest were counted by cell counter. Counts were determined at 7, 14 and 21 days post cellular immunotherapy. -
FIG. 4A illustrates the survival of B16F10 tumor-bearing animals following administration of GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody, when given onday 3 post tumor challenge. -
FIG. 4B illustrates the survival of B16F10 tumor-bearing animals following administration of GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody, when given onday 7 post tumor challenge. -
FIG. 4C illustrates the survival of B16F10 tumor-bearing animals following administration of GM-CSF-secreting cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody, when given onday 11 post tumor challenge. -
FIG. 4D illustrates the memory response of mice which survived an initial tumor challenge following administration of GM-CSF-secreting cells alone or in combination with an anti-PD-1 antibody. On day 90 after initial tumor challenge, animals were re-challenged with 5×105 (2.5 fold of initial dose) B16 tumor cells and monitored for survival. A Kaplan-Meier survival curve was used for evaluation. -
FIG. 5A illustrates the survival of CT26 tumor-bearing animals following administration of GM-CSF-secreting CT26 cells alone (CT26.GM), anti-PD-1 antibody alone (anti-PD-1) or CT26.GM in combination with an anti-PD-1 antibody when given onday 3 post tumor challenge. -
FIG. 5B illustrates the tumor burden of animals following administration of GM-CSF-secreting CT26 cells alone (CT26.GM), anti-PD-1 antibody alone (anti-PD-1) or CT26.GM in combination with an anti-PD-1 antibody when given onday 3 post tumor challenge. -
FIG. 6A illustrates the percentage of CD4+ T-cells in the spleens of mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody. -
FIG. 6B illustrates the percentage of CD8+ T-cells in the spleens of mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody. -
FIG. 6C illustrates the percentage of CD11c+ T-cells in the spleens of mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody. -
FIG. 6D illustrates the percentage of DX5+ T-cells in the spleens of mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody. -
FIG. 7A illustrates the percentage of memory T-cells (Ly6C+/CD69−) in the CD4 subpopulation from spleen taken from mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody. -
FIG. 7B illustrates the percentage of memory T-cells (Ly6C+/CD69−) in the CD8 subpopulation from spleen taken from mice treated with GM-CSF-secreting B16F10 cells alone (B16.Kd.GM) or in combination with an anti-PD-1 antibody. -
FIG. 8 illustrates the reversal of anergy and augmentation of a tumor-specific T-cell response in C57BL/6 mice injected with SIINFEKL peptide (to induce anergy in adoptively transferred OT-1 transgenic T-cells) and immunized with GM-CSF-secreting B16.ova cells (GM.ova) alone, or in combination with an anti-PD-1 antibody. The percentage of antigen-specific T-cells in peripheral blood lymphocytes was determined by tetramer staining at 4, 10, 14, 17, 25 and 31 days following adoptive transfer. -
FIG. 9 illustrates the expansion and contraction of the population of ovalbumin-specific CD8 T-cells in spleens of mice treated with an initial therapy cycle of GM.ova immunotherapy, followed by either (i) anti-PD-1 and immunotherapy administered biweekly; (ii) GM.ova immunotherapy only administered biweekly; or (iii) anti-PD-1 administered biweekly and GM.ova immunotherapy administered monthly. Shown are the absolute numbers of ovalbumin-specific CD8 T-cells in the spleen by tetramer staining (A) and ovalbumin-specific CD8 T-cells co-stained with the activation marker CD107a (B) and IFN-γ (C). - The present invention represents improved cellular immunotherapies for the treatment of cancer in that the compositions and methods described herein comprise at least two components that act in concert to effect an improved therapeutic outcome for the cancer patient under treatment.
- The invention is not limited to the specific compositions and methodology described herein. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
- The terms “regulating the immune response” or “modulating the immune response” as used herein refers to any alteration in a cell of the immune system or any alteration in the activity of a cell involved in the immune response. Such regulation or modulation includes an increase or decrease in the number of various cell types, an increase or decrease in the activity of these cells, or any other changes which can occur within the immune system. Cells involved in the immune response include, but are not limited to, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils. In some cases, “regulating” or “modulating” the immune response means the immune response is stimulated or enhanced, and in other cases “regulating” or “modulating” the immune response means suppression of the immune system. Stimulation of the immune system may include memory responses and/or future protection against subsequent antigen challenge.
- The term “cytokine” or “cytokines” as used herein refers to the general class of biological molecules which effect/affect cells of the immune system. The definition is meant to include, but is not limited to, those biological molecules that act locally or may circulate in the blood, and which, when used in the compositions or methods of the present invention serve to regulate or modulate an individual's immune response to cancer. Exemplary cytokines for use in practicing the invention include but are not limited to interferon-alpha (IFN-α), interferon-beta (IFN-β), and interferon-gamma (IFN-γ), interleukins (e.g., IL-1 to IL-29, in particular, IL-2, IL-5, IL-6, IL-7, IL-10, IL-12, IL-15 and IL-18), tumor necrosis factors (e.g., TNF-alpha and TNF-beta), erythropoietin (EPO), MIP3a, monocyte chemotactic protein (MCP)-1, intracellular adhesion molecule (ICAM), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF).
- The term “cytokine-expressing cellular immunotherapy” as used herein refers to a composition comprising a population of cells that has been genetically modified to express a cytokine, e.g., GM-CSF, and that is administered to a patient as part of a cancer treatment regimen. The cells of such a “cytokine-expressing cellular immunotherapy” comprise a cytokine-encoding DNA sequence operably linked to expression and control elements such that the cytokine is expressed by the cells. The cells of the “cytokine-expressing cellular immunotherapy” are typically tumor cells and may be autologous or allogeneic to the patient undergoing treatment and or may be “bystander cells” that are mixed with tumor cells taken from the patient. A GM-CSF-expressing “cytokine-expressing cellular immunotherapy” may be referred to herein as “GVAX®”.
- The term “operably linked” as used herein relative to a recombinant DNA construct or vector means nucleotide components of the recombinant DNA construct or vector are directly linked to one another for operative control of a selected coding sequence. Generally, “operably linked” DNA sequences are contiguous, and, in the case of a secretory leader, contiguous and in reading frame; however, some sequences, e.g., enhancers do not have to be contiguous to be operative and therefore “operably linked.”
- As used herein, the term “gene” or “coding sequence” means the nucleic acid sequence which is transcribed (DNA) and translated (mRNA) into a polypeptide in vitro or in vivo when operably linked to appropriate regulatory sequences. A “gene” typically comprises the coding sequence plus any non-coding sequences associated with the gene (e.g., regulatory sequences) and hence may or may not include regions preceding and following the coding region, e.g., 5′ untranslated (5′UTR) or “leader” sequences and 3′ UTR or “trailer” sequences, as well as intervening sequences (introns) between individual coding segments (exons). In contrast, a “coding sequence” does not include non-coding DNA.
- The terms “gene-modified” and “genetically-modified” are used herein with reference to a cell or population of cells wherein a nucleic acid sequence has been introduced into the cell or population of cells. The nucleic acid sequence may be heterologous to the cell(s), or it may be an additional copy or altered version of a nucleic acid sequence already present in the cell(s). This term also encompasses cells or a population of cells with altered, e.g., increased or decreased, expression of a nucleic acid sequence endogenous to the cell or population of cells. The cell(s) may be genetically-modified by physical or chemical methods or by the use of recombinant viruses. Chemical and physical methods such as calcium phosphate, electroporation and pressure mediated transfer of genetic material into cells are often used. Several recombinant viral vectors which find utility in effective delivery of genes into mammalian cells include, for example, retroviral vectors, adenovirus vectors, adenovirus-associated vectors (AAV), herpes virus vectors, pox virus vectors. In addition, non-viral means of introduction, for example, naked DNA delivered via liposomes, receptor-mediated delivery, calcium phosphate transfection, electroporation, particle bombardment (gene gun), or pressure-mediated delivery may also be employed to introduce a nucleic acid sequence into a cell or population of cells to render them “gene-modified” or “genetically-modified.
- The terms “cancer,” “cancer cells,” “neoplastic cells,” “neoplasia,” “tumor,” and “tumor cells” (used interchangeably) refer to cells that exhibit relatively autonomous growth, so that they exhibit an aberrant growth phenotype or aberrant cell status characterized by a significant loss of control of cell proliferation. A tumor cell may be a hyperplastic cell, a cell that shows a lack of contact inhibition of growth in vitro or in vivo, a cell that is incapable of metastasis in vivo, or a cell that is capable of metastasis in vivo. Neoplastic cells can be malignant or benign. It follows that cancer cells are considered to have an aberrant cell status.
- The term “antigen from a tumor cell” and “tumor antigen” and “tumor cell antigen” may be used interchangeably herein and refer to any protein, carbohydrate or other component derived from or expressed by a tumor cell which is capable of eliciting an immune response. The definition is meant to include, but is not limited to whole tumor cells that express some or all of the tumor-associated antigens, tumor cell fragments, plasma membranes taken from a tumor cell, proteins purified from the cell surface or membrane of a tumor cell, or unique carbohydrate moieties associated with the cell surface of a tumor cell. The definition also includes those antigens from the surface of the cell which require special treatment of the cells to access. As described herein, a “tumor cell line” comprises cells that were initially derived from a tumor. Such cells typically are transformed (i.e., exhibit indefinite growth in culture).
- The term “systemic immune response” as used herein means an immune response which is not localized, but affects the individual as a whole.
- The term “gene therapy” as used herein means the treatment or prevention of cancer by means of ex vivo or in vivo delivery, through viral or non-viral vectors, of compositions containing a recombinant genetic material.
- The term “ex vivo” delivery as used herein means the introduction, outside of the body of a human, of compositions containing a genetic material into a cell, tissue, organoid, organ, or the like, followed by the administration of cell, tissue, organoid, organ, or the like which contains such introduced compositions into the body of the same (autologous) or a different (allogeneic) human, without limitation as to the formulation, site or route of administration.
- The terms “inactivated cells,” “non-dividing cells” and “non-replicating cells” may be used interchangeably herein and refer to cells that have been treated rendering them proliferation incompetent, e.g., by irradiation. Such treatment results in cells that are unable to undergo mitosis, but retain the capability to express proteins such as cytokines or other cancer therapeutic agents. Typically a minimum dose of about 3500 rads is sufficient, although doses up to about 30,000 rads are acceptable. Effective doses include, but are not limited to, 5000 to 10000 rads. Numerous methods of inactivating cells, such as treatment with Mitomycin C, are known in the art. Any method of inactivation which renders cells incapable of cell division, but allows the cells to retain the ability to express proteins may be used in accordance with the present invention.
- As used herein “treatment” of an individual or a cell is any type of intervention used in an attempt to alter the natural course of the individual or cell. Treatment includes, but is not limited to, administration of e.g., a cytokine-expressing cellular immunotherapy and at least one additional cancer therapeutic agent or treatment, e.g. an anti-PD-1 antibody, and may be performed either prophylactically or subsequent to diagnosis as part of a primary or follow-up therapeutic regimen.
- The term “administering” as used herein refers to the physical introduction of a composition comprising a cytokine-expressing cellular immunotherapy and at least one additional cancer therapeutic agent or treatment to a patient with cancer. Any and all methods of introduction are contemplated according to the invention; the method is not dependent on any particular means of introduction. Means of introduction are well-known to those skilled in the art, examples of which are provided herein.
- The term “co-administering” as used herein means a process whereby the combination of a cytokine-expressing cellular immunotherapy and at least one additional cancer therapeutic agent, e.g., an anti-PD-1 antibody, is administered to the same patient. The cytokine-expressing cellular immunotherapy and additional cancer therapeutic may be administered simultaneously, at essentially the same time, or sequentially. If administration takes place sequentially the cytokine-expressing cellular immunotherapy may be administered before or after a given additional cancer therapeutic agent or treatment. The cytokine-expressing cellular immunotherapy and additional cancer therapeutic agent or treatment need not be administered by means of the same vehicle. The cellular immunotherapy and the additional agent or treatment may be administered one or more times and the number of administrations of each component of the combination may be the same or different. In addition, the cytokine-expressing cellular immunotherapy and additional cancer therapeutic agent or treatment need not be administered at the same site.
- The term “therapeutically effective amount” or “therapeutically effective combination” as used herein refers to an amount or dose of a cytokine-expressing cellular immunotherapy together with the amount or dose of an additional agent or treatment, e.g. an anti-PD-1 antibody, that is sufficient to modulate, either by stimulation or suppression, the systemic immune response of an individual. The amount of cytokine-expressing cellular immunotherapy in a given therapeutically effective combination may be different for different individuals and different tumor types, and will be dependent upon the one or more additional agents or treatments included in the combination. The “therapeutically effective amount” is determined using procedures routinely employed by those of skill in the art such that an “improved therapeutic outcome” results.
- As used herein, the terms “improved therapeutic outcome” and “enhanced therapeutic efficacy,” relative to cancer refers to a slowing or diminution of the growth of cancer cells or a solid tumor, or a reduction in the total number of cancer cells or total tumor burden. An “improved therapeutic outcome” or “enhanced therapeutic efficacy” therefore means there is an improvement in the condition of the patient according to any clinically acceptable criteria, including, for example, decreased tumor size, an increase in time to tumor progression, increased progression-free survival, increased overall survival time, an increase in life expectancy, or an improvement in quality of life. In particular, “improved” or “enhanced” refers to an improvement or enhancement of 1%, 5%, 10%, 25% 50%, 75%, 100%, or greater than 100% of any clinically acceptable indicator of therapeutic outcome or efficacy.
- As used herein, the term “synergism,” “synergistic” or “synergistically” refers to the combined action of two or more agents wherein the combined action is greater than the sum of the actions of each of the agents used alone.
- The term “relative to” or “compared to.” when used in the context of comparing the activity and/or efficacy of a combination composition comprising the cytokine-expressing cellular immunotherapy (GVAX) plus an anti-PD-1 antibody (anti-PD-1) to either GVAX or anti-PD-1 alone, refers to a comparison using amounts known to be comparable according to one of skill in the art. Comparable amounts of GVAX, when comparing the combination therapy to GVAX alone, may be based on cell number, cytokine expression, cytokine secretion, or cytokine activity on a per cell basis. Comparable amounts of anti-PD-1, when comparing the combination therapy to PD-1 alone, may be based on equimolar amounts, weight-to-weight equivalents, or units of PD-1 binding activity.
- The term “reversal of an established tumor” as used herein means the suppression, regression, partial or complete disappearance of a pre-existing tumor. The definition is meant to include any diminution, for example, in the size, growth rate, appearance or cellular compositions of a preexisting tumor.
- The terms “individual” or “subject” as referred to herein is a vertebrate, preferably a mammal, and typically refers to a human.
- The terms “programmed death-1,” “programmed death receptor-1” and “PD-1” are synonymous with one another, and include variants, isoforms, species homologs of human PD-1, and analogs having at least one common epitope with PD-1. The full length human PD-1 cDNA is 2106 nucleotides long and encodes a protein of 288 amino acid residues. The human PD-1 and murine PD-1 genes share 70% homology at the nucleotide level and 60% homology at the amino acid level. The complete cDNA sequence of human PD-1 has the Genbank accession number U64863 (Shinohara et al., Genomics 23(3): 704-706 (1994). The extracellular domain is encoded by amino acids 1-166; the transmembrane domain is encoded by amino acids 167-196; and the cytoplasmic domain is encoded by amino acids 197-288. The extracellular domain contains an immunoglobulin superfamily domain, and the cytoplasmic domain includes an immunoreceptor tyrosine-based inhibitory motif (ITIM). The complete cDNA sequence of murine PD-1 has the Genbank accession number X67914 (Ishida et al., EMBO J. 11(11):3887-3895 (1992)).
- An intact “antibody” comprises at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3. FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with PD-1. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The term antibody includes antigen-binding portions of an intact antibody that retain capacity to bind PD-1. Examples of binding include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); See, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain antibodies are included by reference to the term “antibody.” Fragments can be prepared by recombinant techniques or enzymatic or chemical cleavage of intact antibodies.
- “Conservative substitution” refers to the substitution in a polypeptide of an amino acid with a functionally similar amino acid. The following six groups each contain amino acids that are conservative substitutions for one another:
- Alanine (A), Serine (S), and Threonine (T)
- Aspartic acid (D) and Glutamic acid (E)
- Asparagine (N) and Glutamine (Q)
- Arginine (R) and lysine (K)
- Isoleucine (I), Leucine (L), Methionine (M), and Valine (V)
- Phenylalanine (F), Tyrosine (Y), and Tryptophan (W).
- The term “stringent conditions” refers to conditions under which a probe will hybridize preferentially to its target subsequence, and to a lesser extent to, or not at all to, other sequences. “Stringent hybridization” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments such as Southern and northern hybridizations are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids can be found in Tijssen, 1993, Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes,
part 1,chapter 2, “Overview of principles of hybridization and the strategy of nucleic acid probe assays”, Elsevier, NY; Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 3rd ed., NY; and Ausubel et al., eds., Current Edition, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY. - Generally, highly stringent hybridization and wash conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the Tm for a particular probe.
- One example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than about 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42° C., with the hybridization being carried out overnight. An example of highly stringent wash conditions is 0.15 M NaCl at 72° C. for about 15 minutes. An example of stringent wash conditions is a 0.2×SSC wash at 65° C. for 15 minutes. See Sambrook et al. for a description of SSC buffer. A high stringency wash can be preceded by a low stringency wash to remove background probe signal. An exemplary medium stringency wash for a duplex of, e.g., more than about 100 nucleotides, is 1×SSC at 45° C. for 15 minutes. An exemplary low stringency wash for a duplex of, e.g., more than about 100 nucleotides, is 4-6×SSC at 40° C. for 15 minutes. In general, a signal to noise ratio of 2× (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.
- The term “% sequence identity” is used interchangeably herein with the term “% identity” and refers to the level of amino acid sequence identity between two or more peptide sequences or the level of nucleotide sequence identity between two or more nucleotide sequences, when aligned using a sequence alignment program. For example, as used herein, 80% identity means the same thing as 80% sequence identity determined by a defined algorithm, and means that a given sequence is at least 80% identical to another length of another sequence. Exemplary levels of sequence identity include, but are not limited to, 60, 70, 80, 85, 90, 95, 98% or more sequence identity to a given sequence.
- The term “% sequence homology” is used interchangeably herein with the term “% homology” and refers to the level of amino acid sequence homology between two or more peptide sequences or the level of nucleotide sequence homology between two or more nucleotide sequences, when aligned using a sequence alignment program. For example, as used herein, 80% homology means the same thing as 80% sequence homology determined by a defined algorithm, and accordingly a homologue of a given sequence has greater than 80% sequence homology over a length of the given sequence. Exemplary levels of sequence homology include, but are not limited to, 60, 70, 80, 85, 90, 95, 98% or more sequence homology to a given sequence.
- Exemplary computer programs which can be used to determine identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, BLASTX, and TBLASTX, BLASTP and TBLASTN, publicly available on the Internet at the NCBI website. See also Altschul et al., 1990, J. Mol. Biol. 215:403-10 (with special reference to the published default setting, i.e., parameters w=4, t=17) and Altschul et al., 1997, Nucleic Acids Res., 25:3389-3402. Sequence searches are typically carried out using the BLASTP program when evaluating a given amino acid sequence relative to amino acid sequences in the GenBank Protein Sequences and other public databases. The BLASTX program is preferred for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases. Both BLASTP and BLASTX are run using default parameters of an open gap penalty of 11.0, and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix. See id.
- Another alignment of selected sequences in order to determine “% identity” between two or more sequences, is performed using for example, the CLUSTAL-W-program in MacVector version 6.5, operated with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM 30 similarity matrix.
- The term “about,” as used herein, unless otherwise indicated, refers to a value that is no more than 10% above or below the value being modified by the term. For example, the term “about 5 μg/kg” means a range of from 4.5 μg/kg to 5.5 μg/kg. As another example, “about 1 hour” means a range of from 54 minutes to 66 minutes.
- The practice of the present invention can employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, cell biology, biochemistry and immunology, which are within the knowledge of those of skill of the art. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, third edition (Sambrook et al., 2002); “Current Protocols in Molecular Biology” (F. M. Ausubel et al., eds., 2007); “Culture of Animal Cells: A Manual of Basic Techniqaue,” 4th edition (R. I. Freshney, ed. 2000), each of which is hereby expressly incorporated herein by reference.
- The methods and compositions of the invention provide an improved therapeutic approach to the treatment of cancer by co-administration of a cytokine-expressing cellular immunotherapy and an antibody that specifically binds to human PD-1 to a patient with cancer. “Cancer” as used herein includes cancer localized in tumors, as well as cancer not localized in tumors, such as, for instance, cancer cells that expand from a local tumor by invasion (i.e., metastasis). The invention finds utility in the treatment of any form of cancer, including, but not limited to, cancer of the bladder, breast, colon, kidney, liver, lung, ovary, cervix, pancreas, rectum, prostate, stomach, epidermis; a hematopoietic tumor of lymphoid or myeloid lineage; a tumor of mesenchymal origin such as a fibrosarcoma or rhabdomyosarcoma; other tumor types such as melanoma, teratocarci-noma, neuroblastoma, glioma, adenocarcinoma and non-small lung cell carcinoma.
- In one aspect of the invention, a nucleic acid sequence (i.e., a recombinant DNA construct or vector) encoding a cytokine operably linked to a promoter is introduced into a cell or population of cells. Any and all methods of introduction into a cell or population of cells, typically tumor cells, are contemplated according to the invention. The method is not dependent on any particular means of introduction and is not to be so construed.
- The “vector” may be a DNA molecule such as a plasmid, virus or other vehicle, which contains one or more heterologous or recombinant DNA sequences, e.g., a nucleic acid sequence encoding a cytokine under the control of a functional promoter and in some cases further including an enhancer that is capable of functioning as a vector, as understood by those of ordinary skill in the art. An appropriate viral vector includes, but is not limited to, a retrovirus, a lentivirus, an adenovirus (AV), an adeno-associated virus (AAV), a simian virus 40 (SV-40), a bovine papilloma virus, an Epstein-Barr virus, a herpes virus, a vaccinia virus, a Moloney murine leukemia virus, a Harvey murine sarcoma virus, a murine mammary tumor virus, and a Rous sarcoma virus. Non-viral vectors are also included within the scope of the invention.
- Any suitable vector can be employed that is appropriate for introduction of nucleic acids into eukaryotic tumor cells, or more particularly animal tumor cells, such as mammalian, e.g., human, tumor cells. Preferably the vector is compatible with the tumor cell, e.g., is capable of imparting expression of the coding sequence for a cytokine and is stably maintained or relatively stably maintained in the tumor cell. Desirably the vector comprises an origin of replication and the vector may or may not also comprise a “marker” or “selectable marker” function by which the vector can be identified and selected. While any selectable marker can be used, selectable markers for use in such expression vectors are generally known in the art and the choice of the proper selectable marker will depend on the host cell. Examples of selectable marker genes which encode proteins that confer resistance to antibiotics or other toxins include ampicillin, methotrexate, tetracycline, neomycin (Southern and Berg, J., 1982), myco-phenolic acid (Mulligan and Berg, 1980), puromycin, zeo-mycin, hygromycin (Sugden et al., 1985) or G418.
- In practicing the methods of the present invention, a vector comprising a nucleic acid sequence encoding a cytokine may be transferred to a cell in vitro, preferably a tumor cell, using any of a number of methods which include but are not limited to electroporation, membrane fusion with liposomes, Lipofectamine treatment, high velocity bombardment with DNA-coated microprojectiles, incubation with calcium phosphate-DNA precipitate, DEAE-dextran mediated transfection, infection with modified viral nucleic acids, direct microinjection into single cells, etc. Procedures for the cloning and expression of modified forms of a native protein using recombinant DNA technology are generally known in the art, as described in Ausubel, et al., 2007 and Sambrook, et al., 2002, expressly incorporated by reference, herein.
- Reference to a vector or other DNA sequences as “recombinant” merely acknowledges the operable linkage of DNA sequences which are not typically operably linked as isolated from or found in nature. A “promoter” is a DNA sequence that directs the binding of RNA polymerase and thereby promotes RNA synthesis. “Enhancers” are cis-acting elements that stimulate or inhibit transcription of adjacent genes. An enhancer that inhibits transcription also is termed a “silencer.” Enhancers can function (i.e. be operably linked to a coding sequence) in either orientation, over distances of up to several kilobase pairs (kb) from the coding sequence and from a position downstream of a transcribed region. Regulatory (expression/control) sequences are operatively linked to a nucleic acid coding sequence when the expression/control sequences regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression/control sequences can include promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of the coding sequence, a splicing signal for introns, and stop codons.
- Recombinant vectors for the production of cellular immunotherapies of the invention provide the proper transcription, translation and processing signals (e.g., splicing and polyadenylation signals) such that the coding sequence for the cytokine is appropriately transcribed and translated in the tumor cells into which the vector is introduced. The manipulation of such signals to ensure appropriate expression in host cells is within the skill of the ordinary skilled artisan. The coding sequence for the cytokine may be under control of (i.e., operably linked to) its own native promoter, or a non-native (e.g. heterologous) promoter, including a constitutive promoter, e.g., the cytomegalovirus (CMV) immediate early promoter/enhancer, the Rous sarcoma virus long terminal repeat (RSV-LTR) or the SV-40 promoter.
- Alternately, a tissue-specific promoter (a promoter that is preferentially activated in a particular type of tissue and results in expression of a gene product in that tissue) can be used in the vector. Such promoters include but are not limited to a liver specific promoter (III CR, et al., Blood Coagul Fibrinolysis 8 Suppl 2:S23-30, 1997) and the EF-1 alpha promoter (Kim D W et al. Gene. 91(2):217-23, 1990, Guo Z S et al. Gene Ther. 3(9):802-10, 1996; U.S. Pat. Nos. 5,266,491 and 5,225,348, each of which expressly incorporated by reference herein). Inducible promoters also find utility in practicing the methods described herein, such as a promoter containing the tet responsive element (TRE) in the tet-on or tet-off system as described (ClonTech and BASF), the metallothienein promoter which can be upregulated by addition of certain metal salts and rapamycin inducible promoters (Rivera et al., 1996, Nature Med, 2(9): 1028-1032; Ye et al., 2000, Science 283: 88-91; Sawyer T K et al., 2002, Mini Rev Med Chem. 2(5):475-88). Large numbers of suitable tissue-specific or regulatable vectors and promoters for use in practicing the current invention are known to those of skill in the art and many are commercially available.
- Exemplary vector systems for use in practicing the invention include the retroviral MFG vector, described in U.S. Pat. No. 5,637,483, expressly incorporated by reference herein. Other useful retroviral vectors include pLJ, pEm and [alpha]SGC, described in U.S. Pat. No. 5,637,483 (in particular Example 12), U.S. Pat. Nos. 6,506,604, 5,955,331 and U.S. Ser. No. 09/612,808, each of which is expressly incorporated by reference herein.
- Further exemplary vector systems for use in practicing the invention include second, third and fourth generation lentiviral vectors, U.S. Pat. Nos. 6,428,953, 5,665,577 and 5,981,276 and WO 00/72686, each of which is expressly incorporated by reference herein.
- Additional exemplary vector systems for use in practicing the present invention include adenoviral vectors, described for example in U.S. Pat. No. 5,872,005 and International Patent Publication No. WO 00/72686, each of which is expressly incorporated by reference herein.
- Yet another vector system that is preferred in practicing the methods described herein is a recombinant adeno-associated vector (rAAV) system, described for example in International Patent Publication Nos. WO 98/46728 and WO 00/72686, Samulski et al., Virol. 63:3822-3828 (1989) and U.S. Pat. Nos. 5,436,146, 5,753,500, 6,037,177, 6,040,183 and 6,093,570, each of which is expressly incorporated by reference herein.
- Cytokines and combinations of cytokines have been shown to play an important role in the stimulation of the immune system. The term “cytokine” is understood by those of skill in the art, as referring to any immunopotentiating protein (including a modified protein such as a glycoprotein) that enhances or modifies the immune response to a tumor present in the host. The cytokine typically enhances or modifies the immune response by activating or enhancing the activity of cells of the immune system and is not itself immunogenic to the host.
- It follows from the results presented herein that a variety of cytokines will find use in the present invention. Exemplary cytokines for use in practicing the invention include but are not limited to interferon-alpha (IFN-α), interferon-beta (IFN-β), and interferon-gamma (IFN-γ), interleukins (e.g., IL-1 to IL-29, in particular, IL-2, IL-7, IL-12, IL-15 and IL-18), tumor necrosis factors (e.g., TNF-alpha and TNF-beta), erythropoietin (EPO), MIP3a, intracellular adhesion molecule (ICAM), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF). The cytokine may be from any source, however, optimally the cytokine is of murine or human origin (a native human or murine cytokine) or is a sequence variant of such a cytokine, so long as the cytokine has a sequence with substantial homology to the human form of the cytokine and exhibits a similar activity on the immune system. It follows that cytokines with substantial homology to the human forms of IFN-alpha, IFN-beta, and IFN-gamma, IL-1 to IL-29, TNF-alpha, TNF-beta, EPO, MIP3a, ICAM, M-CSF, G-CSF and GM-CSF are useful in practicing the invention, so long as the homologous form exhibits the same or a similar effect on the immune system. Proteins that are substantially similar to any particular cytokine, but have relatively minor changes in protein sequence find use in the present invention. It is well known that small alterations in protein sequence may not disturb the functional activity of a protein molecule, and thus proteins can be made that function as cytokines in the present invention but differ slightly from current known or native sequences.
- Homologues and variants of native human or murine cytokines are included within the scope of the invention. As used herein, the term “sequence identity” means nucleic acid or amino acid sequence identity between two or more aligned sequences and is typically expressed as a percentage (“%”). The term “% homology” is used interchangeably herein with the term “% identity” or “% sequence identity” and refers to the level of nucleic acid or amino acid sequence identity between two or more aligned sequences, when aligned using a sequence alignment program. For example, as used herein, 80% homology has the same meaning as 80% sequence identity as determined by a defined algorithm, and accordingly a homologue of a given sequence typically has greater than 80% sequence identity over a length of the given sequence. Preferred levels of sequence identity include, but are not limited to, 80, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% or more sequence identity to a native cytokine amino acid or nucleic acid sequence, as described herein.
- Exemplary computer programs that can be used to determine the degree of identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, BLASTX, TBLASTX, BLASTP and TBLASTN, all of which are publicly available on the Internet. See, also, Altschul, S. F. et al. Mol. Biol. 215:403-410, 1990 and Altschul, S. F. et al. Nucleic Acids Res. 25:3389-3402, 1997, expressly incorporated by reference herein. Sequence searches are typically carried out using the BLASTN program when evaluating a given nucleic acid sequence relative to nucleic acid sequences in the GenBank DNA Sequences and other public databases. The BLASTX program is preferred for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases. In determining sequence identity, both BLASTN and BLASTX (i.e. version 2.2.5) are run using default parameters of an open gap penalty of 11.0, and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix. [See, Altschul, et al., 1997, supra.] A preferred alignment of selected sequences in order to determine “% identity” between two or more sequences, is performed using for example, the CLUSTAL-W program in Mac Vector, version 6.5, operated with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM 30 similarity matrix.
- A nucleic acid sequence is considered to be “selectively hybridizable” to a reference nucleic acid sequence if the two sequences specifically hybridize to one another under moderate to high stringency hybridization and wash conditions. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe. For example, “maximum stringency” typically occurs at about TM-5° C. (5° below the Tm of the probe) “high stringency” at about 5-10° below the Tm; “intermediate stringency” at about 10-20° below the Tm of the probe; and “low stringency” at about 20-25° below the Tm. Functionally, maximum stringency conditions may be used to identify sequences having strict identity or near-strict identity with the hybridization probe, while high stringency conditions are used to identify sequences having about 80% or more sequence identity with the probe. An example of high stringency conditions includes hybridization at about 42° C. in 50% formamide, 5×SSC, 5×Denhardt's solution, 0.5% SDS and 100 fig/ml denatured carrier DNA followed by washing two times in 2×SSC and 0.5% SDS at room temperature and two additional times in 0.1×SSC and 0.5% SDS at 42° C. Moderate and high stringency hybridization conditions are well known in the art. See, for example, Sambrook, et al, 1989,
Chapters 9 and 11, and in Ausubel, F. M., et al, 1993, (expressly incorporated by reference herein). - As detailed herein, the present invention is directed to a method of improving an individual's immune response to cancer (e.g., a target cancer antigen or antigens) by co-administering a cytokine-expressing cellular immunotherapy (e.g., GM-CSF) and at an antibody which specifically binds to human Programmed Death (PD)-1 to a patient with cancer.
- PD-1 is an immunoinhibitory receptor belonging to the CD28 family (Freeman et al., J. Exp. Med. 192: 1027 (2000); Okazaki et al., Curr. Opim. Immunol. 14: 779 (2002)) and binds to two ligands, PD-L1 and PD-L2. PD-1 is induced on T-cells, B-cells and myeloid cells in-vitro (Agata et al., Int. Immunol. 8:765 (1996)), but is predominantly expressed on previously activated T-cells in vivo (Iwai et al., Immunol. Lett. 83:215 (2002)).
- Studies indicate that PD-1 plays a critical role in immune responses. Engagement of PD-1 by PD-L1 leads to inhibition of T cell proliferation and cytokine production such as IL-2 and IFN-gamma (Freeman et al., J. Exp. Med. 192: 1027 (2000). In addition, PD-1 deficient mice exhibit a breakdown of peripheral tolerance and develop systemic autoimmune disease (Nishimura et al., Immunity 11: 141-151 (1999); Nishimura et al., Science 291: 319-322 (2001)). Over-expression of PD-L1 has been observed in numerous human cancers, including melanomas and carcinomas of lung, ovary, colon, bladder, breast, cervix, liver, and head and neck, and glioblastoma (Dong et al. Nat. Med. 8:793-800 (2002); Brown et al., J. Immunol. 170:1257-66 (2003). Strome et al. Cancer Res. 63: 6501 (2003); Wintterle et al., Cancer Res. 63:7462-7467 (2003)), and PD-L1/PD-1 interaction has been suggested to play a pivotal role in the immune evasion of tumors from the host immune system (Blank et al. Cancer Immunol. Immunother. 54(4):307-14 (2005)). Therefore, blockade of PD-L1/PD-1 interaction, e.g., with an antibody which specifically binds PD-1, serves as one possible mechanism for enhancing anti-tumor immunity.
- Exemplary anti-PD-1 antibodies and methods for their use are described by Goldberg et al., Blood 110(1):186-192 (2007), Thompson et al., Clin. Cancer Res. 13(6):1757-1761 (2007), and Korman et al., International Application No. PCT/JP2006/309606 (publication no. WO 2006/121168 A1), each of which are expressly incorporated by reference herein.
- The antibodies for use in the present invention include, but are not limited to, monoclonal antibodies, synthetic antibodies, polyclonal antibodies, multispecific antibodies (including bi-specific antibodies), human antibodies, humanized antibodies, chimeric antibodies, single-chain Fvs (scfv) (including bi-specific scFvs), single chain antibodies, Fab fragments, F(ab′) fragments, disulfide-linked Fvs (sdFv), and epitope-binding fragments of any of the above. In particular, antibodies for use in the present invention include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain a PD-1 binding site that immunospecifically binds to PD-1. The immunoglobulin molecules for use in the invention can be of any type (e.g. IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. Preferably, the antibodies for use in the invention are IgG, more preferably, IgG1.
- The antibodies for use in the invention may be from any animal origin including birds and mammals (e.g., human, murine, donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken). Preferably, the antibodies are human or humanized monoclonal antibodies. As used herein, “human” antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from mice or other animals that express antibodies from human genes.
- The antibodies for use in the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may immunospecifically bind to different epitopes of a polypeptide or may immunospecifically bind to both a polypeptide as well a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., International Publication Nos. WO 93/17715, WO 92/08802, WO 91/00360, and WO 92/05793; Tutt, et al., 1991, J. Immunol. 147:60-69; U.S. Pat. Nos. 4,474,893, 4,714,681, 4,925,648, 5,573,920, and 5,601,819; and Kostelny et al., 1992, J. Immunol. 148:1547-1553.
- The antibodies for use in the invention include derivatives of the antibodies. Standard techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding an antibody to be used with the methods for use in the invention, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis which result in amino acid substitutions. Preferably, the derivatives include less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the original molecule. In a preferred embodiment, the derivatives have conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed and the activity of the protein can be determined.
- The antibodies for use in the present invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, synthesis in the presence of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.
- The present invention also provides antibodies for use in the invention that comprise a framework region known to those of skill in the art. In certain embodiments, one or more framework regions, preferably, all of the framework regions, of an antibody to be used in the compositions and methods for use in the invention are human. In certain other embodiments for use in the invention, the fragment region of an antibody for use in the invention is humanized. In certain embodiments, the antibody to be used with the methods for use in the invention is a synthetic antibody, a monoclonal antibody, an intrabody, a chimeric antibody, a human antibody, a humanized chimeric antibody, a humanized antibody, a glycosylated antibody, a multispecific antibody, a human antibody, a single-chain antibody, or a bispecific antibody.
- In certain embodiments, an antibody for use in the invention has a high binding affinity for PD-1. In specific embodiments, an antibody for use in the invention has an association rate constant or kon rate of about 105 M-1s-1 or more, about 5×105 M-1s-1 or more, about 106 M-1s-1 or more, about 5×106 M-1s-1 or more, about 107 M-1s-1 or more, about 5×107 M-1s-1 or more, about 108 M-1s-1 or more, about 5×108 M-1s-1 or more, or about 1×109 M-1s-1 or more.
- In other embodiments, an antibody for use in the invention has a koff rate for PD-1 of about 5×10−1 s-1 or less, about 10−1 s-1 or less, about 5×10−2 s-1 or less, about 10−2 s-1 or less, about 5×10−3 S-1 or less, about 10−3 s-1 or less, about 5×10−4 s-1 or less, about 10−4 s-1 or less, about 5×10−5 s-1 or less, about 10−5 s-1 or less, about 5×10−6 s-1 or less, about 10−6 s-1 or less, about 5×10−7 s-1 or less, about 10−7 s-1 or less, about 5×10−8 s-1 or less, about 10−8 s-1 or less, about 5×10−9 s-1 or less, about 10−9 s-1 or less, about 5×10−10 s-1 or less, or about 10−10 s-1 or less.
- In certain embodiments, an antibody for use in the invention has an affinity constant or Ka (kon/koff) for PD-1 of about 102 M-1 or more, about 5×102 M-1 or more, about 103 M-1 or more, about 5×103 M-1 or more, about 104M-1 or more, about 5×104 M-1 or more, about 105 M-1 or more, about 5×105 M-1 or more, about 106 M-1 or more, about 5×106 M-1 or more, about 107 M-1 or more, about 5×107 M-1 or more, about 108 M-1 or more, about 5×108 M-1 or more, about 109 M-1 or more, about 5×109 M-1 or more, about 1010 M-1 or more, about 5×1010 M-1 or more, about 1×1011 M-1 or more, about 5×1011 M-1 or more, about 1012 M-1 or more, about 5×1012 M-1 or more, about 1013 M-1 or more, about 5×1013 M-1 or more, about 1014 M-1 or more, about 5×1014 M-1 or more, about 1015 M-1 or more, or about 5×1015 M-1 or more.
- In certain embodiments, an antibody for use in the invention has a low dissociation constant. In specific embodiments, the antibody-binding domain of a carrier construct for use in the invention has a dissociation constant or Kd (koff/kon) for antibody about 5×10−1 M or less, about 10−1 M or less, about 5×10−2 M or less, about 10−2 M or less, about 5×10−3 M or less, about 10−3 M or less, about 5×10−4 M or less, about 10−4 M or less, about 5×10−5 M or less, about 10−5 M or less, about 5×10−6 M or less, about 10−6 M or less, about 5×10−7 M or less, about 10−7 M or less, about 5×10−8 M or less, about 10−8 M or less, about 5×10−9 M or less, about 10−9 M or less, about 5×10−10 M or less, or about 10−10 M or less.
- In certain embodiments, an antibody for use in the present invention has a median effective concentration (EC50) of less than 0.01 nM, less than 0.025 nM, less than 0.05 nM, less than 0.1 nM, less than 0.25 nM, less than 0.5 nM, less than 0.75 nM, less than 1 nM, less than 1.25 nM, less than 1.5 nM, less than 1.75 nM, or less than 2 nM, in an in vitro microneutralization assay. The median effective concentration is the concentration of antibody that neutralizes 50% of PD-1 in an in vitro microneutralization assay.
- In certain embodiments, an antibody for use in the invention has a half-life in a subject, preferably a human, of about 12 hours or more, about 1 day or more, about 3 days or more, about 6 days or more, about 10 days or more, about 15 days or more, about 20 days or more, about 25 days or more, about 30 days or more, about 35 days or more, about 40 days or more, about 45 days or more, about 2 months or more, about 3 months or more, about 4 months or more, or about 5 months or more. Antibodies with increased in vivo half-lives can be generated by techniques known to those of skill in the art. For example, antibodies with increased in vivo half-lives can be generated by modifying (e.g., substituting, deleting or adding) amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor (see, e.g., International Publication No. WO 97/34631 and U.S. patent application Ser. No. 10/020,354, entitled “Molecules with Extended Half-Lives, Compositions and Uses Thereof”, filed Dec. 12, 2001, by Johnson et al.; and U.S. Publication Nos. 2005/003700 and 2005/0064514, which are incorporated herein by reference in their entireties). Such antibodies can be tested for binding activity to antigens as well as for in vivo efficacy using methods known to those skilled in the art, for example, by immunoassays described herein.
- Further, antibodies with increased in vivo half-lives can be generated by attaching to the antibodies polymer molecules such as high molecular weight polyethyleneglycol (PEG). PEG can be attached to the antibodies with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C-terminus of the antibodies or via epsilon-amino groups present on lysine residues. Linear or branched polymer derivatization that results in minimal loss of biological activity will be used. The degree of conjugation will be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies. Unreacted PEG can be separated from antibody-PEG conjugates by, e.g., size exclusion or ion-exchange chromatography. PEG-derivatized antibodies can be tested for binding activity to antigens as well as for in vivo efficacy using methods known to those skilled in the art, for example, by immunoassays described herein.
- In certain embodiments, an antibody for use in the present invention includes antigen-binding portions of an intact antibody that retain capacity to bind PD-1. Examples include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, ambivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); See, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad Sci. USA 85:5879-5883). Such single chain antibodies are included by reference to the term “antibody.”
- In certain embodiments, the methods of the invention utilize combination immunotherapies that comprise additional molecules that have the capacity to bind PD-1 and/or antagonize PD-1 function. A potential PD-1 antagonist may be a protein closely related to a ligand of PD-1, for example, a mutated form of PD-L1 or PD-L2, that recognizes the PD-1 receptor but imparts no signaling effect, thereby competitively inhibiting the immunoinhibitory action of the ligand. Other potential PD-1 antagonists include small molecules that bind to the receptor binding site or other relevant binding site of PD-1, thereby blocking its normal biological activity. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds. These small molecules can be identified by screening techniques well known for those skilled in the art.
- Other antagonists may include oligonucleotides that bind to PD-1-encoding nucleic acids, such as antisense RNA or DNA constructs prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of PD-1 mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5′ coding portion of the polynucleotide sequence, which encodes a mature tumor antigen herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix—see, Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (1991)), thereby preventing transcription and the production of the target polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the target polypeptide (antisense-Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, Fla., 1988).
- The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of the PD-1 polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about −10 and +10 positions of the target gene nucleotide sequence, are preferred.
- Granulocyte-macrophage colony stimulating factor (GM-CSF) is a cytokine produced by fibroblasts, endothelial cells, T cells and macrophages. This cytokine has been shown to induce the growth of hematopoetic cells of granulocyte and macrophage lineages. In addition, the cytokine activates the antigen processing and presenting function of dendritic cells, which are the major antigen presenting cells (APC) of the immune system. Results from animal model experiments have convincingly shown that GM-CSF producing tumor cells are able to induce an immune response against parental, non-transduced tumor cells.
- Autologous and allogeneic cancer cells that have been genetically modified to express a cytokine, e.g. GM-CSF, followed by readministration to a patient for the treatment of cancer are described in U.S. Pat. Nos. 5,637,483, 5,904,920 and 6,350.445, expressly incorporated by reference herein. A form of GM-CSF-expressing genetically modified cancer cells or a “cytokine-expressing cellular immunotherapy” for the treatment of pancreatic cancer is described in U.S. Pat. Nos. 6,033,674 and 5,985,290, expressly incorporated by reference herein. A universal immunomodulatory cytokine-expressing bystander cell line is described in U.S. Pat. No. 6,464,973, expressly incorporated by reference herein. Clinical trials employing GM-CSF-expressing autologous or allogeneic cellular immunotherapies have been undertaken for treatment of prostate cancer, melanoma, lung cancer, pancreatic cancer, renal cancer, and multiple myeloma. A number of these trials are currently ongoing, however, and the question still remains open as to whether the immune response to GM-CSF expressing cells alone will be sufficiently powerful to slow or eradicate large or fast growing malignancies.
- The present invention provides an improved method of stimulating an immune response to cancer in a mammalian, preferably a human, subject. Desirably, the method effects a systemic immune response, i.e., a T-cell response and/or a B-cell response, to the cancer. In some embodiments, the method comprises administering to the patient a cytokine-expressing cellular immunotherapy and an antibody that specifically binds to PD-1, wherein the cellular immunotherapy comprises cells which express a cancer antigen or various cancer antigens. The cancer antigen/antigens can be one of the antigens of the cancer found in the patient under treatment. The cells can be rendered proliferation incompetent, such as e.g., by irradiation. Upon administration of the cytokine-expressing cellular immunotherapy and the anti-PD-1 antibody, an immune response to the cancer can be elicited or enhanced.
- In one approach, the cytokine expressing cellular immunotherapy comprises a single population of cells that is modified to express a cytokine, e.g. GM-CSF. In another approach, the immunotherapy comprises a single population of cells that is modified to express a cytokine as well as a single chain antibody that specifically binds to PD-1. In another approach, the immunotherapy comprises a combination of two or more populations of cells individually modified to express one component of the immunotherapy, e.g. a cytokine and a single chain anti-PD-1 antibody.
- In general, a cytokine-expressing cellular immunotherapy for use in practicing the invention comprises tumor cells selected from the group consisting of autologous tumor cells, allogeneic tumor cells and tumor cell lines (i.e., bystander cells). In one aspect of the invention, the cells of the cytokine-expressing cellular immunotherapy are administered to the same individual from whom they were derived (autologous). In another aspect of the invention, the cells of the cytokine-expressing cellular immunotherapy and the tumor are derived from different individuals (allogeneic or bystander). By way of example, in one approach, genetically modified GM-CSF expressing tumor cells are provided as an allogeneic or bystander cell line and one or more additional cancer therapeutic agents, e.g. an anti-PD-1 antibody, is included in the treatment regimen. In another approach, one or more additional transgenes are expressed by an allogeneic or bystander cell line while a cytokine (i.e., GM-CSF) is expressed by autologous or allogeneic cells, and one or more additional cancer therapeutic agents, e.g. an anti-PD-1 antibody, is included in the treatment regimen.
- In a preferred approach, the tumor being treated is selected from the group consisting of cancer of the bladder, breast, colon, kidney, liver, lung, ovary, cervix, pancreas, rectum, prostate, stomach, epidermis, a hematopoetic tumor of lymphoid or myeloid lineage, a tumor of mesenchymal origin such as a fibrosarcoma or rhabdomyosarcoma, melanoma, teratocarcinoma, neuroblastoma, glioma, adenocarcinoma and non-small lung cell carcinoma.
- In previous studies, a direct comparison of murine tumor cells transduced with various cytokines demonstrated that GM-CSF-secreting tumor cells induced the best overall anti-tumor protection. In one preferred embodiment, the cytokine expressed by the cytokine-expressing cellular immunotherapy of the invention is GM-CSF. The preferred coding sequence for GM-CSF is the genomic sequence described in Huebner K. et al, Science 230(4731): 1282-5, 1985. Alternatively the cDNA form of GM-CSF finds utility in practicing the invention (Cantrell et al., Proc. Natl. Acad. Sci., 82, 6250-6254, 1985).
- In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are cryopreserved prior to administration. Prior to administration, the cells of a cytokine-expressing cellular immunotherapy of the invention are rendered proliferation incompetent. While a number of means of rendering cells proliferation incompetent are known, irradiation is the preferred method. Preferably, the cytokine-expressing cellular immunotherapy combination is irradiated at a dose of from about 50 to about 200 rads/min, even more preferably, from about 120 to about 140 rads/min prior to administration to the patient. Most importantly, the cells are irradiated with a total radiation dose sufficient to inhibit growth of substantially 100% of the cells, from further proliferation. Thus, desirably the cells are irradiated with a total dose of from about 10,000 to 20,000 rads, optimally, with about 15,000 rads.
- Typically more than one administration of cytokine (e.g., GM-CSF) producing cells is delivered to the subject in a course of treatment. Dependent upon the particular course of treatment, multiple injections may be given at a single time point with the treatment repeated at various time intervals. For example, an initial or “priming” treatment may be followed by one or more “booster” treatments. Such “priming” and “booster” treatments are typically delivered by the same route of administration and/or at about the same site. When multiple doses are administered, the first immunization dose may be higher than subsequent immunization doses. For example, a 5×106 prime dose may be followed by several booster doses of 106 to 3×106 GM-CSF producing cells.
- A single injection of cytokine-producing cells is typically between about 106 to 108 cells, e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 107, 2×107, 5×107, or as many as 108 cells. In one embodiment, there are between 106 and 108 cytokine-producing cells per unit dose. The number of cytokine-producing cells may be adjusted according, for example, to the level of cytokine produced by a given cytokine producing cellular immunotherapy.
- The use of autologous cytokine-expressing cells in a immunotherapy of the invention provides advantages since each patient's tumor expresses a unique set of tumor antigens that can differ from those found on histologically-similar, MHC-matched tumor cells from another patient. See, e.g., Kawakami et al, J. Immunol, 148, 638-643 (1992); Darrow et al., J. Immunol., 142, 3329-3335 (1989); and Horn et al., J. Immunother., 10, 153-164 (1991). In contrast, MHC-matched tumor cells provide the advantage that the patient need not be taken to surgery to obtain a sample of their tumor for immunotherapy production.
- In one preferred aspect, the present invention comprises a method of treating cancer by carrying out the steps of: (a) obtaining tumor cells from a mammal, preferably a human, harboring a tumor; (b) modifying the tumor cells to render them capable of producing a cytokine or an increased level of a cytokine naturally produced by the cells relative to unmodified tumor cells; (c) rendering the modified tumor cells proliferation incompetent; and (d) readministering the modified tumor cells to the mammal from which the tumor cells were obtained or to a mammal with the same MHC type as the mammal from which the tumor cells were obtained, in combination with administration of an anti-PD-1 antibody. The administered tumor cells are autologous or MHC-matched to the host.
- Researchers have sought alternatives to autologous and MHC-matched cells as tumor immunotherapies, as reviewed by Jaffee et al., Seminars in Oncology, 22, 81-91 (1995). Early tumor immunotherapy strategies were based on the understanding that the vaccinating tumor cells function as the antigen presenting cells (APCs) and present tumor antigens by way of their MHC class I and II molecules, and directly activate the T cell arm of the immune system. The results of Huang et al. (Science, 264, 961-965, 1994), indicate that professional APCs of the host rather than the vaccinating tumor cells prime the T cell arm of the immune system by secreting cytokine(s) such as GM-CSF such that bone marrow-derived APCs are recruited to the region of the tumor. These results suggest that it may not be necessary or optimal to use autologous or MHC-matched tumor cells in order to elicit an anti-cancer immune response and that the transfer of allogeneic MHC genes (from a genetically dissimilar individual of the same species) can enhance tumor immunogenicity. More specifically, in certain cases, the rejection of tumors expressing allogeneic MHC class I molecules resulted in enhanced systemic immune responses against subsequent challenge with the unmodified parental tumor, as reviewed in Jaffee et al., supra, and Huang et al., supra.
- In one preferred aspect, the invention provides a method for treating cancer by carrying out the steps of: (a) obtaining a tumor cell line; (b) modifying the tumor cell line to render the cells capable of producing an increased level of a cytokine relative to the unmodified tumor cell line; (c) rendering the modified tumor cell line proliferation incompetent; and (d) administering the tumor cell line to a mammalian host having at least one tumor that is the same type of tumor as that from which the tumor cell line was obtained or wherein the tumor cell line and host tumor express at least one common antigen, in combination with administration of an anti-PD-1 antibody. The administered tumor cell line is allogeneic and is not MHC-matched to the host. Such allogeneic lines provide the advantage that they can be prepared in advance, characterized, aliquoted in vials containing known numbers of cytokine-expressing cells and stored such that well-characterized cells are available for administration to the patient. Methods for the production of gene-modified allogeneic cells are described for example in International Patent Publication No. WO 00/72686A, expressly incorporated by reference herein.
- In one approach to preparing a cytokine-expressing cellular immunotherapy comprising gene-modified allogeneic cells, cytokine-encoding nucleic acid sequences are introduced into a cell line that is an allogeneic tumor cell line (i.e., derived from an individual other than the individual being treated). The tumor cell line may be of the same type as the tumor or cancer being treated. The tumor and/or tumor cell line may be from any form of cancer, including, but not limited to, carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, cervix, pancreas, rectum, prostate, stomach, epidermis, a hematopoietic tumor of lymphoid or myeloid lineage, a tumor of mesenchymal origin such as a fibrosarcoma or rhabdomyosarcoma, melanoma, teratocarcinoma, neuroblastoma, glioma, adenocarcinoma, and non-small lung cell carcinoma.
- Desirably, the allogeneic cell line expresses GM-CSF in a range from 200-1000 ng/106 cells/24 h. Preferably, the universal bystander cell line expresses at least about 200 ng GM-CSF/106 cells/24 hours.
- In practicing the invention, one or more allogeneic cell lines can be incubated with an autologous cancer antigen, e.g., an autologous tumor cell (which together comprise an allogeneic cell line composition), then the allogeneic cell line composition can be administered to the patient. Typically, the cancer antigen can be provided by (on) a cell of the cancer to be treated, i.e., an autologous cancer cell. In such cases, the composition can be rendered proliferation-incompetent by irradiation, wherein the allogeneic cells and cancer cells are plated in a tissue culture plate and irradiated at room temperature using a Cs source, as detailed above. The ratio of allogeneic cells to autologous cancer cells in a given administration will vary dependent upon the combination.
- Any suitable route of administration can be used to introduce an allogeneic cell line composition into the patient. Preferably, the composition is administered subcutaneously or intratumorally.
- The use of allogeneic cell lines in practicing the present invention enables administration of a cytokine-expressing allogeneic cell line to a patient with cancer, together with an autologous cancer antigen. This treatment can result in an effective immune response to a tumor. This approach advantageously obviates the need to culture and transduce autologous tumor cells for each patient, eliminating the problem of variable and inefficient transduction efficiencies.
- In one further aspect, the present invention provides a universal immunomodulatory cytokine-expressing bystander cell line and an anti-PD-1 antibody. The universal bystander cell line comprises cells which either naturally lack major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens or have been modified so that they lack MHC-I antigens and MHC-II antigens. In one aspect of the invention, a universal bystander cell line is modified by introduction of a vector comprising a nucleic acid sequence encoding a cytokine operably linked to a promoter and expression control sequences necessary for expression thereof. The nucleic acid sequence encoding the cytokine may or may not further comprise a selectable marker sequence operably linked to a promoter. The universal bystander cell line preferably grows in defined, e.g., serum-free, medium, preferably as a suspension.
- An example of a preferred universal bystander cell line is K562 (ATCC CCL-243; Lozzio et al, Blood 45(3): 321-334 (1975); Klein et al., Int. J. Cancer 18: 421-431 (1976)). A detailed description of human bystander cell lines is described for example in U.S. Pat. No. 6,464,973 and International Patent Publication No. WO 9938954. Desirably, the universal bystander cell line expresses the cytokine, e.g., GM-CSF in the range from 200-1000 ng/106 cells/24 h. Preferably, the universal bystander cell line expresses at least about 200 ng GM-CSF/106 cells/24 hours.
- In practicing the invention, the universal bystander cell lines can be incubated with an autologous cancer antigen, e.g., an autologous tumor cell (which together comprise a universal bystander cell line composition), then the universal bystander cell line composition can be administered to the patient. Any suitable route of administration can be used to introduce a universal bystander cell line composition into the patient. Preferably, the composition is administered subcutaneously or intratumorally.
- Typically, the cancer antigen can be provided by (on) a cell of the cancer to be treated, i.e., an autologous cancer cell. In such cases, the composition can be rendered proliferation-incompetent by irradiation, wherein the bystander cells and cancer cells are plated in a tissue culture plate and irradiated at room temperature using a Cs source, as detailed above.
- The ratio of bystander cells to autologous cancer cells in a given administration will vary dependent upon the combination. With respect to GM-CSF-producing bystander cells, the ratio of bystander cells to autologous cancer cells in a given administration should be such that at least 36 ng GM-CSF/106 cells/24 hrs is produced, as the therapeutic effect may be decreased if the concentration of GM-CSF is less than this. In addition to the GM-CSF threshold, the ratio of bystander cells to autologous cancer cells should not be greater than 1:1. Appropriate ratios of bystander cells to tumor cells or tumor antigens can be determined using routine methods in the art.
- The use of bystander cell lines in practicing the present invention enables administration of a cytokine-expressing bystander cell line to a patient with cancer, together with an autologous cancer antigen. This treatment can result in an effective immune response to a tumor. This approach advantageously obviates the need to culture and transduce autologous tumor cells for each patient, eliminating the problem of variable and inefficient transduction efficiencies.
- In one approach, the efficacy of a cytokine-expressing cellular immunotherapy co-administered with an anti-PD-1 antibody can be evaluated by carrying out animal studies in the syngeneic B16F10 melanoma tumor model in the treatment setting. See, e.g., Griswold D P Jr.,
Cancer Chemother Rep 2; 3(1):315-24, 1972 and Berkelhammer J et al, Cancer Res 42(8):3157-63, 1982. The murine melanoma cell line B16 is a well-defined cell line which is weakly immunogenic in syngeneic C57B16 mice and therefore readily forms tumors in C57BL6 mice. Furthermore, several tumor associated antigens have been identified in this model which allow one to monitor tumor specific as well as antigen specific immune responses. In addition, several murine-specific reagents are commercially available and are used to monitor anti-tumor immune responses in the various immunotherapy strategies. A typical study in the B16F10 melanoma tumor model makes use of at least 6 and generally 10-15 mice per group in order to obtain statistically significant results. Statistical significance can be evaluated using the Student's t-test. - Vaccination of C57BL/6 mice with irradiated GM-CSF-secreting B16F10 tumor cells stimulates potent, long-lasting and specific anti-tumor immunity that prevents tumor growth in most mice subsequently challenged with wild-type B16F10 cells. However, this protection is less effective when GM-CSF-producing tumor cell immunotherapies are administered to mice with preexisting tumor burden. In carrying out studies using the B16F10 melanoma tumor model, female C57BL/6 mice are obtained from Taconic and are 6-8 weeks old at the start of each experiment. In a typical experiment, mice are injected with 1-2×105 B16BF10 cells on
day 0 subcutaneously in a dorsal/anterior location. Onday 3, mice are vaccinated in a ventral/posterior location with 1-3×106 irradiated (10,000 rads) B16F10 or cytokine-expressing cellular immunotherapy. Mice are followed for tumor development and survival. After 14-21 days, mice are sacrificed and their tumor burden assessed by harvesting the mice lungs and counting the surface tumor metastasis and measuring the weight of the lung. An alternative B16F10 melanoma tumor model involves subcutaneous injection of B16F10 tumor cells. A typical in vivo study in the B16F10 melanoma tumor model employs the following groups: HBSS only (negative control); cytokine-expressing cellular immunotherapy/HBSS; (cellular monotherapy control); anti-PD-1 antibody (antibody only control); cytokine-expressing cellular immunotherapy plus anti-PD-1 antibody. - Previous experiments have demonstrated that HBSS or irradiated B16F10 alone do not protect challenged mice from tumor formation. GM-CSF-expressing cellular immunotherapies alone were shown to protect from 10-20% of the challenged mice. The combination of a cytokine-expressing cellular immunotherapy plus an anti-PD-1 antibody is expected to increase the efficacy of anti-tumor protection. The degree of protection depends on several factors, such as the expression level of the cytokine-expressing cellular immunotherapy, the dosage and dosing frequency of the anti-PD-1 antibody, and the relative timing of administration of the anti-PD-1 antibody relative to the timing of administration of the cytokine-expressing cellular immunotherapy.
- Several tumor associated antigens have been identified which allow one to monitor tumor specific as well as antigen-specific immune-responses. For example, tumor antigen-specific T cells can be identified by the release of IFN-gamma following antigenic restimulation in vitro (Hu, H-M. et al, Cancer Research, 2002, 62; 3914-3919) (
FIGS. 2C , 3B). Yet another example of new methods used to identify tumor antigen-specific T cells is the development of soluble MHC I molecules also known as MHC tetramers (Beckman Coulter, Immunomics), reported to be loaded with specific peptides shown to be involved in an anti-tumor immune response. (FIG. 2A ). - Tetramer staining may be used to monitor tumor-specific T-cell responses and to identify very low frequencies of antigen-specific T-cells. Because tetramer staining is performed on freshly isolated lymphocytes within several hours of removal, and without further in vitro stimulation, the technique can be used to estimate the frequency of tumor antigen-specific T-cells in vivo. This provides a means to compare the potency of different tumor immunotherapy strategies.
- Examples within the B16F10 melanoma tumor model include but are not limited to gp100, Trp2, Trp-1, and tyrosinase. Similar melanoma-associated antigens have been identified in humans. Such tools provide information that can then be translated into the clinical arena.
- Tumor burden can be assessed at various time points after tumor challenge using techniques well known in the art. Assays for monitoring anti-tumor response and determining the efficacy of combination immunotherapy are described below. While an improved or enhanced anti-tumor immune response may be most dramatically observed shortly following administration of the immunotherapy, e.g. within 5-10 days, the response may be delayed in some instances, depending on factors such as the expression level of the cytokine-expressing cellular immunotherapy, the dosage and dosing frequency of the anti-PD-1 antibody, and the relative timing of administration of the anti-PD-1 antibody relative to the timing of administration of the cytokine-expressing cellular immunotherapy. Thus, the following assays may be performed on biological samples harvested at much later time points than is indicated below in order to fully assess the anti-tumor response following immunotherapy.
- Cytotoxic T lymphocyte (CTL) activity may be determined both in vitro and in vivo. Typically, spleen cells are assessed for CTL activity by in vitro whole cell stimulation for 5 days. Target cells are labeled with 51Cr and co-incubated with splenic effector CTL, and release of 51Cr into the supernatants is an indicator of CTL lysis of target cells. On
day 3, in vitro stimulated CTL supernatants are tested for IFN-gamma production by CTL. In brief, wells are coated with coating antibody specific for IFN-gamma, supernatant is then added to wells, and IFN-gamma is detected using an IFN-gamma specific detecting antibody. IFN-gamma can also be detected by flow cytometry, in order to measure cell-specific IFN-gamma production. - In vivo CTL activity may be assessed-via carboxyfluoroscein diacetate succinimidyl ester (CSFE) labeling of syngeneic splenocytes. In brief, splenocyte target populations are evenly split into two populations. The first population is pulsed with antigen specific peptide, e.g. SIINFEKL peptide from OVA, and labeled with a high concentration of CSFE, e.g. 2.5 μM (CSFEhi), while the second population is non-pulsed and labeled with a low concentration of CSFE, e.g. 0.25 μM. (CSFElo). An equal number of cells from each population are mixed together and injected into mice immunized with cytokine expressing tumor cell immunotherapy alone, or in combination with anti-PD-1 antibody. 18 hours following injection, splenocytes are harvested and cell suspensions are analyzed by flow cytometry, and cell populations are distinguished based on varying fluorescent intensities. Percent specific lysis is determined by the loss of the peptide-pulsed CSFEhi population compared to the control CSFElo population. (
FIG. 2B ). - Another indication of an effective anti-tumor immune response is the production of effector cytokines such as TNF-alpha, IFN-gamma, IL-5, IL-6, IL-10 and monocyte chemotactic protein (MCP)-1 upon restimulation in vitro. Cytokine levels were measured in supernatants from spleen cells restimulated in vitro for 48 hours with irradiated GM-CSF-expressing cells. (
FIG. 3 ) - A further method used to monitor tumor-specific T cell responses is via intracellular cytokine staining (ICS). ICS can be used to monitor tumor-specific T-cell responses and to identify very low frequencies of antigen-specific T-cells. Because ICS is performed on freshly isolated lymphocytes within 5 hours of removal, unlike the CTL and cytokine release assays, which often require 2-7 days of in vitro stimulation, it can be used to estimate the frequency of tumor antigen-specific T-cells in vivo. This provides a powerful technique to compare the potency of different tumor immunotherapy strategies. ICS has been used to monitor T-cell responses to melanoma-associated antigens such as
gp 100 and Trp2 following various melanoma immunotherapy strategies. Such T-cells can be identified by the induction of intracellular IFN-gamma expression following stimulation with a tumor-specific peptide bound to MHC I. - In some studies, in vivo luminescence of tumor bearing mice is monitored by monitoring of B16F10-luciferase (Xenogen Inc.) injected mice. In brief, Balb/c nu/nu mice are injected with 5×104 or 2×105 cells of B16F10-luc cells via tail vein on
day 0. Mice are monitored for tumor burden when necessary by intra-peritoneal injection of excess luciferin substrate at 1.5 mg/g mice weight. In a typical analysis, twenty minutes after substrate injection, mice are anesthesized and monitored for in vivo luminescence with Xenogen IVIS Imaging System (Xenogen Inc.) luminescence sensitive CCD camera by dorsal or ventral position. Data is collected and analyzed by Living Image 2.11 software. - Previous reports indicate that GM-CSF-secreting tumor cell immunotherapy provides partial protection of mice when used as a monotherapy for non-immunogenic tumors such as B16 melanoma. The results presented herein demonstrate that the combination of GM-CSF-secreting B16 tumor cells and an anti-PD-1 antibody can act synergistically, resulting in highly protective antitumor immune responses. In order to achieve the maximal synergistic effect of these two agents in clinical trials, possible treatment regimens should be carefully evaluated in preclinical studies. In ongoing clinical trials GM-CSF-secreting tumor cell immunotherapies or anti-PD-1 antibodies are administered to patients repeatedly over a period of several months. In studies described herein, the efficacy of the combination was evaluated in preclinical studies following repeated administration of both GM-CSF-secreting tumor cell immunotherapies and anti-PD-1 antibodies. Example 4 details studies where a cytokine expressing cellular immunotherapy was tested in both a B16F10 and CT26 tumor model with and without co-administration of an anti-PD-1 antibody. The GM-CSF-secreting tumor cell immunotherapy was less effective than the combination therapy of anti-PD-1 antibody and GM-CSF-secreting tumor cell immunotherapies (
FIGS. 4 , 5). - These results demonstrate that in practicing the present invention, an autologous, allogeneic, or bystander cytokine-expressing cellular immunotherapy may be administered to a cancer patient in combination with an anti-PD-1 antibody, resulting in enhanced therapeutic efficacy and prolonged survival relative to either monotherapy alone.
- In a preferred aspect of the methods described herein, a cytokine-expressing cellular immunotherapy is administered in combination with an anti-PD-1 antibody to a cancer patient, wherein the cytokine-expressing cellular immunotherapy comprises mammalian, preferably human tumor cells, and the cells in the cytokine-expressing cellular immunotherapy are rendered proliferation incompetent, such as by irradiation. Administration of a cytokine-expressing cellular immunotherapy in combination with an anti-PD-1 antibody results in an enhanced immune response to the cancer as compared to the immune response to the same cancer following administration of the cytokine-expressing cellular immunotherapy or anti-PD-1 antibody alone.
- The cytokine-expressing cellular immunotherapy combination may be administered by any suitable route. Preferably, the composition is administered subcutaneously or intratumorally. Local or systemic delivery can be accomplished by administration comprising administration of the combination into body cavities, by parenteral introduction, comprising intramuscular, intravenous, intraportal, intrahepatic, peritoneal, subcutaneous, or intradermal administration. In the event that the tumor is in the central nervous system, the composition is administered in the periphery to prime naive T-cells in the draining lymph nodes. The activated tumor-specific T-cells are able to cross the blood/brain barrier to find their targets within the central nervous system.
- In some embodiments of the combination immunotherapy described herein, the cells of the cytokine-expressing cellular immunotherapy and the anti-PD-1 antibody can be administered at essentially the same time, i.e., concurrently, e.g. within the same hour or same day, etc., or at separately staggered times, i.e. sequentially prior to or subsequent to the administration of the second agent of the combination immunotherapy, e.g. on separate days, weeks, etc. The instant methods are therefore to be understood to include all such regimes of simultaneous or non-simultaneous treatment. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered within 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or more than 18 hours of administration of the anti-PD-1 antibody. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more than 14 days of administration of the anti-PD-1 antibody. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered within 1, 2, 3, 4, 5 or more than 5 weeks of administration of the anti-PD-1 antibody.
- In some embodiments of the combination immunotherapy described herein, the cells of the cytokine-expressing cellular immunotherapy are administered simultaneously with administration of the anti-PD-1 antibody, for example, with the first administration of the combination therapy and with subsequent administrations of the combination therapy. In a particular embodiment, the cells of the cytokine-expressing cellular immunotherapy are administered simultaneously with the first administration of the anti-PD-1 antibody, and the cells of the cytokine-expressing cellular immunotherapy are administered simultaneously with administration of the anti-PD-1 antibody on a biweekly basis thereafter. In another particular embodiment, the cells of the cytokine-expressing cellular immunotherapy are administered within 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours of administration of the anti-PD-1 antibody, and the cells of the cytokine-expressing cellular immunotherapy are administered within 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours of administration of the anti-PD-1 antibody, on a biweekly basis thereafter.
- In certain embodiments, cells of the cytokine-expressing cellular immunotherapy are administered prior to administration of the anti-PD-1 antibody. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered one, two, three, four, five, six, seven, or more days prior to administration of the anti-PD-1 antibody. In other embodiments, cells of the cytokine-expressing cellular immunotherapy are administered after administration of the anti-PD-1 antibody. In some embodiments, the cells of the cytokine-expressing cellular immunotherapy are administered one, two, three, four, five, six, seven, or more days after administration of the anti-PD-1 antibody.
- As will be understood by those of skill in the art, the optimal treatment regimen will vary. As a result, it will be understood that the status of the cancer patient and the general health of the patient prior to, during, and following administration of a cytokine-expressing cellular immunotherapy in combination with an anti-PD-1 antibody, the patient will be evaluated in order to determine if the dose of each component and relative timing of administration should be optimized to enhance efficacy or additional cycles of administration are indicated. Such evaluation is typically carried out using tests employed by those of skill in the art to evaluate traditional cancer chemotherapy, as further described below in the section entitled “Monitoring Treatment.”
- One skilled in the art is aware of means to monitor the therapeutic outcome and/or the systemic immune response upon administering a combination treatment of the present invention. In particular, the therapeutic outcome can be assessed by monitoring attenuation of tumor growth and/or tumor regression and or the level of tumor specific markers. The attenuation of tumor growth or tumor regression in response to treatment can be monitored using one or more of several end-points known to those skilled in the art including, for instance, number of tumors, tumor mass or size, or reduction/prevention of metastasis.
- The combination immunotherapy composition can be included in a kit, container, pack, or dispenser together with instructions for administration. When the composition is supplied as a kit, the different components of the composition may be packaged in separate containers so as to permit long-term storage without losing the active components' functions. The reagents included in the kits can be supplied in containers of any sort such that the life of the different components are preserved, and are not adsorbed or altered by the materials of the container. For example, cytokine-expressing cells may be housed in containers such as test tubes, vials, flasks, bottles, syringes, or the like. Sealed glass ampules may be used to contain lyophilized anti-PD-1 antibody that has been packaged under a neutral, non-reacting gas, such as nitrogen. Ampoules may consist of any suitable material, such as glass, organic polymers, such as polycarbonate, polystyrene, etc., ceramic, metal or any other material typically employed to hold reagents. Other examples of suitable containers include simple bottles that may be fabricated from similar substances as ampules, and envelopes, that may consist of foil-lined interiors, such as aluminum or an alloy. Containers may have a sterile access port, such as a bottle having a stopper that can be pierced by a hypodermic injection needle. Other containers may have two compartments that are separated by a readily removable membrane that upon removal permits the components to mix. Removable membranes may be glass, plastic, rubber, etc.
- Kits may also be supplied with instructional materials. Instructions may be printed on paper or other substrate, and/or may be supplied as an electronic-readable medium, such as a floppy disc, CD-ROM, DVD-ROM, Zip disc, videotape, audio tape, etc. Detailed instructions may not be physically associated with the kit; instead, a user may be directed to an internet web site specified by the manufacturer or distributor of the kit, or supplied as electronic mail.
- Immune responses were measured as increases in tumor antigen-specific T-cells. Such T-cells can be identified by immunological monitoring methods, as described above, including (A) tetramer staining, (B) in vivo CTL activity, and (C) the induction of intracellular IFN-gamma expression following stimulation with a tumor-specific peptide or tumor cells.
-
FIG. 1A illustrates the anti-tumor T-cell response induced by administration of GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody, as determined by tetramer staining. Onday day 3, mice were immunized with 1×106 irradiated GM-CSF-secreting B16 cells expressing ovalbumin as a surrogate antigen (GM.ova) as immunotherapy alone, or immunotherapy was followed by 200 μg and 100 μg of anti-PD-1 antibody ondays -
FIG. 1B illustrates the in vivo cytolytic activity of T-cells in mice treated with GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody. Onday 0, mice were inoculated with 2×105 live B16F10 cells transduced with the surrogate antigen, ovalbumin (F10.ova). Onday 3, mice were immunized with 1×106 irradiated GM-CSF-secreting F10.ova cells (GM.ova) as immunotherapy alone, or immunotherapy was followed by 200 μg and 100 μg of anti-PD-1 antibody ondays -
FIG. 1C illustrates the anti-tumor T-cell response induced by administration of GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody, measured as an increase in IFNγ-secretion. Onday 0, mice were inoculated subcutaneously with live B16F10 cells. Onday days - Taken together, these results demonstrate that anti-PD-1 antibody augments the anti-tumor T-cell response induced by GM-CSF expressing tumor cell immunotherapy, and support the utility of GM-CSF-secreting tumor cell and anti-PD-1 antibody combination immunotherapy for the induction and/or enhancement of anti-tumor immunity.
- A further suggestion as to the potential utility of the combination of GM-CSF-secreting immunotherapies and anti-PD-1 antibody in eliciting an anti-tumor immune response is the production of pro-inflammatory cytokines such as TNF-alpha, IFN-gamma, IL-2, IL-5, IL-6, IL-10 and MCP-1 upon restimulation in vitro. Release of such cytokines is often used as a surrogate marker for monitoring tumor-specific immune responses following immunotherapeutic strategies designed to induce anti-tumor immunity.
-
FIG. 2 illustrates the secretion of pro-inflammatory cytokines following administration of GM-CSF-secreting B16F10 cells alone and in combination with an anti-PD-1 antibody. Onday 0, mice were inoculated subcutaneously with live B16F10 cells. Onday 3, mice were immunized with 1×106 irradiated GM-CSF-secreting B16F10 cells (B16.Kd.GM) as immunotherapy alone, or immunotherapy was followed by 200 μg and 100 μg of anti-PD-1 antibody ondays - For each cytokine assayed, cytokine secretion was significantly higher in splenocytes from mice receiving combination immunotherapy compared to those receiving GM-CSF expressing tumor cell immunotherapy alone. Thus, these results further support the utility of GM-CSF-secreting tumor cell immunotherapy and anti-PD-1 antibody combination immunotherapy for the induction and/or enhancement of anti-tumor immunity.
-
FIG. 3 illustrates effector CD8 T-cell infiltration into tumors in mice treated with GM-CSF-secreting B16F10 cells alone or in combination with an anti-PD-1 antibody. High numbers of tumor infiltrating lymphocytes (TIL) within tumors have been shown to correlate with overall therapeutic benefit (Dunn et al., Nat. Immunol. 3(11):991-8, 39 (2002); Smyth et al., Nat Immunol. 2(4):293-9 (2001). Thus, the extent of infiltrating lymphocytes in tumors of B16.Kd.GM-treated animals compared to animals treated with the combination therapy was examined. Onday 0, mice were inoculated subcutaneously with live B16F10 cells. Onday days FIG. 3 shows the percentage of IFNγ and CD107α expressing cells in the CD8 tumor infiltrating lymphocyte (TIL) subpopulation from mice immunized with (A) GM-CSF expressing tumor cell immunotherapy alone, and GM-CSF expressing tumor cell immunotherapy alone plus anti-PD-1 antibody. Also shown is the ratio of CD8+/FoxP3+ cells in the tumor at 3 wks post cellular immunotherapy (B). Also shown are the kinetics of (C) CD4+ T-cells, (D) CD8+ T-cells, (E) CD8+ and CD107α+ T-cells, and (F) CD8+ and IFNγ+ T-cells per 1×106 tumor cells. Tumor progression for these animals is shown in (G). - CD4/IFN-γ co-staining was used to identify effector CD4 T-cells and CD8/1FN-γ or CD8/CD107a co-staining was used to identify effector CD8 T-cells within tumors. IFN-Y secreted by T-cells has previously been shown to correlate with immunoregulatory and anti-tumor properties (Schroder et al., J. Leukoc. Biol. 75(2):163-89 (2004), while expression of CD107a is associated with cytolytic activity of T-cells (Betts et al. J. Immunol. Methods 281(1-2):65-78, (2003); and Rubio et al., Nat Med. 9(11):1377-82 (2003)). Animals receiving the combination therapy showed an increased in the percentage of activated CD8 effector T-cells within tumors compared to animals that received B16. Kd.GM monotherapy (
FIG. 3A ). Furthermore, HBSS control animals had minimal CD4 and CD8 T-cell infiltration into tumors, correlating with tumor progression of these animals (FIGS. 3C-D and 3G). Comparatively, animals treated with B16.Kd.GM monotherapy displayed gradual infiltration of T-cells into the tumor environment with peak infiltration seen on day 14, which correlated with the delay in tumor growth observed in this group (*p<0.05 HBSS vs. B16.Kd.GM for all time points). Animals treated with the combination therapy exhibited a rapid and persistent tumor infiltration of functional CD4 and CD8 T-cells (*p<0.05 B16.Kd.GM vs. combination therapy on day 21) that correlated with its increased anti-tumor efficacy. - A favorable intratumoral ratio of effector T-cells (Teff) to regulatory T-cells (Treg) post immunotherapy has been described to correlate with overall anti-tumor activity (Quezada et al., J. Clin Invest. 16(7):1935-45 (2006)) and was therefore assessed in tumors of animals treated with either B16.Kd.GM monotherapy or the combination therapy. At the early time points (
week FIG. 3B ). The correlation between the improved Teff to Treg ratio observed in animals treated with the combination therapy and the better control of tumor growth in this group again suggests that the presence of Tregs in tumors blunts CD8 T-cell activity and that cancer immunotherapies that shift this ratio in favor of the T effector cells are more effective at providing anti-tumor responses. In summary, these data demonstrated a strict correlation between the potency of the anti-tumor T-cell responses measured in the periphery, the number of effector T-cells infiltrating into the tumors and the overall control of disease progression in animals treated with either B16.Kd.GM monotherapy or in combination with an anti-PD-1 antibody. - In vivo studies were carried out using allogeneic B16F10 and autologous CT26 tumor models to determine if an anti-PD-1 antibody in combination with a cytokine-expressing cellular immunotherapy can enhance anti-tumor efficacy compared to immunotherapy alone.
- For studies utilizing the B16F10 model, mice were inoculated subcutaneously with 2×105 live tumor cells on
day 0. Mice were then injected with 1×106 irradiated GM-CSF-secreting B16F10 cells (B16.Kd.GM) as immunotherapy alone, or as combination therapy with 200 μg of anti-PD-1, followed by 100 μg of anti-PD-1 on the following day. Therapy was started at 3 days, 7 days and 11 days following inoculation to assess the effect of delayed administration on efficacy. Mice were monitored for the formation of palpable tumors twice weekly. Mice were assessed daily for any obvious abnormality, and if subcutaneous tumors reached 15-20 mm-diameter in size or started to ulcerate through the skin, animals were euthanized. A Kaplan-Meier survival curve was used for evaluation. Survival curves are shown for mice treated with immunotherapy at 3 days (FIG. 4A ), 7 days (FIG. 4B ), or 11 days (FIG. 4C ) post inoculation. - For each dosing regimen, survival was significantly enhanced in mice treated with the combination therapy compared to immunotherapy alone. HBSS-injected control animals had a MST of 26 days and animals treated with B16.Kd.GM immunotherapy on
day 3 had a MST of 44 days with 10% long-term survival (*p=0.01 HBSS vs. B16.Kd.GM). MST was further prolonged to 57 days in animals that were treated with the combination therapy onday 3 with 50% long-term survival (*p<0.05 B16.Kd.GM+anti-PD-1 vs. B16.Kd.GM) (FIG. 4A ). MSTs were 30 days when B16.Kd.GM immunotherapy was delayed to eitherday 7 orday 11 post-tumor challenge and all animals succumbed to tumor burden by day 45-50. Again, enhanced anti-tumor activity was observed in animals that received the combination therapy initiated either onday 7 orday 11, with 60% (MST=not reached) and 30% (MST=42 days) of animals surviving long-term, respectively (day 7 initiation of therapy *p<0.005 orday 11 initiation of therapy *p=0.01, long-term survival of B16.Kd.GM+anti-PD-1 vs. B16.Kd.GM) (FIGS. 4B and 4C ). Furthermore, on day 90, re-challenge of surviving mice on day 90 in both immunotherapy alone and combination therapy groups with 2.5-times the initial dose of live tumor cells demonstrated the presence of a potent B16-specific memory response, suggesting that the induction of memory responses is B16.Kd.GM dependent (FIG. 4D ). Thus, the combination of GM-CSF-secreting tumor cell immunotherapy and anti-PD-1 antibody is potent enough to significantly delay tumor growth of well established primary tumors and to maintain memory responses for protection against tumor re-occurrence. - To evaluate the potency of this combination therapy in a second model, the in vivo study was repeated in the autologous immunogenic CT26 colon carcinoma tumor model in Balb/c animals. In this study, mice were inoculated subcutaneously with 2×105 live tumor cells on
day 0. Onday 3, mice were then injected with er 1×106 irradiated GM-CSF-secreting CT26 cells (CT26.GM) as immunotherapy alone or as combination therapy with 200 μg of anti-PD-1, followed by 100 μg of anti-PD-1 onday 4. Anti-PD-1 antibody alone was also administered as a control, at 200 μg onday 3 post challenge followed by 100 μg anti-PD-1 onday 4. - As shown in
FIGS. 5A and 5B , anti-PD-1 antibody and CT26.GM monotherapies both prolonged the survival of tumor bearing animals to 25 days compared to HBSS-injected control animals with a MST of 18 days. Consistent with the findings in the B16 model, CT26 tumor-bearing animals treated with the combination therapy showed a significant survival advantage over animals treated with either monotherapy, with 90% of animals surviving long-term (*p<0.01 compared to CT26.GM alone). Thus, anti-PD-1 antibody in combination with GM-CSF-secreting tumor cell immunotherapy significantly prolonged the survival of animals bearing either a non-immunogenic or an immunogenic tumor when compared to either monotherapy. -
FIG. 6 illustrates the enhancement of the percentage of CD8+ T-cells in spleen from mice treated with GM-CSF-secreting B16F10 cells alone or in combination with an anti-PD-1 antibody. Onday 0, mice were inoculated subcutaneously with live B16F10 cells. Onday days day 10 following inoculation, spleens from mice were excised, digested and stained, and splenocytes were evaluated by flow cytometry. Shown are the percentage of T-cells positive for (A) CD4; (B) CD8; (C) CD11c; and (D) DX5. The percentage of CD8 positive T-cells are enhanced in B16.Kd.GM+anti-PD1 treated mice. -
FIG. 7 illustrates the percentage of memory T-cells in spleen from mice treated with GM-CSF-secreting B16F10 cells alone or in combination with an anti-PD-1 antibody. Onday 0, mice were inoculated subcutaneously with live B16F10 cells. Onday days day 10 following inoculation, spleens from mice were excised, digested and stained, and splenocytes were evaluated by flow cytometry. The percentage of memory T-cells was assessed by staining cells with for surface markers CD69 and Ly6C. Ly6C has been described as a marker for memory CD8+ T cells (Walumas et al., J. Immunol. 155:1973-1883 (1995) while CD69 is a marker for early T-cell activation. Memory T-cells were designated as the population of cells that were Ly6C+/CD69− within CD4 and CD8 positive cells.FIG. 7 shows the percentage of Ly6C+/CD69− cells within (A) the CD4 subpopulation; and (B) the CD8 subpopulation. The percentage of memory T-cells is significantly enhanced in spleens from mice treated with the B16.Kd.GM+anti-PD1 combination therapy compared to B16.Kd.GM immunotherapy alone. - On
day day 11, mice were immunized with 1×106 irradiated GM-CSF-secreting B16 cells expressing ovalbumin as a surrogate antigen (GM.ova) as immunotherapy alone or immunotherapy was followed by 200 mg and 100 mg of anti-PD-1 antibody ondays 11 and 12, respectively, as combination therapy. At indicated timepoints, peripheral blood leukocyte (PBL) from mice were drawn and evaluated for the percentage of antigen-specific T-cells by tetramer staining. -
FIG. 8 illustrates an increase in the percentage of antigen-specific T-cells was induced by immunotherapy with both GM.ova and GM.ova plus anti-PD-1 antibody (16 days following adoptive transfer) following the establishment of anergy with SIINFEKL peptide. However, the percentage of antigen-specific T-cells was nearly 2-fold higher atday 16 in GM.ova plus anti-PD-1 antibody treated mice compared to mice treated with GM.ova alone. These data demonstrate that anti-PD-1 reverses anergy and augments tumor-specific T-cell response induced by GM-CSF tumor cell immunotherapy. - To determine the optimal schedule for administration of each component of the combination therapy to expand antigen-specific T-cells effectively in a bi-weekly multi-treatment setting, three different combination therapy treatment schedules were evaluated.
- To first establish an antigen-specific T-cell response, all B16 tumor-bearing animals received GM.ova immunotherapy and anti-PD-1 antibody at the first therapy cycle. On
day day 3, mice were immunized with 1×106 irradiated GM-CSF-secreting B16 cells expressing ovalbumin (GM.ova) as immunotherapy alone or GM.ova immunotherapy was followed by 200 μg and 100 μg of anti-PD-1 antibody ondays - At indicated time points, splenocytes from selected animals were isolated and evaluated for the presence of ovalbumin-specific CD8+ T-cells by co-staining the cells with anti-CD8 antibody and the SIINFEKL tetramer. The study showed the expansion and contraction of the population of ovalbumin-specific CD8 T-cells in the spleen after each treatment cycle (
FIG. 9A ) and that ovalbumin-specific CD8 T-cells expanded and peaked 7 days after each therapy cycle in animals that received the cellular immunotherapy and the PD-1 blockade concurrently. In animals that received bi-weekly cellular immunotherapy alone, the peak of ovalbumin-specific CD8 T-cell expansion from the second immunotherapy cycle was observed 2 weeks later (day 28). In contrast, in animals that received bi-weekly anti-PD-1 antibody and monthly GM.ova immunotherapy, the expansion of the ovalbumin-specific CD8 T-cells was only observed after the treatment cycle that consisted of the cellular immunotherapy and the PD-1 blockade and not when only the antibody was administered. - The effector phenotype of these ovalbumin-specific CD8 T-cells was confirmed by co-staining the cells with the activation markers, CD107a and IFNγ (
FIGS. 9B and C). In animals that received the combination therapy at each therapy cycle, a similar trend in the number of tetramer-positive cells and the number of cells with an effector phenotype was observed. However, in animals that received bi-weekly cellular immunotherapy alone or bi-weekly anti-PD-1 antibody and monthly GM.ova immunotherapy, the peak of the IFNγ-secreting ovalbumin-specific CD8 T-cells did not always correlate with the peak of total ovalbumin-specific CD8 T-cells. After the second treatment cycle, in the bi-weekly cellular immunotherapy alone group, the number of IFNγ-secreting ovalbumin-specific CD8 T-cells peaked on day 21 while total ovalbumin-specific CD8 T-cells peaked on day 28. Similarly, in the bi-weekly anti-PD-1 antibody and monthly GM.ova immunotherapy group, the number of IFNγ-secreting ovalbumin-specific CD8 T-cells peaked on day 21 while total ovalbumin-specific CD8 T-cells did not change. After the second treatment cycle, the data showed that the combination therapy most efficiently expanded the number of IFNγ-secreting ovalbumin-specific CD8 T-cells (21.92+/−3.31×106 cells) and that cellular immunotherapy alone (13.57+/−1.95×106 cells) is more effective than anti-PD-1 antibody alone (6.11+/−1.20×106 cells). In summary, these data suggested that readministration of the cellular immunotherapy with the anti-PD-1 antibody in subsequent immunotherapy cycles was required to reactivate these T-cell responses. - The present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those having skill in the art from the foregoing description and accompanying drawings, Such modifications are intended to fall within the scope of the appended claims. All references cited herein are hereby incorporated by reference in their entireties.
Claims (55)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/178,122 US20090028857A1 (en) | 2007-07-23 | 2008-07-23 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US12/839,163 US8287856B2 (en) | 2007-07-23 | 2010-07-19 | PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US13/619,699 US8580247B2 (en) | 2007-07-23 | 2012-09-14 | PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US14/078,042 US20140271684A1 (en) | 2007-07-23 | 2013-11-12 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US14/733,614 US20150265705A1 (en) | 2007-07-23 | 2015-06-08 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96174307P | 2007-07-23 | 2007-07-23 | |
US12/178,122 US20090028857A1 (en) | 2007-07-23 | 2008-07-23 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/839,163 Continuation US8287856B2 (en) | 2007-07-23 | 2010-07-19 | PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090028857A1 true US20090028857A1 (en) | 2009-01-29 |
Family
ID=40282035
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/178,122 Abandoned US20090028857A1 (en) | 2007-07-23 | 2008-07-23 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US12/839,163 Expired - Fee Related US8287856B2 (en) | 2007-07-23 | 2010-07-19 | PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US13/619,699 Active US8580247B2 (en) | 2007-07-23 | 2012-09-14 | PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US14/078,042 Abandoned US20140271684A1 (en) | 2007-07-23 | 2013-11-12 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US14/733,614 Abandoned US20150265705A1 (en) | 2007-07-23 | 2015-06-08 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/839,163 Expired - Fee Related US8287856B2 (en) | 2007-07-23 | 2010-07-19 | PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US13/619,699 Active US8580247B2 (en) | 2007-07-23 | 2012-09-14 | PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US14/078,042 Abandoned US20140271684A1 (en) | 2007-07-23 | 2013-11-12 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US14/733,614 Abandoned US20150265705A1 (en) | 2007-07-23 | 2015-06-08 | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
US (5) | US20090028857A1 (en) |
WO (1) | WO2009014708A2 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100150946A1 (en) * | 2008-08-28 | 2010-06-17 | Cell Genesys, Inc. | Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer |
US20110229461A1 (en) * | 2010-03-11 | 2011-09-22 | Kerry Louise Tyson | PD-1 Antibodies |
US20140341978A1 (en) * | 2011-09-19 | 2014-11-20 | The Johns Hopkins University | Cancer immunotherapy |
US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
WO2016024228A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
WO2017122175A1 (en) | 2016-01-13 | 2017-07-20 | Acerta Pharma B.V. | Therapeutic combinations of an antifolate and a btk inhibitor |
US9815897B2 (en) | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
WO2020061429A1 (en) | 2018-09-20 | 2020-03-26 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
WO2020096682A2 (en) | 2018-08-31 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
EP3747472A1 (en) | 2015-09-15 | 2020-12-09 | Acerta Pharma B.V. | Therapeutic combinations of a cd19 inhibitor and a btk inhibitor |
WO2020255011A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
WO2020255009A2 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
EP3351261B1 (en) | 2011-10-11 | 2021-06-02 | Universität Zürich | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US11155624B2 (en) | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
WO2021216920A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
CN113925964A (en) * | 2016-02-15 | 2022-01-14 | 崔泽尔有限公司 | Improved interferon therapy |
WO2022094567A1 (en) | 2020-10-28 | 2022-05-05 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
US11407830B2 (en) | 2017-01-09 | 2022-08-09 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US11497544B2 (en) | 2016-01-15 | 2022-11-15 | Immunsys, Inc. | Immunologic treatment of cancer |
US11571463B2 (en) | 2016-05-18 | 2023-02-07 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (IL12) and uses thereof |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US11696797B2 (en) | 2013-12-05 | 2023-07-11 | Immunsys, Inc. | Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB) |
US11865159B2 (en) | 2017-02-28 | 2024-01-09 | Sanofi | Therapeutic RNA |
US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
US11981921B2 (en) | 2022-04-15 | 2024-05-14 | Iovance Biotherapeutics, Inc. | TIL expansion processes using specific cytokine combinations and/or AKTi treatment |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
Families Citing this family (194)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3153526B1 (en) | 2008-01-31 | 2020-09-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
PL2350129T3 (en) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Compositions of pd-1 antagonists and methods of use |
EP3939572B1 (en) | 2012-04-12 | 2024-03-27 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
NZ631405A (en) | 2012-10-02 | 2017-01-27 | Bristol Myers Squibb Co | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
US20150377891A1 (en) | 2013-02-07 | 2015-12-31 | (Institute National De La Santé Et De La Rechere Médicale) | Methods for Predicting the Survival Time of Patients Suffering from Diffuse Large B-Cell Lymphomas |
CN105431449B (en) * | 2013-04-05 | 2021-08-24 | 港大科桥有限公司 | Novel PD1 isoform and use thereof for boosting immune responses |
CN105209054A (en) | 2013-04-18 | 2015-12-30 | 阿尔莫生物科技股份有限公司 | Methods of using interleukin-10 for treating diseases and disorders |
EP3178849B1 (en) | 2013-09-20 | 2019-03-20 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
CN110302162A (en) | 2013-11-01 | 2019-10-08 | 耶鲁大学 | Modularization particle for immunotherapy |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
JP6502959B2 (en) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | PD-1 antibodies, antigen binding fragments thereof and their medical use |
NZ721908A (en) * | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
EP3610924B1 (en) | 2014-06-06 | 2021-11-03 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
TWI693232B (en) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
EP3166616B1 (en) * | 2014-07-10 | 2021-04-07 | Biothera, Inc. | Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment |
CA2955084C (en) | 2014-07-16 | 2023-08-29 | Transgene Sa | Combination of oncolytic virus with immune checkpoint modulators |
PL3169341T3 (en) | 2014-07-16 | 2019-12-31 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
SG11201700672YA (en) | 2014-08-05 | 2017-02-27 | MabQuest SA | Immunological reagents binding to pd-1 |
RU2718914C2 (en) | 2014-09-13 | 2020-04-15 | Новартис Аг | Combined treatment methods using alk inhibitors |
ES2825576T3 (en) | 2014-09-16 | 2021-05-17 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
RU2746804C2 (en) | 2014-10-10 | 2021-04-21 | Иннейт Фарма | Blockade cd73 |
WO2016073759A1 (en) | 2014-11-05 | 2016-05-12 | The Regents Of The University Of California | Combination immunotherapy |
EP4046656A1 (en) * | 2014-11-06 | 2022-08-24 | HiberCell, Inc. | Beta-glucan methods and compositions that affect the tumor microenvironment |
EA035766B1 (en) | 2014-11-21 | 2020-08-07 | Бристол-Майерс Сквибб Компани | Antibodies against cd73 and uses thereof |
SI3221346T1 (en) | 2014-11-21 | 2020-11-30 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
CA2971732A1 (en) | 2014-12-23 | 2016-06-30 | Bristol-Myers Squibb Company | Antibodies to tigit |
CA2975123A1 (en) | 2015-01-30 | 2016-08-04 | Rfemb Holdings, Llc | Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
EP3770171A1 (en) | 2015-04-03 | 2021-01-27 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
US10835585B2 (en) | 2015-05-20 | 2020-11-17 | The Broad Institute, Inc. | Shared neoantigens |
HRP20230060T1 (en) | 2015-05-29 | 2023-03-17 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
TW201709929A (en) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | Combination therapy for the treatment of cancer |
CN107922500A (en) | 2015-06-29 | 2018-04-17 | 洛克菲勒大学 | The anti-CD 40 antibodies of agonist activity with enhancing |
CN108368170B (en) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
IL297090A (en) | 2015-07-30 | 2022-12-01 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
CN108025040A (en) | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | The method that disease and illness are treated using interleukin-10 |
US10287352B2 (en) | 2015-10-02 | 2019-05-14 | Hoffman-La Roche Inc. | Bispecific antibodies specific for PD1 and TIM3 |
RU2746409C1 (en) | 2015-10-02 | 2021-04-13 | Ф. Хоффманн-Ля Рош Аг | Pd1 antibodies and their application methods |
RU2731202C2 (en) | 2015-10-08 | 2020-08-31 | Макродженикс, Инк. | Combined therapy for cancer treatment |
US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
US11213586B2 (en) | 2015-11-19 | 2022-01-04 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) |
TW202208440A (en) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | Bispecific Molecules Having Immunoreactivity with PD-1 and CTLA-4, and Methods of Use Thereof |
EP3405495B1 (en) | 2016-01-21 | 2021-02-24 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
EP3964529A1 (en) | 2016-01-22 | 2022-03-09 | Mabquest SA | Non-blocking pd1 specific antibodies |
SG11201806861SA (en) | 2016-03-04 | 2018-09-27 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
WO2017155981A1 (en) | 2016-03-07 | 2017-09-14 | Massachusetts Institute Of Technology | Protein-chaperoned t-cell vaccines |
EP3426688A1 (en) | 2016-03-08 | 2019-01-16 | Innate Pharma | Siglec neutralizing antibodies |
WO2017167921A1 (en) | 2016-03-30 | 2017-10-05 | Centre Léon-Bérard | Lymphocytes expressing cd73 in cancerous patient dictates therapy |
CA3021328A1 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
TWI786044B (en) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | Methods of treating skin cancer by administering a pd-1 inhibitor |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
SG10201911972QA (en) | 2016-07-14 | 2020-02-27 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
RU2757394C2 (en) | 2016-08-03 | 2021-10-14 | Нексткьюр, Инк. | Compositions and methods for modulating the transmission of a lair signal |
EP3506916B1 (en) | 2016-09-01 | 2021-04-07 | Chimera Bioengineering Inc. | Gold optimized car t-cells |
US11090391B2 (en) | 2016-09-16 | 2021-08-17 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
US11390675B2 (en) | 2016-09-21 | 2022-07-19 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
EP4360714A2 (en) | 2016-09-21 | 2024-05-01 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
CN110291105B (en) | 2017-01-05 | 2024-03-01 | 奈特里斯药物公司 | Combination therapy of guide-1 interfering drugs and immune checkpoint inhibitor drugs |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US20200023071A1 (en) | 2017-02-06 | 2020-01-23 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
WO2018156888A1 (en) | 2017-02-24 | 2018-08-30 | Biothera Pharmaceuticals, Inc. | Beta glucan immunopharmacodynamics |
MX2019010848A (en) | 2017-03-16 | 2019-10-30 | Innate Pharma | Compositions and methods for treating cancer. |
CN110392692B (en) | 2017-04-03 | 2023-07-21 | 豪夫迈·罗氏有限公司 | Immunoconjugates of anti-PD-1 antibodies with mutant IL-2 or with IL-15 |
AU2018247794A1 (en) | 2017-04-05 | 2019-08-22 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to PD1 and LAG3 |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
JP2020517737A (en) | 2017-04-21 | 2020-06-18 | シルラゼン, インコーポレイテッド | Combination therapy of oncolytic vaccinia virus and checkpoint inhibitor |
EP3615070A1 (en) | 2017-04-26 | 2020-03-04 | Bristol-Myers Squibb Company | Methods of antibody production that minimize disulfide bond reduction |
EP3625260A1 (en) | 2017-05-16 | 2020-03-25 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
SG10201913206RA (en) | 2017-05-25 | 2020-02-27 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant regions |
AU2018277824A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
US11723975B2 (en) | 2017-05-30 | 2023-08-15 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
EP3630842A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
AU2018291081A1 (en) | 2017-06-27 | 2020-01-16 | Neuracle Science Co., Ltd. | Use of anti-FAM19A5 antibodies for treating cancers |
EP3652208A1 (en) | 2017-07-10 | 2020-05-20 | Innate Pharma | Siglec-9-neutralizing antibodies |
JP2020532991A (en) | 2017-09-07 | 2020-11-19 | オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド | Antibodies to Programmed Cell Death Protein 1 |
CN111542539B (en) | 2017-10-06 | 2023-10-20 | 先天制药公司 | Recovery of T cell Activity by CD39/CD73 axis |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
EP3704159A1 (en) | 2017-11-01 | 2020-09-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
US11946094B2 (en) | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
US11306149B2 (en) | 2017-12-27 | 2022-04-19 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
US11324774B2 (en) | 2018-01-05 | 2022-05-10 | Augusta University Research Institute, Inc. | Compositions of oral alkaline salts and metabolic acid inducers and uses thereof |
EP3737700A1 (en) | 2018-01-12 | 2020-11-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
EP3737696A1 (en) | 2018-01-12 | 2020-11-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
AU2019210332A1 (en) | 2018-01-22 | 2020-09-10 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
JP2021512151A (en) | 2018-01-23 | 2021-05-13 | ネクストキュア インコーポレイテッド | B7-H4 antibody and how to use it |
CN111655730A (en) | 2018-01-31 | 2020-09-11 | 豪夫迈·罗氏有限公司 | Bispecific antibodies comprising an antigen binding site that binds to LAG3 |
US20200405806A1 (en) | 2018-02-08 | 2020-12-31 | Bristol-Myers Squibb Company | Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors |
WO2019169229A1 (en) | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
MX2020009786A (en) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | ANTIBODIES BINDING TO VISTA AT ACIDIC pH. |
SG11202009839PA (en) | 2018-04-12 | 2020-11-27 | Bristol Myers Squibb Co | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
RU2020136057A (en) | 2018-05-04 | 2022-05-04 | Толлиз | TLR3 LIGANDS THAT ACTIVATE BOTH EPITHELIAL AND MYELOID CELLS |
EP3810109A4 (en) | 2018-05-31 | 2022-03-16 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
SG11202012435UA (en) | 2018-06-18 | 2021-01-28 | Innate Pharma | Compositions and methods for treating cancer |
TWI819024B (en) | 2018-07-09 | 2023-10-21 | 美商戊瑞治療有限公司 | Antibodies binding to ilt4 |
CN112638948A (en) | 2018-07-11 | 2021-04-09 | 戊瑞治疗有限公司 | Antibodies that bind to VISTA at acidic pH |
US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
AU2019306628A1 (en) | 2018-07-20 | 2021-02-11 | Surface Oncology, Inc. | Anti-CD112R compositions and methods |
CN112739371A (en) | 2018-07-26 | 2021-04-30 | 百时美施贵宝公司 | LAG-3 combination therapy for the treatment of cancer |
WO2020047345A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
EP3863722A2 (en) | 2018-10-10 | 2021-08-18 | Tilos Theapeutics, Inc. | Anti-lap antibody variants and uses thereof |
US20210338813A1 (en) | 2018-10-19 | 2021-11-04 | Bristol-Myers Squibb Company | Combination Therapy for Melanoma |
AU2019379325A1 (en) | 2018-11-16 | 2021-06-03 | Genexine, Inc. | Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor |
US20220106400A1 (en) | 2018-11-28 | 2022-04-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
JP2022511112A (en) | 2018-12-11 | 2022-01-28 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Diazanaphthalene and quinoline derivatives as ALK5 inhibitors |
EP3911302A1 (en) | 2019-01-17 | 2021-11-24 | Georgia Tech Research Corporation | Drug delivery systems containing oxidized cholesterols |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
CN114126637A (en) | 2019-03-29 | 2022-03-01 | 居里研究所 | Interleukin-2 variants with modified biological activity |
SG11202111106WA (en) | 2019-04-23 | 2021-11-29 | Innate Pharma | Cd73 blocking antibodies |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
AU2020350689A1 (en) | 2019-09-19 | 2022-03-31 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
WO2021078910A1 (en) | 2019-10-22 | 2021-04-29 | Institut Curie | Immunotherapy targeting tumor neoantigenic peptides |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
AU2020385400A1 (en) | 2019-11-22 | 2022-06-09 | Theravance Biopharma R&D Ip, Llc | Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors |
EP3824954A1 (en) | 2019-11-22 | 2021-05-26 | Centre National de la Recherche Scientifique | Device, apparatus and method for minibeam radiation therapy |
WO2021108025A1 (en) | 2019-11-26 | 2021-06-03 | Massachusetts Institute Of Technology | Cell-based cancer vaccines and cancer therapies |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
JP2023509359A (en) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | Combination anticancer therapy with inducers of iron-dependent cell degradation |
CN115397859A (en) | 2020-01-30 | 2022-11-25 | Ona疗法有限公司 | Combination therapy for the treatment of cancer and cancer metastasis |
IL295979A (en) | 2020-03-06 | 2022-10-01 | Ona Therapeutics S L | Anti-cd36 antibodies and their use to treat cancer |
CN115485302A (en) | 2020-03-09 | 2022-12-16 | 百时美施贵宝公司 | Antibodies against CD40 with enhanced agonist activity |
TW202204339A (en) | 2020-03-31 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Substituted pyrimidines and methods of use |
US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
WO2021224186A1 (en) | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
US20210354984A1 (en) | 2020-05-13 | 2021-11-18 | Massachusetts Institute Of Technology | Compositions of polymeric microdevices and methods of use thereof in cancer immunotherapy |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
CA3182333A1 (en) | 2020-05-20 | 2021-11-25 | Institut Curie | Single domain antibodies and their use in cancer therapies |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
US20210387983A1 (en) | 2020-06-10 | 2021-12-16 | Theravance Biopharma R&D Ip, Llc | Crystalline alk5 inhibitors and uses thereof |
UY39298A (en) | 2020-06-26 | 2022-01-31 | Amgen Inc | IL-10 MUTEINS AND FUSION PROTEINS THEREOF |
JP2023532339A (en) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | Viruses engineered to promote sanotransmission and their use in treating cancer |
MX2023000197A (en) | 2020-07-07 | 2023-02-22 | BioNTech SE | Therapeutic rna for hpv-positive cancer. |
EP4196502A1 (en) | 2020-08-13 | 2023-06-21 | Bristol-Myers Squibb Company | Methods of redirecting of il-2 to target cells of interest |
WO2022074206A1 (en) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Trispecific binders |
WO2022079270A1 (en) | 2020-10-16 | 2022-04-21 | Université D'aix-Marseille | Anti-gpc4 single domain antibodies |
WO2022084325A1 (en) | 2020-10-20 | 2022-04-28 | Institut Curie | Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer |
WO2022106505A1 (en) | 2020-11-18 | 2022-05-27 | Institut Curie | Dimers of biguanidines and their therapeutic uses |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
IL304031A (en) | 2021-01-14 | 2023-08-01 | Inst Curie | Her2 single domain antibodies variants and cars thereof |
WO2022165403A1 (en) | 2021-02-01 | 2022-08-04 | Yale University | Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment |
WO2022189618A1 (en) | 2021-03-12 | 2022-09-15 | Institut Curie | Nitrogen-containing heterocycles as radiosensitizers |
TW202304506A (en) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
WO2022238386A1 (en) | 2021-05-10 | 2022-11-17 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
CA3226281A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
EP4380682A1 (en) | 2021-08-05 | 2024-06-12 | Institut Curie | Scanning dynamic device for minibeams production |
WO2023041744A1 (en) | 2021-09-17 | 2023-03-23 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
TW202333802A (en) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | Therapeutic rna for lung cancer |
WO2023077034A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023180552A1 (en) | 2022-03-24 | 2023-09-28 | Institut Curie | Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma |
WO2023187024A1 (en) | 2022-03-31 | 2023-10-05 | Institut Curie | Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression |
WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
WO2023194607A1 (en) | 2022-04-07 | 2023-10-12 | Institut Curie | Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy |
WO2023194608A1 (en) | 2022-04-07 | 2023-10-12 | Institut Curie | Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024040264A1 (en) | 2022-08-19 | 2024-02-22 | Massachusetts Institute Of Technology | Compositions and methods for targeting dendritic cell lectins |
WO2024068617A1 (en) | 2022-09-26 | 2024-04-04 | Institut Curie | Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy |
WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
WO2024112867A1 (en) | 2022-11-23 | 2024-05-30 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for increasing immune responses |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
WO2024116140A1 (en) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5098702A (en) * | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US5225348A (en) * | 1989-03-14 | 1993-07-06 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5266491A (en) * | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5573920A (en) * | 1991-04-26 | 1996-11-12 | Surface Active Limited | Antibodies, and methods for their use |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
US5665577A (en) * | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
US5904920A (en) * | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
US5955331A (en) * | 1988-09-01 | 1999-09-21 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
US5985290A (en) * | 1995-12-28 | 1999-11-16 | Johns Hopkins University School Of Medicine | Purified pancreatic tumor cell lines and related compositions and method |
US6037177A (en) * | 1997-08-08 | 2000-03-14 | Cell Genesys, Inc. | Method for increasing the efficiency of recombinant AAV production |
US6040183A (en) * | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
US6093570A (en) * | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6428953B1 (en) * | 1997-12-12 | 2002-08-06 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6464973B1 (en) * | 1998-02-02 | 2002-10-15 | Johns Hopkins University, School Of Medicine | Universal GM-CSF expressing bystander human K562 cell line |
US6506604B2 (en) * | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US20050002916A1 (en) * | 2003-04-02 | 2005-01-06 | Karin Jooss | Cytokine-expressing cellular vaccine combinations |
US20090217401A1 (en) * | 2005-05-09 | 2009-08-27 | Medarex, Inc | Human Monoclonal Antibodies To Programmed Death 1(PD-1) And Methods For Treating Cancer Using Anti-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
DE69128253T2 (en) | 1990-10-29 | 1998-06-18 | Chiron Corp | SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
NZ500546A (en) | 1997-04-14 | 2001-09-28 | Cell Genesys Inc | Methods for increasing the production of high titre stocks of recombinant adeno-associated virus (AAV) |
WO2000072686A1 (en) | 1999-06-02 | 2000-12-07 | Cell Genesys, Inc. | Regulation of systemic immune responses utilizing cytokines and antigens |
-
2008
- 2008-07-23 US US12/178,122 patent/US20090028857A1/en not_active Abandoned
- 2008-07-23 WO PCT/US2008/008925 patent/WO2009014708A2/en active Application Filing
-
2010
- 2010-07-19 US US12/839,163 patent/US8287856B2/en not_active Expired - Fee Related
-
2012
- 2012-09-14 US US13/619,699 patent/US8580247B2/en active Active
-
2013
- 2013-11-12 US US14/078,042 patent/US20140271684A1/en not_active Abandoned
-
2015
- 2015-06-08 US US14/733,614 patent/US20150265705A1/en not_active Abandoned
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5098702A (en) * | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5955331A (en) * | 1988-09-01 | 1999-09-21 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5665577A (en) * | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
US5225348A (en) * | 1989-03-14 | 1993-07-06 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5266491A (en) * | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5753500A (en) * | 1989-09-07 | 1998-05-19 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
US5573920A (en) * | 1991-04-26 | 1996-11-12 | Surface Active Limited | Antibodies, and methods for their use |
US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
US5904920A (en) * | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
US6506604B2 (en) * | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US6040183A (en) * | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
US6093570A (en) * | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6033674A (en) * | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
US6350445B1 (en) * | 1995-12-28 | 2002-02-26 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
US5985290A (en) * | 1995-12-28 | 1999-11-16 | Johns Hopkins University School Of Medicine | Purified pancreatic tumor cell lines and related compositions and method |
US6037177A (en) * | 1997-08-08 | 2000-03-14 | Cell Genesys, Inc. | Method for increasing the efficiency of recombinant AAV production |
US6428953B1 (en) * | 1997-12-12 | 2002-08-06 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6464973B1 (en) * | 1998-02-02 | 2002-10-15 | Johns Hopkins University, School Of Medicine | Universal GM-CSF expressing bystander human K562 cell line |
US20050002916A1 (en) * | 2003-04-02 | 2005-01-06 | Karin Jooss | Cytokine-expressing cellular vaccine combinations |
US20090217401A1 (en) * | 2005-05-09 | 2009-08-27 | Medarex, Inc | Human Monoclonal Antibodies To Programmed Death 1(PD-1) And Methods For Treating Cancer Using Anti-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9669081B2 (en) | 2008-08-28 | 2017-06-06 | Aduro Gvax, Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
US20100150946A1 (en) * | 2008-08-28 | 2010-06-17 | Cell Genesys, Inc. | Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer |
US20110229461A1 (en) * | 2010-03-11 | 2011-09-22 | Kerry Louise Tyson | PD-1 Antibodies |
US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
US9102728B2 (en) | 2010-03-11 | 2015-08-11 | Ucb Biopharma Sprl | PD-1 antibodies |
US9308253B2 (en) * | 2011-09-19 | 2016-04-12 | The Johns Hopkins University | Cancer immunotherapy |
US20140341978A1 (en) * | 2011-09-19 | 2014-11-20 | The Johns Hopkins University | Cancer immunotherapy |
US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
EP3351261B1 (en) | 2011-10-11 | 2021-06-02 | Universität Zürich | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
US9815897B2 (en) | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
US10738117B2 (en) | 2013-05-02 | 2020-08-11 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US11696797B2 (en) | 2013-12-05 | 2023-07-11 | Immunsys, Inc. | Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB) |
WO2016024231A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
WO2016024228A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
EP3747472A1 (en) | 2015-09-15 | 2020-12-09 | Acerta Pharma B.V. | Therapeutic combinations of a cd19 inhibitor and a btk inhibitor |
WO2017122175A1 (en) | 2016-01-13 | 2017-07-20 | Acerta Pharma B.V. | Therapeutic combinations of an antifolate and a btk inhibitor |
US11497544B2 (en) | 2016-01-15 | 2022-11-15 | Immunsys, Inc. | Immunologic treatment of cancer |
US11612426B2 (en) * | 2016-01-15 | 2023-03-28 | Immunsys, Inc. | Immunologic treatment of cancer |
CN113925964A (en) * | 2016-02-15 | 2022-01-14 | 崔泽尔有限公司 | Improved interferon therapy |
US11571463B2 (en) | 2016-05-18 | 2023-02-07 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (IL12) and uses thereof |
US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
US11667890B2 (en) | 2016-10-31 | 2023-06-06 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
US11155624B2 (en) | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
EP4046989A1 (en) | 2017-01-09 | 2022-08-24 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US11407830B2 (en) | 2017-01-09 | 2022-08-09 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US11865159B2 (en) | 2017-02-28 | 2024-01-09 | Sanofi | Therapeutic RNA |
WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
WO2020096682A2 (en) | 2018-08-31 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
EP4378530A2 (en) | 2018-08-31 | 2024-06-05 | Iovance Biotherapeutics, Inc. | Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody |
WO2020061429A1 (en) | 2018-09-20 | 2020-03-26 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
WO2020255011A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
WO2020255009A2 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
WO2021216920A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
WO2022094567A1 (en) | 2020-10-28 | 2022-05-05 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
US11981921B2 (en) | 2022-04-15 | 2024-05-14 | Iovance Biotherapeutics, Inc. | TIL expansion processes using specific cytokine combinations and/or AKTi treatment |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
Also Published As
Publication number | Publication date |
---|---|
US8287856B2 (en) | 2012-10-16 |
WO2009014708A2 (en) | 2009-01-29 |
US20150265705A1 (en) | 2015-09-24 |
US20100285013A1 (en) | 2010-11-11 |
WO2009014708A3 (en) | 2009-03-19 |
US20140271684A1 (en) | 2014-09-18 |
US8580247B2 (en) | 2013-11-12 |
US20130022600A1 (en) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8580247B2 (en) | PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | |
JP7214238B2 (en) | Pharmaceutical composition containing IL-12 and T-cell inhibitory molecular blockers for tumor therapy | |
JP5607000B2 (en) | Combination of cytokine-expressing cell vaccine | |
Huang et al. | Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand | |
JP2022553192A (en) | cancer vaccine | |
US8425897B2 (en) | Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use | |
KR20220027864A (en) | IL2 agonists | |
Danishmalik et al. | Tumor regression is mediated via the induction of HER263-71-specific CD8+ CTL activity in a 4T1. 2/HER2 tumor model: no involvement of CD80 in tumor control | |
Burkhardt et al. | IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells | |
WO2008037225A1 (en) | Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor | |
Ruffini et al. | Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma | |
Rotte et al. | Promising immunotherapeutic approaches in clinical trials | |
Xiao | Dendritic cell-specific vaccine utilizing antibody-mimetic ligand and lentivector system | |
Danishmalik et al. | Tumor regression is mediated via the induction of HER2 | |
US20080267935A1 (en) | AraC in combination with a cytokine-secreting cell and methods of use thereof | |
WO1999053931A9 (en) | Tumor cells with increased immunogenicity and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELL GENESYS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, BETTY;JOOSS, KARIN;KORMAN, ALAN J.;REEL/FRAME:021407/0314;SIGNING DATES FROM 20080805 TO 20080813 Owner name: MEDAREX, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, BETTY;JOOSS, KARIN;KORMAN, ALAN J.;REEL/FRAME:021407/0314;SIGNING DATES FROM 20080805 TO 20080813 |
|
AS | Assignment |
Owner name: BIOSANTE PHARMACEUTICALS, INC., ILLINOIS Free format text: MERGER;ASSIGNOR:CELL GENESYS, INC.;REEL/FRAME:023509/0320 Effective date: 20091014 Owner name: BIOSANTE PHARMACEUTICALS, INC.,ILLINOIS Free format text: MERGER;ASSIGNOR:CELL GENESYS, INC.;REEL/FRAME:023509/0320 Effective date: 20091014 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: BIOSANTE PHARMACEUTICALS, INC., ILLINOIS Free format text: MERGER;ASSIGNOR:CELL GENESYS, INC;REEL/FRAME:042117/0971 Effective date: 20091014 |